

CITATION REPORT

List of articles citing

Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee

DOI: 10.1002/art.1780230510

Arthritis and Rheumatism, 1980, 23, 581-90.

Source: <https://exaly.com/paper-pdf/14581565/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2302	The relationship arrhythmias and conduction disturbances to other manifestations of cardiopulmonary disease in progressive systemic sclerosis (PSS). 1981 , 71, 38-46		79
2301	Immunologic enhancement of collagen accumulation in progressive systemic sclerosis (PSS). 1981 , 21, 128-33		25
2300	HLA-D related (DR) antigens in various kinds of myositis. 1981 , 3, 181-6		59
2299	The spectrum of systemic sclerosis--current concepts. 1981 , 16, 61-7, 70-2		2
2298	Reiter's syndrome. Evaluation of preliminary criteria for definite disease. <i>Arthritis and Rheumatism</i> , 1981 , 24, 844-9		208
2297	Increased frequency of HLA-DR5 in scleroderma. <i>Arthritis and Rheumatism</i> , 1981 , 24, 854-6		85
2296	The arthropathy of advanced progressive systemic sclerosis. A radiographic survey. <i>Arthritis and Rheumatism</i> , 1981 , 24, 874-84		73
2295	Clinical criteria for systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1981 , 24, 1589-90		10
2294	Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies. 1982 , 41, 382-7		91
2293	T. Duckett Jones Memorial Lecture. The Jones criteria and the challenges of clinimetrics. 1982 , 66, 1-5		293
2292	The articular manifestations of progressive systemic sclerosis (scleroderma). 1982 , 41, 147-52		106
2291	Hepatitis B virus infection in patients with rheumatic diseases. 1982 , 41, 479-82		26
2290	The treatment of severe Raynaud's phenomenon with verapamil. 1982 , 22, 74-6		45
2289	Distribution of glycosaminoglycans in dermal connective tissue from scleroderma patients. 1982 , 9, 405-8		10
2288	Cerebellar coning and uncal herniation in childhood acute leukaemia. 1982 , 2, 702-4		5
2287	TOXIC EPIDEMIC SYNDROME, SPAIN, 1981. 1982 , 320, 697-702		67
2286	Office nail fold capillary microscopy using ophthalmoscope. 1982 , 7, 190-3		30

2285	Serial pulmonary function in systemic sclerosis. 1982 , 73, 385-94	67
2284	Interdigestive Motor Activity in Patients with Systemic Sclerosis. 1982 , 83, 575-580	93
2283	Mixed connective tissue disease revisited. 1982 , 1, 136-7	1
2282	Hemiplegia and peripheral gangrene secondary to large and medium size vessels involvement in C.R.E.S.T. syndrome. 1982 , 1, 295-9	5
2281	Autologous and allogeneic mixed lymphocyte reactions in progressive systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1982 , 25, 390-5	15
2280	The arthropathy of progressive systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1982 , 25, 1026	
2279	Immune complexes in progressive systemic sclerosis (scleroderma). <i>Arthritis and Rheumatism</i> , 1982 , 25, 1167-73	43
2278	Circulating immune complexes in patients with progressive systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1982 , 25, 1174-9	31
2277	Digital sclerosis in children with insulin-dependent diabetes mellitus. <i>Arthritis and Rheumatism</i> , 1982 , 25, 1357-61	62
2276	Bony ankylosis of the hips in progressive systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1982 , 25, 1497-500	4
2275	Histocompatibility antigens in progressive systemic sclerosis (PSS; scleroderma). 1982 , 2, 314-8	39
2274	Cutaneous manifestations of primary Sjögren's syndrome: a reflection of vasculitis and association with anti-Ro(SSA) antibodies. 1983 , 80, 386-91	98
2273	Lower esophageal rings as a cause of dysphagia in progressive systemic sclerosis--coincidence or consequence?. 1983 , 28, 780-3	5
2272	Factors limiting exercise performance in progressive systemic sclerosis. 1983 , 13, 174-81	20
2271	Overlapping connective tissue diseases in children. 1983 , 2, 375-80	5
2270	Differences in the kinetics of the autologous mixed lymphocyte reaction between the various connective tissue diseases. 1983 , 3, 117-28	13
2269	Frequency and clinical significance of anticentromere and anti Scl-70 antibodies in an English connective tissue disease population. 1983 , 3, 19-21	31
2268	Anticentromere antibody. Clinical Correlations and association with favorable prognosis in patients with scleroderma variants. <i>Arthritis and Rheumatism</i> , 1983 , 26, 1-7	102

2267	Cytotoxicity of sera from patients with scleroderma. Effects on human endothelial cells and fibroblasts in culture. <i>Arthritis and Rheumatism</i> , 1983 , 26, 170-8	69
2266	Nifedipine in digital ulceration in scleroderma. <i>Arthritis and Rheumatism</i> , 1983 , 26, 809	9
2265	⁶⁷ Gallium lung scans in progressive systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1983 , 26, 969-74	25
2264	Human fibroblasts, a convenient nuclear substrate for detection of anti-nuclear antibodies including anti-centromere antibodies. 1983 , 12, 193-200	12
2263	Human anticentriole autoantibody in patients with scleroderma and Raynaud's phenomenon. 1983 , 29, 381-90	33
2262	T-cell subpopulations in the peripheral blood of patients with connective tissue diseases as determined by flow cytometry using monoclonal antibodies. 1983 , 27, 340-7	37
2261	Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon. 1983 , 308, 880-3	195
2260	Cyclofenil treatment of scleroderma--a controlled study. 1983 , 22, 218-23	20
2259	Serological markers in progressive systemic sclerosis: clinical correlations. 1983 , 42, 23-7	148
2258	Clinical and prognostic significance of vasculitis as an early manifestation of connective tissue disease syndromes. 1984 , 101, 743-8	24
2257	Clinical and serological comparison of 17 chronic progressive systemic sclerosis (PSS) and 17 CREST syndrome patients matched for sex, age, and disease duration. 1984 , 43, 794-801	36
2256	Nifedipine in ulnar artery occlusion. 1984 , 35, 320-3	7
2255	Elevated ANA titers in patients with severely abnormal gastrointestinal motility. 1984 , 29, 735-9	3
2254	Pathogenesis of scleroderma. Current concepts. 1984 , 23, 85-9	15
2253	Clinical spectrum of connective tissue disease after cosmetic surgery. Observations on eighteen patients and a review of the Japanese literature. <i>Arthritis and Rheumatism</i> , 1984 , 27, 1-12	220
2252	A long-term longitudinal study of anticentromere antibodies. <i>Arthritis and Rheumatism</i> , 1984 , 27, 121-4	80
2251	Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1984 , 27, 125-31	202
2250	Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin ₂ (5-HT ₂) receptor. <i>Arthritis and Rheumatism</i> , 1984 , 27, 139-46	101

2249	Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. <i>Arthritis and Rheumatism</i> , 1984 , 27, 361-8	4028
2248	The clinical utility of the lupus band test. <i>Arthritis and Rheumatism</i> , 1984 , 27, 382-7	29
2247	Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. <i>Arthritis and Rheumatism</i> , 1984 , 27, 645-53	323
2246	Scleroderma: possible significance of silent alleles at the C4B locus. <i>Arthritis and Rheumatism</i> , 1984 , 27, 711-2	28
2245	A new serologic marker in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 1984 , 27, 961-7	27
2244	Interstitial lung disease in scleroderma. Analysis by bronchoalveolar lavage. <i>Arthritis and Rheumatism</i> , 1984 , 27, 1254-62	73
2243	Characterization of a new antigen-antibody system (Su) in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1984 , 27, 1263-71	20
2242	Clinical profiles of patients with antibodies to nuclear ribonucleoprotein. 1984 , 3, 483-92	12
2241	A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome. 1984 , 27, 61-65	
2240	Differences in the production of and/or the response to interleukin-2 by T lymphocytes from patients with the various connective tissue diseases. 1984 , 4, 39-44	32
2239	Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes. 1984 , 4, 40-4	166
2238	Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. 1984 , 310, 142-8	196
2237	Occlusive digital artery disease in patients with Raynaud's phenomenon. 1984 , 77, 995-1001	19
2236	Factors predicting development of renal involvement in progressive systemic sclerosis. 1984 , 76, 779-86	192
2235	Early changes in oesophageal function in progressive systemic sclerosis: a comparison of manometry and radiology. 1984 , 4, 147-58	15
2234	Oral and gingival changes in systemic sclerosis (scleroderma). 1984 , 55, 175-8	30
2233	Lung involvement in scleroderma. 1984 , 85, 318-24	63
2232	Digital Gangrene in a Heavy Smoker. 1984 , 19, 177-178	

2231	Clinical significance of lymphocyte responsiveness to scleroderma-inducing glycosaminoglycan-associated antigen in systemic scleroderma. 1985 , 171, 435-41	1
2230	Nifedipine and alpha 1-adrenergic blockade in Raynaud's phenomenon. 1985 , 6, 702-5	21
2229	Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis?. 1985 , 102, 182-6	189
2228	Coexistence of severe palmo-plantar Dupuytren's contracture, Raynaud's phenomenon and digital joint erosions. 1985 , 5, 95-6	2
2227	Announcements. 1985 , 5, 96-96	
2226	Environmentally Induced Systemic Sclerosis-like Disorders. 1985 , 24, 147-151	60
2225	Environmentally induced systemic sclerosis-like disorders. 1985 , 24, 147-51	43
2224	Differences in red cell behaviour between patients with Raynaud's phenomenon and systemic sclerosis and patients with Raynaud's disease. 1985 , 113, 265-72	15
2223	Antinuclear antibodies in the relatives of patients with systemic sclerosis. 1985 , 112, 23-33	44
2222	Anticentromere antibody: an immunological marker of a subset of systemic sclerosis. 1985 , 113, 381-9	29
2221	Anti-nuclear RNP antibodies in two sisters. 1985 , 113, 617-22	1
2220	Gastrointestinal function in patients with progressive systemic sclerosis. 1985 , 4, 441-8	19
2219	Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease. <i>Arthritis and Rheumatism</i> , 1985 , 28, 87-92	82
2218	Circulating natural killer cells in Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 1985 , 28, 182-7	16
2217	Double-blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1985 , 28, 308-14	33
2216	Nifedipine and esophageal dysfunction in progressive systemic sclerosis. A controlled manometric study. <i>Arthritis and Rheumatism</i> , 1985 , 28, 490-5	29
2215	Relationship between nailfold capillary abnormalities and organ involvement in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1985 , 28, 496-501	43
2214	Selective inhibition of excessive scleroderma fibroblast collagen production by lymphokines from normal human mononuclear cells. <i>Arthritis and Rheumatism</i> , 1985 , 28, 502-10	17

2213	Decreased coronary reserve in primary scleroderma myocardial disease. <i>Arthritis and Rheumatism</i> , 1985 , 28, 637-46	95
2212	Juvenile progressive systemic sclerosis: clinical and serologic findings. <i>Arthritis and Rheumatism</i> , 1985 , 28, 699-702	25
2211	Autoantibodies in Argentine patients with systemic sclerosis (scleroderma). <i>Arthritis and Rheumatism</i> , 1985 , 28, 715-7	3
2210	Pulmonary involvement in systemic sclerosis (scleroderma). <i>Arthritis and Rheumatism</i> , 1985 , 28, 759-67	129
2209	The effect of D-penicillamine on pulmonary findings in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1985 , 28, 882-8	77
2208	Anticytoskeletal autoantibodies in the connective tissue diseases. <i>Arthritis and Rheumatism</i> , 1985 , 28, 889-98	68
2207	The leukergy test in rheumatic diseases. New implications for an old test. <i>Arthritis and Rheumatism</i> , 1985 , 28, 899-903	27
2206	Anticentromere antibody is not specific for connective tissue disease with a promising prognosis. <i>Arthritis and Rheumatism</i> , 1985 , 28, 1076-7	6
2205	Modulatory effect of sera from scleroderma patients on lymphocyte-induced angiogenesis. <i>Arthritis and Rheumatism</i> , 1985 , 28, 1133-9	20
2204	Two types of inflammatory vascular disease in Sjögren's syndrome. Differential association with seroreactivity to rheumatoid factor and antibodies to Ro (SS-A) and with hypocomplementemia. <i>Arthritis and Rheumatism</i> , 1985 , 28, 1251-8	81
2203	Noninvasive evaluation of cardiac dysrhythmias, and their relationship with multisystemic symptoms, in progressive systemic sclerosis patients. <i>Arthritis and Rheumatism</i> , 1985 , 28, 1259-66	63
2202	Cancer and systemic sclerosis. An epidemiologic study. <i>Arthritis and Rheumatism</i> , 1985 , 28, 1336-40	171
2201	Peripheral inflammatory vascular disease in Sjögren's syndrome. Association with nervous system complications. <i>Arthritis and Rheumatism</i> , 1985 , 28, 1341-7	87
2200	Prostacyclin biosynthesis and platelet function in autonomic dysfunction. 1985 , 35, 120-3	5
2199	Raised serum hyaluronate levels in scleroderma: an effect of growth factor induced activation of connective tissue cells?. 1985 , 44, 614-20	105
2198	Silica, silicosis, and progressive systemic sclerosis. 1985 , 42, 838-43	21
2197	Antikeratin antibodies in serum and synovial fluid show specificity for rheumatoid arthritis in a study of connective tissue diseases. 1985 , 44, 450-4	48
2196	Lung involvement in Sjögren's syndrome: a comparison between patients with primary and with secondary syndrome. 1985 , 44, 455-61	46

2195	Serum immune complexes in systemic sclerosis: relationship with precipitating nuclear antibodies. 1985 , 44, 89-92	11
2194	A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon. 1985 , 44, 30-3	57
2193	Decreased nailfold capillary density in Raynaud's phenomenon: a reflection of immunologically mediated local and systemic vascular disease?. 1985 , 44, 603-9	34
2192	Plasma or serum from patients with systemic sclerosis alters behaviour of normal erythrocytes. 1985 , 44, 395-8	7
2191	Effects of verapamil on calcium-induced rigidity and on filterability of red blood cells from healthy volunteers and patients with progressive systemic sclerosis. 1985 , 19, 731-7	17
2190	Evaluation of methods for detection of anticentromere antibodies and other antinuclear antibodies. 1985 , 12, 289-95	10
2189	The blood supply to fingers during Raynaud's attack: a comparison of laser-Doppler flowmetry with other techniques. 1985 , 5, 447-53	20
2188	Perturbation of fibrinolysis inhibitors in progressive systemic sclerosis. 1985 , 16, 253-60	3
2187	Prediction of survival in progressive systemic sclerosis by multivariate analysis of clinical features. 1985 , 110, 123-7	49
2186	The electrocardiogram in systemic sclerosis (scleroderma). Study of 102 consecutive cases with functional correlations and review of the literature. 1985 , 79, 183-92	79
2185	Pulmonary vascular response during Raynaud's phenomenon in progressive systemic sclerosis. 1985 , 78, 221-7	39
2184	Reduced coronary flow and resistance reserve in primary scleroderma myocardial disease. 1986 , 112, 309-15	33
2183	Primary Sjögren's syndrome in men. Clinical, serologic, and immunogenetic features. 1986 , 80, 23-31	75
2182	Left ventricular dysfunction induced by cold exposure in patients with systemic sclerosis. 1986 , 80, 385-92	40
2181	The microvascular localization of laminin and fibronectin in scleroderma muscle by immune electron microscopy. 1986 , 10, 221-6	1
2180	Impotence in silicosis-associated scleroderma. 1986 , 15, 1294-6	5
2179	[Prognosis of generalized scleroderma. A retrospective study of 78 cases]. 1986 , 7, 233-41	2
2178	Penicillamine-induced rapidly progressive glomerulonephritis in patients with progressive systemic sclerosis: successful treatment of two patients and a review of the literature. 1986 , 8, 159-63	37

2177	Abnormalities in the cellular phase of blood fibrinolytic activity in systemic lupus erythematosus and in venous thromboembolism. 1986 , 43, 595-602	8
2176	Screening for intrauterine growth retardation using ratio of mid-arm circumference to occipitofrontal circumference. 1986 , 292, 1039-40	25
2175	The toxicity of D-penicillamine in systemic sclerosis. 1986 , 104, 699-705	66
2174	Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis. 1986 , 105, 661-8	96
2173	Primary Sjögren's syndrome with central nervous system disease mimicking multiple sclerosis. 1986 , 104, 323-30	159
2172	Impotence in scleroderma. 1986 , 104, 794-8	39
2171	Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis. 1986 , 314, 1397-402	127
2170	Placental lesions in maternal autoimmune diseases. 1986 , 12, 78-86	69
2169	Nailfold capillary microscopy in mixed connective tissue disease. Comparison with systemic sclerosis and systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1986 , 29, 189-95	68
2168	Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1986 , 29, 515-24	307
2167	Interstitial lung disease in scleroderma. Immune complexes in sera and bronchoalveolar lavage fluid. <i>Arthritis and Rheumatism</i> , 1986 , 29, 525-31	25
2166	Inhibition of excessive scleroderma fibroblast collagen production by recombinant gamma-interferon. Association with a coordinate decrease in types I and III procollagen messenger RNA levels. <i>Arthritis and Rheumatism</i> , 1986 , 29, 851-6	97
2165	Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. <i>Arthritis and Rheumatism</i> , 1986 , 29, 1039-49	4857
2164	Anticardiolipin antibodies in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1986 , 29, 1052-3	24
2163	Evidence of an immunopathogenic basis for central nervous system disease in primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 1986 , 29, 1223-31	46
2162	A strong association between null alleles at the C4A locus in the major histocompatibility complex and systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1986 , 29, 1274-7	36
2161	Association between HLA and Sjögren's syndrome in Japanese patients. <i>Arthritis and Rheumatism</i> , 1986 , 29, 1518-21	25
2160	Nodular regenerative hyperplasia of the liver associated with the toxic oil syndrome: report of five cases. 1986 , 6, 687-93	51

2159	Clinical and laboratory effects of nifedipine in Raynaud's phenomenon. 1986 , 6, 85-8	10
2158	Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I. 1986 , 94, 132-8	125
2157	Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon. 1986 , 40, 219-25	35
2156	Enhanced angiogenic capability of monocyte-enriched mononuclear cell suspensions from patients with systemic scleroderma. 1986 , 86, 355-8	10
2155	Type III collagen aminopropeptide levels in serum of patients with progressive systemic scleroderma. 1986 , 87, 788-91	47
2154	Scl 70 antibody--a specific marker of systemic sclerosis. 1986 , 115, 393-401	77
2153	Pathogenesis of progressive systemic sclerosis. 1986 , 25, 286-93	32
2152	Scleroderma and scleroderma-like disorders. 1986 , 16, 22-69	50
2151	The cardiovascular manifestations of systemic sclerosis (scleroderma). 1986 , 11, 241-98	31
2150	Sister-chromatid exchange frequencies in lymphocytes of controls and patients with connective tissue diseases. 1986 , 162, 113-20	16
2149	Lung function abnormalities in different connective tissue diseases. 1986 , 5, 181-8	13
2148	Symmetrical widening of the periodontal ligament space in a patient with multiple systemic problems. 1986 , 113, 307-8	3
2147	Regressive systemic sclerosis. 1986 , 45, 384-8	9
2146	Pharmacodynamic effect of dipyridamole on thallium-201 myocardial perfusion in progressive systemic sclerosis with diffuse scleroderma. 1986 , 45, 718-25	37
2145	Skin, joint, and pulmonary changes in type I diabetes mellitus. 1986 , 140, 420-3	15
2144	Antinuclear antibodies in the relatives and spouses of patients with systemic sclerosis. 1986 , 45, 793-9	26
2143	Long-term griseofulvin treatment for progressive systemic sclerosis. 1986 , 15, 356-62	9
2142	Sclerodactyly, CREST syndrome, proximal scleroderma. 1986 , 45, 86	4

2141	Ultrasound examination of skin thickness in patients with progressive systemic sclerosis (scleroderma). 1986 , 27, 91-4	37
2140	Autonomic neuropathy in systemic sclerosis: a case report and evaluation of six patients. 1986 , 45, 957-60	43
2139	Progressive dementia and epilepsy in a young adult: unusual intraneuronal inclusions. 1986 , 36, 68-71	20
2138	Association of bronchiolitis with connective tissue disorders. 1986 , 45, 656-62	24
2137	Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. 1986 , 292, 1037-9	75
2136	Long-term ranitidine in progressive systemic sclerosis (scleroderma) with gastroesophageal reflux. 1986 , 21, 799-805	33
2135	Rabbit antisera to cross-reactive organisms--where's the problem. 1986 , 45, 85-6	3
2134	Defective Epstein-Barr virus specific suppressor T cell function in progressive systemic sclerosis. 1986 , 45, 553-60	16
2133	Objective relief of vasospasm by glyceryl trinitrate in secondary Raynaud's phenomenon. 1986 , 62, 15-8	15
2132	HLA-DR4 and Gm(1,3;5,21) are associated with U1-nRNP antibody positive connective tissue disease. 1987 , 46, 189-96	46
2131	Mast Cell Numbers in Diffuse Scleroderma. 1987 , 123, 205	71
2130	Pulmonary involvement in systemic sclerosis. Association with anti-Scl 70 antibody and digital pitting. 1987 , 92, 509-13	33
2129	Bioavailability of D-penicillamine in relation to gastrointestinal involvement of generalized scleroderma. 1987 , 16, 121-6	8
2128	Comparison of immunofluorescence and immunoperoxidase for demonstration of antinuclear antibodies on HEp-2 substrate. 1987 , 26, 188-92	2
2127	The clinical significance of the anticentromere antibody. 1987 , 26, 17-21	14
2126	The Autoimmune Diseases. 1987 , 258, 2920	9
2125	Nicardipine in the treatment of Raynaud's phenomenon: a randomized double-blind trial. 1987 , 38, 333-7	26
2124	Enhanced oxidative metabolism of neutrophils from patients with systemic sclerosis. 1987 , 26, 113-7	15

2123	Trigeminal sensory neuropathy. A study of 22 cases. 1987 , 110 (Pt 6), 1463-85	120
2122	Polymorphonuclear neutrophil function in systemic sclerosis. 1987 , 46, 302-6	13
2121	Langerhans cells in connective tissue diseases. 1987 , 16, 273-9	3
2120	Nifedipine in primary Raynaud's phenomenon and in scleroderma: oral versus sublingual hemodynamic effects. 1987 , 27, 907-13	19
2119	Esophagitis in scleroderma. Prevalence and risk factors. 1987 , 92, 421-8	125
2118	Lymphocyte subpopulations in bronchoalveolar lavage in Sjögren's syndrome. Evidence for an expansion of cytotoxic/suppressor subset in patients with alveolar neutrophilia. 1987 , 92, 1025-31	46
2117	Silica-dust-exposed mine workers with scleroderma (systemic sclerosis). 1987 , 92, 260-2	76
2116	Significant increase of urinary low-sulfated heparan-sulfate-related protein in patients with severe systemic sclerosis. 1987 , 174, 166-72	
2115	Western-blotting method for detecting antibodies against human muscle contractile proteins in myositis. 1987 , 105, 15-21	8
2114	Significance of anticentromere antibody in idiopathic Raynaud's syndrome. 1987 , 83, 893-8	27
2113	How to classify Raynaud's phenomenon. Long-term follow-up study of 73 cases. 1987 , 83, 494-8	69
2112	Anticardiolipin antibodies in unselected autoimmune rheumatic disease patients. 1987 , 44, 297-307	81
2111	Plasma exchange in the treatment of progressive systemic sclerosis. 1987 , 8, 169-176	8
2110	Frequency, levels, and significance of blood eosinophilia in systemic sclerosis, localized scleroderma, and eosinophilic fasciitis. 1987 , 17, 648-56	75
2109	Plasma exchange therapy in progressive systemic sclerosis. 1987 , 8, 113-118	5
2108	Esophageal dysfunction and radionuclide transit in progressive systemic sclerosis. 1987 , 16, 291-9	32
2107	Angiotensin converting enzyme (ACE) in scleroderma. 1987 , 6, 300-1	4
2106	Disease manifestations of progressive systemic sclerosis: sensitivity and specificity. 1987 , 6, 532-8	8

2105	Serum levels of type III collagen aminopropeptide in patients with systemic scleroderma. 1987 , 279, 484-6	17
2104	Origin of the enhanced activity of lysosomal beta-galactosidase in serum and skin in progressive systemic sclerosis. 1987 , 279, 299-302	7
2103	Esophageal manometric findings in autoimmune rheumatic diseases: is scleroderma esophagus a specific entity?. 1987 , 7, 23-7	21
2102	D-penicillamine therapy and interstitial lung disease in scleroderma. A long-term followup study. <i>Arthritis and Rheumatism</i> , 1987 , 30, 643-50	68
2101	The autoimmune antigen Me is distinct and related to undifferentiated connective tissue disease. <i>Arthritis and Rheumatism</i> , 1987 , 30, 1239-46	8
2100	Antibodies to collagen in scleroderma. <i>Arthritis and Rheumatism</i> , 1987 , 30, 597	1
2099	Serum from patients with Raynaud's phenomenon inhibits prostacyclin production. 1987 , 89, 555-9	18
2098	Transforming growth factor-beta: selective increase in glycosaminoglycan synthesis by cultures of fibroblasts from patients with progressive systemic sclerosis. 1987 , 89, 100-4	122
2097	Scleroderma-polymyositis overlap syndrome. Clinical and serologic aspects. 1987 , 26, 419-25	40
2096	Colour changes during 'Raynaud's phenomenon' and finger blood supply during direct and indirect cooling procedures. 1987 , 12, 339-42	7
2095	Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis. 1987 , 117, 237-41	35
2094	The skin changes of POEMS syndrome. 1987 , 117, 523-6	61
2093	Natural killer cell activity of peripheral blood mononuclear cells from patients with various forms of systemic scleroderma. 1987 , 116, 1-8	17
2092	Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. 1988 , 18, 9-17	191
2091	Systemic sclerosis: another disease with autonomic dysfunction. 1988 , 23, 421-2	2
2090	Characterization of the antigen reactive with anti-Scl-70 antibodies and its application in an enzyme-linked immunosorbent assay. <i>Arthritis and Rheumatism</i> , 1988 , 31, 108-15	21
2089	HLA and immunoglobulin allotypes in mixed connective tissue disease. <i>Arthritis and Rheumatism</i> , 1988 , 31, 131-4	56
2088	Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1988 , 31, 196-203	495

2087	The AI/RHEUM knowledge-based computer consultant system in rheumatology. Performance in the diagnosis of 59 connective tissue disease patients from Japan. <i>Arthritis and Rheumatism</i> , 1988 , 31, 219-26	64
2086	Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients. <i>Arthritis and Rheumatism</i> , 1988 , 31, 378-85	206
2085	Autoantibodies to mitochondria in systemic sclerosis. Frequency and characterization using recombinant cloned autoantigen. <i>Arthritis and Rheumatism</i> , 1988 , 31, 386-92	37
2084	Renal vascular histology and morphometry in systemic sclerosis. A case-control autopsy study. <i>Arthritis and Rheumatism</i> , 1988 , 31, 393-400	63
2083	Enhanced production of interleukin-2 in patients with progressive systemic sclerosis. Hyperactivity of CD4-positive T cells?. <i>Arthritis and Rheumatism</i> , 1988 , 31, 401-7	48
2082	A recombinant autoantigen derived from the human (U1) small nuclear RNP-specific 68-kd protein. Expression in <i>Escherichia coli</i> and serodiagnostic application. <i>Arthritis and Rheumatism</i> , 1988 , 31, 616-22	37
2081	Immunologic dysfunction in scleroderma: evidence for increased mast cell releasability and HLA-DR positivity in the dermis. <i>Arthritis and Rheumatism</i> , 1988 , 31, 672-7	36
2080	A retrospective study of antibodies against basement membrane antigens (type IV collagen and laminin) in patients with primary and secondary Raynaud's phenomenon. <i>Arthritis and Rheumatism</i> , 1988 , 31, 1432-6	28
2079	Reduced natural killer cell activity in patients with systemic sclerosis. Correlation with clinical disease type. <i>Arthritis and Rheumatism</i> , 1988 , 31, 1515-23	20
2078	The effects of scleroderma serum on human microvascular endothelial cells. Induction of antibody-dependent cellular cytotoxicity. <i>Arthritis and Rheumatism</i> , 1988 , 31, 1524-34	53
2077	Antinuclear antibodies in scleroderma, mixed connective tissue disease and "primary" Raynaud's phenomenon. 1988 , 7, 80-6	9
2076	Evaluation of lymphocyte activation in skin lesions of patients with mixed connective tissue disease and discoid lupus erythematosus. 1988 , 280, 1-4	9
2075	Lymphocytotoxic autoantibodies in progressive systemic sclerosis. 1988 , 280, 399-404	10
2074	Effect of a platelet release fraction on glycosaminoglycan synthesis by cultured dermal fibroblasts from patients with progressive systemic sclerosis. 1988 , 118, 339-45	8
2073	Decreased stratum corneum ceramides in atopic individuals--a pathobiochemical factor in xerosis?. 1988 , 119, 547-9	107
2072	Failure to demonstrate the lupus anticoagulant in systemic sclerosis. 1988 , 119, 549	2
2071	Diffuse soft tissue calcifications (calcinosis cutis) in a patient with discoid lupus erythematosus. 1988 , 13, 193-6	7
2070	Theophylline-resistant and theophylline-sensitive "active" and "total" E rosette-forming lymphocytes in patients with systemic scleroderma. 1988 , 90, 851-6	5

2069	The lungs in systemic sclerosis (scleroderma): a review and new information. 1988 , 17, 271-83	37
2068	Progressive systemic sclerosis: mode of presentation, rapidly progressive disease course, and mortality based on an analysis of 91 patients. 1988 , 18, 1-13	69
2067	Analysis of the oral manifestations of systemic sclerosis (scleroderma). 1988 , 65, 172-8	91
2066	Prospective study of the evolution of Raynaud's phenomenon. 1988 , 84, 718-26	60
2065	Prognostic importance of cardiac arrhythmias in systemic sclerosis. 1988 , 84, 1007-15	98
2064	Familial clustering of scleroderma spectrum disease. 1988 , 84, 1023-32	37
2063	Serum complement activation in central nervous system disease in Sjögren's syndrome. 1988 , 85, 513-8	29
2062	. 1988 , 76, 672-679	1
2061	Clinical, pathologic, and immunopathologic manifestations of the toxic oil syndrome. Analysis of fourteen cases. 1988 , 18, 313-24	25
2060	Mononuclear cell-fibroblast interactions in scleroderma. 1988 , 46, 412-20	14
2059	Systemic scleroderma. Clinical and pathophysiologic aspects. 1988 , 18, 457-81	175
2058	Abstracts. 1988 , 18, 324	
2057	Esophageal dysfunction in primary biliary cirrhosis. 1988 , 7, 362-7	8
2056	The use of immunoblotting to detect antibodies to nuclear and cytoplasmic antigens. Clinical and serological associations in rheumatic diseases. 1988 , 17, 353-64	51
2055	Autonomic neuropathy in systemic sclerosis. 1988 , 47, 542-5	49
2054	Visceral improvement following combined plasmapheresis and immunosuppressive drug therapy in progressive systemic sclerosis. 1988 , 17, 313-23	29
2053	Anticardiolipin antibodies, livedo reticularis, and major cerebrovascular and renal disease in systemic lupus erythematosus. 1988 , 47, 110-5	60
2052	Studies on anti-granulocyte and anti-platelet antibodies in patients with systemic sclerosis. Chemotaxis, phagocytosis and opsonized effect of PSS sera on normal granulocytes. 1988 , 17, 43-50	4

2051	Activated alveolar macrophages in subclinical pulmonary inflammation in collagen vascular diseases. 1988 , 43, 24-30	23
2050	Sequential nailfold capillary microscopy in scleroderma and related disorders. 1988 , 47, 53-61	23
2049	More on autonomic neuropathy in systemic sclerosis. 1988 , 47, 261-3	8
2048	Decreased oesophageal blood flow in patients with Raynaud's phenomenon. 1988 , 27, 426-30	17
2047	Cutaneous Hypoxia in Patients With Systemic Sclerosis (Scleroderma). 1988 , 124, 1379	71
2046	Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. 1988 , 47, 43-7	59
2045	The diagnosis and classification of scleroderma (systemic sclerosis). 1988 , 64, 121-5	23
2044	Sjögren's syndrome: a study of its neurological complications. 1988 , 27, 275-80	48
2043	Apparent finger systolic pressures during cooling in patients with Raynaud's syndrome. 1988 , 77, 988-96	26
2042	Outcome of pregnancy in patients with autoimmune rheumatic disease before the disease onset. 1988 , 47, 982-7	63
2041	Normal cardiovascular autonomic function in patients with systemic sclerosis (CREST variant). 1988 , 47, 672-4	9
2040	Esophageal candidosis in progressive systemic sclerosis: occurrence, significance, and treatment with fluconazole. 1988 , 23, 1182-6	44
2039	Dose-response study of prazosin in Raynaud's phenomenon: clinical effectiveness versus side effects. 1988 , 28, 1089-93	8
2038	Acute synovial rupture in scleroderma. 1988 , 17, 119-22	
2037	Are nailfold capillary changes indicators of organ involvement in progressive systemic sclerosis?. 1988 , 176, 18-21	10
2036	Magnetic resonance imaging of cerebral lesions in patients with the Sjögren syndrome. 1988 , 108, 815-23	76
2035	Anti-Scl-70 antibodies detected by immunoblotting in progressive systemic sclerosis: specificity and clinical correlations. 1989 , 48, 992-7	28
2034	Anti-IgE autoantibodies in systemic sclerosis (scleroderma). 1989 , 48, 201-5	17

2033	Organ manifestations in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma. 1989 , 28, 281-6	114
2032	Use of computerized digital thermometry for diagnosis of Raynaud's phenomenon. 1989 , 40, 863-71	13
2031	Serum type III procollagen peptide concentrations in systemic sclerosis and Raynaud's phenomenon: relationship to disease activity and duration. 1989 , 28, 98-103	26
2030	Anticentromere antibody in patients without CREST and scleroderma: association with active digital vasculitis, rheumatic and connective tissue disease. 1989 , 48, 771-5	9
2029	Platelet serotonin in systemic sclerosis. 1989 , 48, 586-9	21
2028	Exocrine pancreatic function in patients with progressive systemic sclerosis. 1989 , 24, 461-6	18
2027	Pulmonary hypertension in the CREST syndrome: variant of systemic sclerosis (scleroderma)--a case report. 1989 , 40, 764-7	6
2026	The progress of oesophageal involvement in progressive systemic sclerosis during D-penicillamine treatment. 1989 , 18, 149-55	11
2025	Is ischemia implicated in chronic multifocal demyelinating neuropathy?. 1989 , 39, 106-10	27
2024	Cardiac involvement in systemic sclerosis. 1989 , 19, 110-6	14
2023	Frequency of mitral valve prolapse in systemic lupus erythematosus, progressive systemic sclerosis and mixed connective tissue disease. 1989 , 63, 369-70	25
2022	Prophylactic aspirin use among US physicians. 1989 , 63, 370-2	4
2021	Marker antibodies in scleroderma and polymyositis: clinical associations. 1989 , 8, 231-7	15
2020	Avascular necrosis of the femoral head in long-term follow-up of systemic sclerosis: report of two cases. 1989 , 8, 386-92	8
2019	Environmentally-induced systemic sclerosis-like illness. 1989 , 3, 63-79	11
2018	DNA-DR typing shows HLA-DRw11 RFLPs are increased in frequency in both progressive systemic sclerosis and CREST variants of scleroderma. 1989 , 33, 418-20	27
2017	Lymphocyte proliferative response to mitogenic monoclonal antibodies in systemic sclerosis. Evidence for unresponsiveness to murine monoclonal antibodies of IgG1 isotype. 1989 , 33, 457-65	1
2016	Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. <i>Arthritis and Rheumatism</i> , 1989 , 32, 54-60	78

2015	The "neck sign" in scleroderma. <i>Arthritis and Rheumatism</i> , 1989 , 32, 209-11	8
2014	Home central venous hyperalimentation in fifteen patients with severe scleroderma bowel disease. <i>Arthritis and Rheumatism</i> , 1989 , 32, 212-6	29
2013	Increased proto-oncogene expression in peripheral blood T lymphocytes from patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1989 , 32, 430-6	26
2012	Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study. <i>Arthritis and Rheumatism</i> , 1989 , 32, 584-93	98
2011	Prevalence of scleroderma spectrum disorders in the general population of South Carolina. <i>Arthritis and Rheumatism</i> , 1989 , 32, 998-1006	148
2010	Normotensive renal failure in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1989 , 32, 1128-34	151
2009	Activation of the complement system in systemic sclerosis. Relationship to clinical severity. <i>Arthritis and Rheumatism</i> , 1989 , 32, 1262-7	37
2008	Elevated plasma levels of alpha 2-plasmin inhibitor-plasmin complex in patients with rheumatic diseases. Possible role of fibrinolytic mechanism in vasculitis. <i>Arthritis and Rheumatism</i> , 1989 , 32, 1427-33	25
2007	Purification and characterization of Ki antigen and detection of anti-Ki antibody by enzyme-linked immunosorbent assay in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1989 , 32, 1554-62	27
2006	Lack of association between scleroderma and types I and III procollagen gene restriction fragment length polymorphisms. <i>Arthritis and Rheumatism</i> , 1989 , 32, 1597-600	1
2005	Heterogeneity of ribosomal autoantibodies from human, murine and canine connective tissue diseases. 1989 , 23, 35-41	20
2004	Impaired late suppression of Epstein-Barr virus (EBV)-induced immunoglobulin synthesis: a common feature of autoimmune disease. 1989 , 9, 103-10	10
2003	Immunopathologic findings in systemic sclerosis patients: clinical and immunopathologic relationships. 1989 , 28, 650-6	11
2002	Antibodies to Ro/SSA detected by ELISA: correlation with clinical features in systemic scleroderma. 1989 , 121, 35-41	21
2001	Gm allotype distribution and lack of HLA-DR, Gm interaction in SLE and CREST/PSS. 1989 , 67 (Pt 4), 261-5	3
2000	Treatment of scleroderma skin ulcers with a hydrocolloid membrane. 1989 , 21, 200-4	28
1999	Raynaud syndrome in childhood. 1989 , 114, 73-8	46
1998	Progressive systemic sclerosis (scleroderma) and impotence. 1989 , 33, 189-92	7

1997	Postocclusive reactive hyperemia of fingertips, monitored by laser Doppler velocimetry in the diagnosis of Raynaud's phenomenon. 1989 , 38, 286-95	19
1996	International study of ketanserin in Raynaud's phenomenon. 1989 , 87, 264-8	52
1995	Recombinant interferon-gamma in the treatment of systemic sclerosis. 1989 , 87, 273-7	92
1994	The diagnostic value of several immunological tests for anti-nuclear antibody in predicting the development of connective tissue disease in patients presenting with Raynaud's phenomenon. 1989 , 19, 535-41	47
1993	Enzyme-linked immunosorbent assay using isolated (U) small nuclear ribonucleoprotein polypeptides as antigens to investigate the clinical significance of autoantibodies to these polypeptides. 1989 , 50, 213-30	74
1992	Antinuclear antibodies detected by indirect immunofluorescence on HEp2 cells and by immunoblotting in patients with systemic sclerosis. 1989 , 2, 165-76	11
1991	Ketanserin: an effective treatment regimen for digital ischaemia in systemic sclerosis. 1989 , 18, 107-11	9
1990	Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. 1989 , 298, 561-4	152
1989	Systemic sclerosis after augmentation mammoplasty with silicone implants. 1989 , 111, 377-83	142
1988	Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration. 1989 , 110, 446-50	104
1987	Longitudinal study of patients with anticentromere antibody. 1990 , 181, 202-6	9
1986	The radiographic changes of scleroderma in the hands. 1990 , 34, 53-8	4
1985	Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. 1990 , 113, 352-7	278
1984	Type III collagen aminopropeptide and laminin P1 levels in serum of patients with silicosis-associated and idiopathic systemic scleroderma. 1990 , 123, 1-7	10
1983	Silica-associated systemic sclerosis is clinically, serologically and immunologically indistinguishable from idiopathic systemic sclerosis. 1990 , 123, 725-34	82
1982	Cyclosporin A treatment of systemic sclerosis. 1990 , 122, 677-81	35
1981	Progressive systemic sclerosis in a child. 1990 , 29, 147-8	2
1980	Evaluation of transforming growth factor beta and type I procollagen gene expression in fibrotic skin diseases by in situ hybridization. 1990 , 94, 365-71	129

1979	Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquin, and mephenytoin. 1990 , 48, 286-95	45
1978	Non-invasive assessment of left ventricular diastolic function in patients with systemic sclerosis. 1990 , 228, 183-92	42
1977	Clinical associations of antiribonucleoprotein antibodies in patients with systemic lupus erythematosus. 1990 , 20, 164-73	59
1976	Scleroderma esophagus. 1990 , 5, 204-10	17
1975	Cytotoxic effects of sera from patients with systemic scleroderma: comparison of three different in vitro methods. 1990 , 10, 65-70	3
1974	Pulmonary hypertension in connective tissue disease. Clinical analysis of sixty patients in multi-institutional study. 1990 , 9, 56-62	39
1973	Penicillamine in systemic sclerosis: a reappraisal. 1990 , 9, 517-22	9
1972	The effects of scleroderma sera on endothelial cell survival in vitro. 1990 , 282, 516-9	4
1971	Antikinetochore and antitopoisomerase I antibodies in systemic scleroderma: comparative study using immunoblotted recombinant antigens, immunofluorescence, and double immunodiffusion. 1990 , 282, 76-83	14
1970	Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations. <i>Arthritis and Rheumatism</i> , 1990 , 33, 375-80	96
1969	Long-term immunomodulatory effects of T lymphocyte depletion in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1990 , 33, 511-9	19
1968	Association of scleroderma with a T cell antigen receptor gamma gene restriction fragment length polymorphism. <i>Arthritis and Rheumatism</i> , 1990 , 33, 569-73	13
1967	Secretion and binding of transforming growth factor beta by scleroderma and normal dermal fibroblasts. <i>Arthritis and Rheumatism</i> , 1990 , 33, 650-6	54
1966	Immunogenetic associations of scleroderma-related antinuclear antibodies. <i>Arthritis and Rheumatism</i> , 1990 , 33, 657-65	134
1965	Epitope patterns of anti-RNP antibodies in rheumatic diseases. Evidence for an antigen-driven autoimmune response. <i>Arthritis and Rheumatism</i> , 1990 , 33, 834-41	37
1964	In vitro identification of a subpopulation of fibroblasts that produces high levels of collagen in scleroderma patients. <i>Arthritis and Rheumatism</i> , 1990 , 33, 842-52	36
1963	Enhanced production of interleukin-1 and tumor necrosis factor alpha by cultured peripheral blood monocytes from patients with scleroderma. <i>Arthritis and Rheumatism</i> , 1990 , 33, 893-7	38
1962	Histologic and electron microscopic characterization of the antiperinuclear factor antigen. <i>Arthritis and Rheumatism</i> , 1990 , 33, 960-9	24

1961	The analysis of antinuclear and antinucleolar autoantibodies of scleroderma by radioimmunoprecipitation assays. <i>Arthritis and Rheumatism</i> , 1990 , 33, 1431-7	86
1960	Use of molecular cloning methods to map the distribution of epitopes on topoisomerase I (Scl-70) recognized by sera of scleroderma patients. <i>Arthritis and Rheumatism</i> , 1990 , 33, 1501-11	42
1959	Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1990 , 33, 1534-41	101
1958	The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. <i>Arthritis and Rheumatism</i> , 1990 , 33, 1601-10	867
1957	The post-occlusive hyperemic response in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1990 , 33, 1620-5	52
1956	Diffusing capacity of the lung and nifedipine in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1990 , 33, 1634-9	21
1955	Dermal mast cell degranulation in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1990 , 33, 1702-9	113
1954	Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1990 , 33, 1822-8	96
1953	Increased expression of type VI collagen genes in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1990 , 33, 1829-35	90
1952	Increased expression of intercellular adhesion molecule 1 on the fibroblasts of scleroderma patients. <i>Arthritis and Rheumatism</i> , 1990 , 33, 1847-51	44
1951	Effect of transcutaneous nerve stimulation on esophageal motility in patients with achalasia and scleroderma. 1990 , 25, 1018-23	13
1950	Sjögren's syndrome in systemic sclerosis. A clinical study of 26 patients. 1990 , 19, 57-65	19
1949	Antireticulin antibody in systemic sclerosis. 1990 , 49, 177-80	5
1948	The effect of local temperature versus sympathetic tone on digital perfusion in Raynaud's phenomenon. 1990 , 41, 715-23	13
1947	The frequency of cryoglobulinaemia in systemic sclerosis (scleroderma). 1990 , 29, 234	2
1946	Cyanosis and Raynaud's phenomenon: the relation to underlying disease and venous abnormalities. 1990 , 41, 432-8	6
1945	The brachial plexus tension test of Elvey. 1990 , 29, 234-5	2
1944	Muscle Involvement in the Scleroderma Syndromes. 1990 , 150, 2550	23

1943	Factor VIII related antigen in connective tissue disease patients and relatives. 1990 , 29, 6-9	17
1942	Lung disease associated with progressive systemic sclerosis. Assessment of interlobar variation by bronchoalveolar lavage and comparison with noninvasive evaluation of disease activity. 1990 , 141, 301-6	28
1941	Increase in activated T cells and reduction in suppressor inducer T cells in systemic sclerosis. 1990 , 49, 40-5	57
1940	Thyroid dysfunction in a prospectively followed series of patients with progressive systemic sclerosis. 1990 , 13, 161-9	44
1939	Clinical manifestations in anticardiolipin antibody-positive patients with progressive systemic sclerosis. 1990 , 23, 198-201	25
1938	Unusual cause of acute urinary tract infection in Muslim youths. 1990 , 335, 1095	4
1937	Silica-induced scleroderma. 1990 , 22, 444-8	95
1936	von Willebrand factor activity in primary and in scleroderma-associated Raynaud's phenomenon. 1990 , 335, 1095	2
1935	Clinical correlations of plasma angiotensin converting enzyme (ACE) activity in systemic sclerosis: a longitudinal study of plasma ACE level, endothelial injury and lung involvement. 1990 , 84, 283-7	29
1934	Observations in the potential role of transforming growth factor-beta in cutaneous fibrosis. Systemic sclerosis. 1990 , 593, 161-71	28
1933	The pulmonary pathologic manifestations of the CREST syndrome. 1990 , 21, 467-74	146
1932	Mitral regurgitation and diastolic flow profile in systemic sclerosis. 1990 , 29, 357-63	19
1931	Anaphylactic shock after game of squash in atopic woman with latex allergy. 1990 , 335, 1095	80
1930	Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon. 1990 , 336, 1530-3	94
1929	The effect of sympathetic blockade and cooling in Raynaud's phenomenon. 1990 , 10, 131-6	12
1928	Pulmonary diffusing capacity disturbances are related to nailfold capillary changes in patients with Raynaud's phenomenon with and without an underlying connective tissue disease. 1990 , 89, 34-41	25
1927	Progressive systemic sclerosis complicated by severe hypertension: reversal after silicone implant removal. 1990 , 89, 390-2	58
1926	Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. 1990 , 88, 470-6	192

1925	Capillary microscopy during eosinophilic fasciitis in 15 patients: distinction from systemic scleroderma. 1990 , 88, 598-600	19
1924	Expression of autoantibodies to recombinant (U1) RNP-associated 70K antigen in systemic lupus erythematosus. 1990 , 54, 266-80	25
1923	Autoantibodies to topoisomerase I (Scl-70): analysis by gel diffusion, immunoblot, and enzyme-linked immunosorbent assay. 1990 , 57, 399-410	38
1922	Soluble and cellular markers of immune activation in patients with systemic sclerosis. 1990 , 56, 259-70	33
1921	An antibody reacting with splenic red pulp macrophages in the sera of patients with rheumatic diseases. 1991 , 58, 217-35	8
1920	Soluble immunologic products in scleroderma sera. 1991 , 58, 139-44	31
1919	The effect of cisapride on gastro-oesophageal dysfunction in systemic sclerosis: a controlled manometric study. 1991 , 31, 683-7	40
1918	Anticardiolipin antibodies in systemic sclerosis. 1991 , 25, 133-4	6
1917	Fibrin and fibrinogen-related antigens in systemic sclerosis (scleroderma). 1991 , 25, 771-5	10
1916	Enteritis due to multiresistant enteroadherent Escherichia coli. 1991 , 337, 235-6	16
1915	Eosinophilic fasciitis associated with use of L-tryptophan: a case-control study and comparison of clinical and histopathologic features. 1991 , 66, 892-8	16
1914	Mitochondrial inclusions in neurons of Creutzfeldt-Jakob-like disease. 1991 , 337, 236-7	4
1913	Expression of class II-MHC antigens in the dermis of patients with progressive systemic sclerosis. 1991 , 182, 234-55	21
1912	Reply. 1991 , 25, 134	1
1911	Antibodies against central nervous system tissue (anti-CNS) detected by ELISA and western blotting: marker antibodies for neuropsychiatric manifestations in connective tissue diseases. 1991 , 10, 133-44	22
1910	Defects of the retinal pigment epithelium in scleroderma. 1991 , 30, 112-4	18
1909	Clinical aspects of systemic sclerosis (scleroderma). 1991 , 50 Suppl 4, 854-61	46
1908	Cardiopulmonary hemodynamics in systemic sclerosis and response to nifedipine and captopril. 1991 , 90, 541-546	19

1907	Childhood scleromyositis: an overlap syndrome associated with PM-Scl antibody. 1991 , 8, 1-8	35
1906	Immunologic markers of systemic scleroderma in children. 1991 , 8, 13-20	9
1905	Cardiopulmonary hemodynamics in systemic sclerosis and response to nifedipine and captopril. 1991 , 90, 541-546	28
1904	Evidence for peripheral impaired glucose handling in patients with connective tissue diseases. 1991 , 40, 902-7	47
1903	Altered T cell subpopulations and lymphocytes expressing natural killer cell phenotypes in patients with progressive systemic sclerosis. 1991 , 87, 773-9	25
1902	A method to differentiate between anti-C1q antibodies and C1q-binding immune complexes using collagenase-digested solid phase C1q. 1991 , 138, 165-71	7
1901	Endothelin-1 in patients with Raynaud's phenomenon. 1991 , 337, 236	21
1900	Round fingerpad sign: an early sign of scleroderma. 1991 , 24, 67-9	9
1899	Distal and proximal colon adenomas. 1991 , 114, 603-4	
1898	Interferon inhibitors. 1991 , 114, 606-7	3
1897	Resource center for occupational and environmental medicine. 1991 , 114, 607	
1896	Non-invasive assessment of systolic left ventricular function in systemic sclerosis. 1991 , 12, 151-6	20
1895	"Low-probability" ventilation-perfusion scans. 1991 , 114, 604-5	1
1894	AIDS and residency training. 1991 , 114, 605-6	1
1893	Iloprost for scleroderma. 1991 , 114, 606	4
1892	Evaluation of cardiac structures and function in systemic sclerosis by Doppler echocardiography. 1991 , 79, 165-71	15
1891	The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1991 , 4, 27-31	182
1890	Scleroderma hypertensive renal crisis and the changing pattern of mortality in systemic sclerosis (scleroderma). 1991 , 57, 111-2	5

1889	Local and central orthostatic sympathetic reflexes in Raynaud's phenomenon. 1991 , 51, 191-6	3
1888	Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease. 1991 , 68, 1687-91	62
1887	Classification of disease: osteoarthritis. 1991 , 20, 40-7	157
1886	Nodular regenerative hyperplasia of the liver in rheumatic diseases: report of seven cases and review of the literature. 1991 , 21, 47-54	53
1885	Lupus erythematosus in the 1980s: a survey of 570 patients. 1991 , 21, 55-64	324
1884	The scleroderma-like syndrome of insulin-dependent diabetes mellitus. 1991 , 7, 121-128	33
1883	Clinical correlations and prognosis based on hyaluronic acid serum levels in patients with progressive systemic sclerosis. 1991 , 124, 423-8	19
1882	Isotretinoin and lung function in systemic sclerosis. 1991 , 16, 11-3	11
1881	Antibodies to mouse laminin in patients with systemic sclerosis (scleroderma) recognize galactosyl (alpha 1-3)-galactose epitopes. 1991 , 86, 367-73	23
1880	Digital cutaneous vascular responses to histamine and neuropeptides in Raynaud's phenomenon. 1991 , 96, 314-7	21
1879	Steady-state mRNA levels of collagens I, III, fibronectin, and collagenase in skin biopsies of systemic sclerosis patients. 1991 , 97, 219-22	35
1878	Expression of intercellular adhesion molecule-1 (ICAM-1) in the skin of patients with systemic scleroderma. 1991 , 97, 667-71	46
1877	Drug-induced scleroderma. 1991 , 5, 13-20	7
1876	Non-invasive evaluation of long-term cardiac effects of captopril in systemic sclerosis. 1991 , 230, 203-12	15
1875	Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study. <i>Arthritis and Rheumatism</i> , 1991 , 34, 68-77	135
1874	The effect of nifedipine on myocardial perfusion and metabolism in systemic sclerosis. A positron emission tomographic study. <i>Arthritis and Rheumatism</i> , 1991 , 34, 198-203	52
1873	Association of the complement allele C4AQ0 with primary Sjögren's syndrome in Japanese patients. <i>Arthritis and Rheumatism</i> , 1991 , 34, 224-7	10
1872	Elevated plasma levels of endothelin-1 in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1991 , 34, 243-4	72

1871	Plasma levels of tissue-type plasminogen activator and von Willebrand factor in patients with Raynaud's phenomenon. <i>Arthritis and Rheumatism</i> , 1991 , 34, 255-6	7
1870	A double-blind randomized controlled trial of ketotifen versus placebo in early diffuse scleroderma. <i>Arthritis and Rheumatism</i> , 1991 , 34, 362-6	39
1869	Predictors of survival in systemic sclerosis (scleroderma). <i>Arthritis and Rheumatism</i> , 1991 , 34, 403-13	237
1868	Eosinophil activation in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1991 , 34, 414-22	47
1867	Association of immunoglobulin Km and Gm allotypes with specific antinuclear antibodies and disease susceptibility among connective tissue disease patients. <i>Arthritis and Rheumatism</i> , 1991 , 34, 453-8	48
1866	The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. <i>Arthritis and Rheumatism</i> , 1991 , 34, 505-14	1418
1865	Detection and quantification of human anti-Sm antibodies using synthetic peptide and recombinant SmB antigens. <i>Arthritis and Rheumatism</i> , 1991 , 34, 572-9	31
1864	Increased interleukin-2 production in response to human type I collagen stimulation in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1991 , 34, 580-7	21
1863	Human basophil releasability. VIII. Increased basophil releasability in patients with scleroderma. <i>Arthritis and Rheumatism</i> , 1991 , 34, 1289-96	24
1862	Manometric evaluation of esophageal function in progressive systemic sclerosis with special regard to the disease severity. 1991 , 26, 575-81	5
1861	Oropharyngeal and esophageal function in scleroderma. 1991 , 6, 219-23	46
1860	Diffuse systemic sclerosis and related diseases in Thailand. 1991 , 10, 124-9	25
1859	Neurological features in overlap syndrome. 1991 , 10, 5-9	13
1858	Osteopenia in systemic sclerosis. Evidence of a participating role of earlier menopause. 1991 , 10, 18-22	40
1857	Image analysis quantification of peptide-immunoreactive nerves in the skin of patients with Raynaud's phenomenon and systemic sclerosis. 1991 , 164, 245-52	61
1856	Transcutaneous oxygen pressure in systemic sclerosis: evaluation at different sensor temperatures and relationship to skin perfusion. 1991 , 283, 285-8	11
1855	Response of scleroderma fibroblasts to various growth factors. 1991 , 283, 461-4	17
1854	Epidemiological study of patients with systemic sclerosis in Tokyo. 1991 , 283, 366-71	104

1853	Idiopathic and L-Tryptophan-Associated Eosinophilic Fasciitis Before and After L-Tryptophan Contamination. 1991 , 127, 1159	31
1852	Review of UK data on the rheumatic diseases--9. Scleroderma. 1991 , 30, 365-7	4
1851	A controlled study of stanozolol in primary Raynaud's phenomenon and systemic sclerosis. 1991 , 50, 41-7	21
1850	A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. 1991 , 50, 800-4	46
1849	Primary Sjögren's syndrome in north east England--a longitudinal study. 1991 , 30, 437-42	58
1848	Mixed connective tissue disease, overlap syndromes, and eosinophilic fasciitis. 1991 , 50 Suppl 4, 887-93	25
1847	Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. 1991 , 325, 1461-7	324
1846	Retrospective comparison of iloprost with other treatments for secondary Raynaud's phenomenon. 1991 , 50, 359-61	11
1845	Markers of collagen and basement membrane metabolism in sera of patients with progressive systemic sclerosis. 1991 , 50, 481-6	16
1844	Acquired factor VIII deficiency and polyradiculoneuropathy. 1991 , 324, 1139	43
1843	Structural features of interstitial lung disease in systemic sclerosis. 1991 , 144, 706-13	215
1842	Scleroderma and survival. 1991 , 50, 267-9	31
1841	Increased concentrations of soluble interleukin-2 receptor in the serum of patients with systemic sclerosis. 1991 , 50, 270-1	4
1840	Abnormalities of T lymphocyte subsets in systemic sclerosis demonstrated with anti-CD45RA and anti-CD29 monoclonal antibodies. 1991 , 50, 354-8	16
1839	Raynaud's phenomenon: its relevance to scleroderma. 1991 , 50 Suppl 4, 839-45	35
1838	Cold-induced changes in plasma norepinephrine, epinephrine and dopamine concentrations in patients with Raynaud's phenomenon. 1991 , 29, 111-4	4
1837	Epidemiology of scleroderma. 1991 , 50 Suppl 4, 846-53	50
1836	Clinical significance of serum levels of a carbohydrate antigen, sialyl SSEA-1, in patients with fibrosing lung disease. 1991 , 144, 1177-81	19

1835	Long-term evaluation of penicillamine or cyclofenil in systemic sclerosis. Results from a two-year randomized study. 1992 , 21, 238-44	12
1834	Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. 1992 , 42, 60-3	223
1833	Serum masks the inhibition of thrombin-induced prostacyclin release produced by anticardiolipin antibodies. 1992 , 31, 179-83	5
1832	Capillary Abnormalities, Raynaud's Phenomenon, and Systemic Sclerosis in Patients With Localized Scleroderma. 1992 , 128, 630	28
1831	The evolution of a case of overlap syndrome with systemic sclerosis, rheumatoid arthritis and systemic lupus erythematosus. 1992 , 31, 783-6	13
1830	Evaluation of the severity of systemic sclerosis by nailfold capillary microscopy in 112 patients. 1992 , 43, 203-10	21
1829	Reliability of skin involvement measures in scleroderma. The UK Scleroderma Study Group. 1992 , 31, 457-60	65
1828	Outcome of patients with systemic rheumatic disease admitted to medical intensive care units. 1992 , 51, 627-31	41
1827	Interstitial pulmonary fibrosis with and without associated collagen vascular disease: results of a two year follow up. 1992 , 47, 1035-40	52
1826	Nervous system disease, immunological features, and HLA phenotype in Sjögren's syndrome. 1992 , 51, 506-9	4
1825	Values Listed in Incorrect Columns. 1992 , 128, 632	2
1824	Evidence for the association of unexplained pulmonary hypertension in children with the major histocompatibility complex. 1992 , 85, 249-58	38
1823	Localized scleroderma and hemiatrophy in association with antibodies to double-stranded DNA. 1992 , 68, 216-8	16
1822	Treatment of Raynaud's phenomenon with triiodothyronine corrects co-existent autonomic dysfunction: preliminary findings. 1992 , 68, 263-7	2
1821	High resolution computed tomography as a predictor of lung histology in systemic sclerosis. 1992 , 47, 738-42	111
1820	High resolution computed tomography as a predictor of lung histology in systemic sclerosis. 1992 , 47, 508-512	22
1819	Dietary intake and nutritional status in patients with systemic sclerosis. 1992 , 51, 1143-8	61
1818	Chromosome studies in systemic sclerosis with consideration of antibodies to topoisomerase I. 1992 , 51, 624-6	2

1817	Microalbuminuria in systemic sclerosis. 1992 , 51, 384-8	15
1816	HLA alleles in systemic sclerosis: association with pulmonary hypertension and outcome. 1992 , 31, 609-13	30
1815	Comparative studies of esophageal function in systemic sclerosis. 1992 , 102, 1551-6	41
1814	Carpal tunnel syndrome and systemic sclerosis. 1992 , 185, 101-3	22
1813	Serum levels of soluble interleukin-2 receptor in systemic and circumscribed scleroderma. 1992 , 184, 233-4	2
1812	Short- and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease. 1992 , 102, 1407-12	63
1811	Small airways dysfunction in systemic sclerosis. A controlled study. 1992 , 102, 875-81	13
1810	Serum levels of aminoterminal type III procollagen peptide and hyaluronan predict mortality in systemic sclerosis. 1992 , 21, 5-9	34
1809	Clinical utility of non invasive methods in the evaluation of scleroderma lung in pediatric age. 1992 , 21, 82-4	6
1808	Mortality in Systemic Sclerosis (Scleroderma). 1992 ,	
1807	Cardiac involvement in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1992 , 35, 1356-61	24
1806	Enlarged mediastinal lymph nodes in the fibrosing alveolitis of systemic sclerosis. 1992 , 65, 983-6	25
1805	Expression of adhesion proteins involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis. 1992 , 27, 169-77	67
1804	Serum adenosine deaminase activity in systemic sclerosis (scleroderma) and related disorders. 1992 , 27, 411-4	12
1803	Scleroderma/polymyositis overlap syndromes and their immunologic markers. 1992 , 10, 457-72	17
1802	Increased interleukin 1 receptor, type I, at messenger RNA and protein level in skin fibroblasts from patients with systemic sclerosis. 1992 , 184, 1504-10	20
1801	Enhanced expression of high-affinity interleukin-2 receptors in scleroderma: possible role for IL-6. 1992 , 62, 97-102	11
1800	Presence of autoantibodies to peptidyl-prolyl cis-trans isomerase (cyclosporin A-binding protein) in systemic lupus erythematosus. 1992 , 63, 58-65	11

1799	Cytokine production and serum levels in systemic sclerosis. 1992 , 65, 278-85	47
1798	Decreased monocyte-mediated angiogenesis in scleroderma. 1992 , 64, 153-60	19
1797	Clinical relevance of immunologic findings in scleroderma. 1992 , 10, 407-21	8
1796	Antinuclear autoantibodies in women with silicone breast implants. 1992 , 340, 1304-7	108
1795	Autonomic dysfunction in systemic sclerosis: sympathetic overactivity and instability. 1992 , 93, 143-50	80
1794	Pulmonary function in systemic lupus erythematosus is related to distinct clinical, serologic, and nailfold capillary patterns. 1992 , 93, 619-27	51
1793	Transforming growth factor beta within fibrotic scleroderma lungs. 1992 , 93, 628-36	22
1792	Initial predictors of survival in patients with systemic sclerosis (scleroderma). 1992 , 41, 141-5	14
1791	B-cell epitopes of scleroderma-specific autoantigens. 1992 , 16, 183-9	15
1790	Analysis of an immunodominant epitope of topoisomerase I in patients with systemic sclerosis. 1992 , 16, 117-23	15
1789	A long-term longitudinal isotypic study of anti-topoisomerase I autoantibodies. 1993 , 12, 231-4	22
1788	Clinical evaluation of scleroderma spectrum disorders using a points system. 1992 , 284, 391-5	49
1787	Sequential dermal microvascular and perivascular changes in the development of scleroderma. 1992 , 166, 255-63	294
1786	Increased adhesion of fibroblasts from patients with scleroderma to extracellular matrix components: in vitro modulation by IFN-gamma but not by TGF-beta. 1992 , 98, 86-91	15
1785	Relaxin alone and in conjunction with interferon-gamma decreases collagen synthesis by cultured human scleroderma fibroblasts. 1992 , 99, 337-42	54
1784	Systemic sclerosis sine scleroderma presenting with vitiligo-like depigmentation and interstitial pulmonary fibrosis. 1992 , 17, 127-31	14
1783	Nodular (keloidal) scleroderma. 1992 , 31, 422-3	23
1782	Scleroderma and the kidney. 1992 , 41, 462-77	37

1781	Prolonged clearance is the primary abnormal reflux parameter in patients with progressive systemic sclerosis and esophagitis. 1992 , 37, 833-41	41
1780	Long-term follow-up study of 164 patients with definite systemic sclerosis: classification considerations. 1992 , 11, 356-63	13
1779	Pulmonary hypertension in MCTD: report of two cases with anticardiolipin antibody. 1992 , 11, 195-201	9
1778	Prevalence of anti-endothelial cell antibodies in patients with autoimmune diseases. 1992 , 11, 248-53	10
1777	High resolution computed tomography in systemic sclerosis. Real diagnostic utilities in the assessment of pulmonary involvement and comparison with other modalities of lung investigation. 1992 , 11, 465-72	27
1776	Systemic sclerosis in the elderly. 1992 , 11, 483-5	23
1775	Prognostic significance of nailfold capillary microscopy in patients with Raynaud's phenomenon and scleroderma-pattern abnormalities. A six-year follow-up study. 1992 , 11, 536-41	51
1774	HLA-DPB1*0401 is associated with the presence of autoantibodies reactive with the U1-70 kD polypeptide antigen of U1-small nuclear ribonucleoprotein among connective tissue disease patients. 1992 , 39, 272-5	13
1773	HLA-DPB1 alleles and autoantibody subsets in systemic lupus erythematosus, Sjögren's syndrome and progressive systemic sclerosis: a question of disease relevance. 1992 , 40, 45-8	29
1772	Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. <i>Arthritis and Rheumatism</i> , 1992 , 35, 67-72	273
1771	Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1992 , 35, 95-100	173
1770	Racial differences in the frequencies of scleroderma-related autoantibodies. <i>Arthritis and Rheumatism</i> , 1992 , 35, 216-8	60
1769	Elevated expression of beta 1 and beta 2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. <i>Arthritis and Rheumatism</i> , 1992 , 35, 290-8	83
1768	Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inflammatory muscle disease. <i>Arthritis and Rheumatism</i> , 1992 , 35, 449-56	108
1767	Phenotypic and functional similarities between 5-azacytidine-treated T cells and a T cell subset in patients with active systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1992 , 35, 647-62	160
1766	Detection and quantification of anti-Ki antibodies by enzyme-linked immunosorbent assay using recombinant Ki antigen. <i>Arthritis and Rheumatism</i> , 1992 , 35, 667-71	17
1765	Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1992 , 35, 688-93	148
1764	Lymphokine-activated killer cell and natural killer cell activities in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1992 , 35, 694-9	18

1763	Association of anti-topoisomerase I with cancer. <i>Arthritis and Rheumatism</i> , 1992 , 35, 724	40
1762	Isolated diffusing capacity reduction in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1992 , 35, 765-70	191
1761	Adhesion of peripheral blood mononuclear cells to vascular endothelium in patients with systemic sclerosis (scleroderma). <i>Arthritis and Rheumatism</i> , 1992 , 35, 771-5	20
1760	Mast cell changes in scleroderma. Presence of MCT cells in the skin and evidence of mast cell activation. <i>Arthritis and Rheumatism</i> , 1992 , 35, 933-9	65
1759	Anti-interleukin-6 autoantibodies in rheumatic diseases. Increased frequency in the sera of patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1992 , 35, 940-3	47
1758	T cell receptor V beta repertoire of double-negative alpha/beta T cells in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1992 , 35, 944-8	24
1757	Treatment of systemic sclerosis with recombinant interferon-gamma. A phase I/II clinical trial. <i>Arthritis and Rheumatism</i> , 1992 , 35, 1134-42	70
1756	Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. <i>Arthritis and Rheumatism</i> , 1992 , 35, 1211-7	169
1755	Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. <i>Arthritis and Rheumatism</i> , 1993 , 36, 340-7	1275
1754	Localized scleroderma progressing to systemic disease. Case report and review of the literature. <i>Arthritis and Rheumatism</i> , 1993 , 36, 410-5	51
1753	Cancer in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1993 , 36, 460-4	137
1752	Gastrointestinal regulatory peptides in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1993 , 36, 698-703	20
1751	A molecular and serologic analysis of the major histocompatibility complex and complement component C4 in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1993 , 36, 943-54	39
1750	Antihistone antibodies in patients with localized scleroderma. <i>Arthritis and Rheumatism</i> , 1993 , 36, 1137-41	136
1749	Connective tissue activation. XXXVI. The origin, variety, distribution, and biologic fate of connective tissue activating peptide-III isoforms: characteristics in patients with rheumatic, renal, and arterial disease. <i>Arthritis and Rheumatism</i> , 1993 , 36, 1142-53	22
1748	Frequencies of scleroderma-related autoantibodies in patients meeting the American Collage of Rheumatology criteria for system sclerosis:replay. <i>Arthritis and Rheumatism</i> , 1993 , 36, 1333-1334	13
1747	Predictors of psychosocial adjustment in systemic sclerosis. The influence of formal education level, functional ability, hardiness, uncertainty, and social support. <i>Arthritis and Rheumatism</i> , 1993 , 36, 1398-405	35
1746	Autoantigenic epitopes on DNA topoisomerase I. Clinical and immunogenetic associations in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1993 , 36, 1406-13	43

1745	The course of skin involvement in systemic sclerosis over three years in a trial of chlorambucil versus placebo. <i>Arthritis and Rheumatism</i> , 1993 , 36, 1575-9	32
1744	Isolated congenital heart block. Long-term outcome of mothers and characterization of the immune response to SS-A/Ro and to SS-B/La. <i>Arthritis and Rheumatism</i> , 1993 , 36, 1588-98	122
1743	Cutaneous signs (Raynaud's phenomenon, sclerodactylia, and edema of the hands) and hand-arm vibration exposure. 1993 , 64, 587-91	19
1742	Effects of tumor necrosis factor-alpha on connective tissue metabolism in normal and scleroderma fibroblast cultures. 1993 , 284, 440-4	19
1741	Asymptomatic cerebral involvement in Sjögren's syndrome: MRI findings of 15 cases. 1993 , 35, 378-80	118
1740	Anti-"dividing cell antigen" autoantibody: a novel antinuclear antibody pattern related to histones in systemic lupus erythematosus. 1993 , 13, 329-38	7
1739	Extracorporeal photochemotherapy in progressive systemic sclerosis. 1993 , 32, 417-21	36
1738	Investigation of basophil cell proteinase release in progressive systemic sclerosis. 1993 , 48, 164-7	
1737	The vascular basement membrane in systemic sclerosis skin: heterogeneity of type IV collagen. 1993 , 129, 384-8	12
1736	Systemic sclerosis terminating as systemic necrotizing angiitis. 1993 , 129, 736-8	9
1735	The HLA-DP locus in systemic sclerosis--no primary association. 1993 , 42, 144-5	6
1734	Outcome measurement in scleroderma clinical trials. 1993 , 23, 22-33	36
1733	Survival analysis of 118 patients with systemic sclerosis. 1993 , 234, 335-7	23
1732	Easy detection of mutations in acute intermittent porphyria and hepatocellular carcinoma on paraffin-embedded tissue. 1993 , 234, 339-40	5
1731	Anorectal dysfunction and delayed colonic transit in patients with progressive systemic sclerosis. 1993 , 38, 1525-9	39
1730	The complement system and systemic sclerosis. 1993 , 12, 312-6	15
1729	Myocarditis as a complication in scleroderma patients with myositis. 1993 , 16, 895-9	30
1728	Acute and chronic upper extremity ischemia. II. Small vessel arterial occlusive disease. 1993 , 7, 195-9	4

1727	Echocardiographic findings in patients with primary Sjögren's syndrome. 1993 , 12, 214-8	21
1726	Plasma concentration of human atrial natriuretic hormone in patients with connective tissue diseases. 1993 , 12, 231-5	8
1725	Soluble CD4 and CD8 molecules in patients with systemic sclerosis. 1993 , 12, 490-3	2
1724	Complete saturation of protamine sulphate by dsDNA is necessary in order to obtain a highly sensitive and specific anti-dsDNA ELISA. 1993 , 160, 245-52	2
1723	Antibodies to the constitutive 73-kd heat shock protein: a new marker of mixed connective tissue disease?. 1993 , 95, 595-600	13
1722	Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. 1993 , 125, 194-203	160
1721	Autoantibody to the nuclear antigen RA33: a marker for early rheumatoid arthritis. 1993 , 32, 199-203	56
1720	Elevated serum soluble interleukin-2 receptor levels in subacute cutaneous lupus erythematosus. 1993 , 5, 143-9	5
1719	Use of a durometer to assess skin hardness. 1993 , 29, 47-51	142
1718	[Development of an immunoenzyme assay technique of ELISA type for detecting anti-SSB antibodies. Comparative study of 2 kits]. 1993 , 14, 288-93	1
1717	Natural history of dysplastic nevi. 1993 , 29, 51-7	91
1716	Systemic sclerosis. 1993 , 28, 525-47	45
1715	Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon. 1993 , 342, 80-3	67
1714	Autoantibodies against topoisomerase I detected with the natural enzyme and overlapping recombinant peptides. 1993 , 165, 241-52	14
1713	Expression of c-myc, c-myb, and c-sis in fibroblasts from affected and unaffected skin of patients with systemic sclerosis. 1993 , 16, 167-71	10
1712	Oxidative DNA damage and cellular sensitivity to oxidative stress in human autoimmune diseases. 1993 , 52, 659-66	184
1711	Relationship between autoantibodies and clinical parameters in Sjögren's syndrome. 1993 , 22, 1-9	18
1710	Progressive systemic sclerosis sine scleroderma in a child presenting as nocturnal seizures and Raynaud's phenomenon. 1993 , 82, 122-3	16

1709	Multiple clinical and biological autoimmune manifestations in 50 workers after occupational exposure to silica. 1993 , 52, 534-8	108
1708	Anticentromere antibodies in subjects with no apparent connective tissue disease. 1993 , 52, 586-9	21
1707	Occurrence of autoimmune diseases and relationship of autoantibody expression with HLA phenotypes in multicase rheumatoid arthritis families. 1993 , 22, 152-7	16
1706	Baseline plasma fibrinolysis and its correlation with clinical manifestations in patients with Raynaud's phenomenon. 1993 , 52, 443-8	17
1705	Increased whole blood platelet aggregation in patients with Raynaud's phenomenon with or without systemic sclerosis. 1993 , 22, 97-101	30
1704	More evidence of distinctive features of mixed connective tissue disease. 1993 , 22, 63-8	30
1703	Patients with anticentromere antibodies, clinical features, diagnoses and evolution. 1993 , 32, 297-301	57
1702	The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. 1993 , 148, 1076-82	188
1701	Mast cells' contribution to the fibrosing alveolitis of the scleroderma lung. 1993 , 147, 1497-502	60
1700	Analysis of the outcome of idiopathic inflammatory myopathies with particular emphasis on muscle capillary damage. 1993 , 22, 292-8	5
1699	Antinuclear antibodies in routine analysis: the relevance of putative clinical associations. 1993 , 52, 110-4	15
1698	Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity. 1993 , 52, 272-7	49
1697	Effects of methotrexate on glycosaminoglycan production by scleroderma fibroblasts in culture. 1993 , 52, 758-61	10
1696	Labial capillary microscopy in systemic sclerosis. 1993 , 52, 564-9	30
1695	Reliability of skin score in scleroderma. 1993 , 32, 170	5
1694	Acid clearance and oesophageal sensitivity in patients with progressive systemic sclerosis. 1993 , 34, 1487-91	19
1693	Early pulmonary disease in systemic sclerosis: a comparison between carbon monoxide transfer factor and static lung compliance. 1993 , 52, 725-9	10
1692	Left ventricular wall thickness and disease duration in systemic sclerosis. 1993 , 69, 285-90	7

1691	Autoantibody reactive with RNA polymerase III in systemic sclerosis. 1993 , 119, 1005-13	157
1690	Coexistence of morphea and systemic sclerosis. 1993 , 186, 103-5	37
1689	Incidental epidermolytic hyperkeratosis in progressive systemic sclerosis. 1993 , 20, 178-9	4
1688	Activation of Dermal Connective Tissue in Scleroderma. 1993 , 25, 511-518	50
1687	Interstitial lung disease and myositis in a patient with simultaneously occurring sarcoidosis and scleroderma. 1993 , 104, 1298-300	12
1686	A clinical and immunologic evaluation of women with silicone breast implants and symptoms of rheumatic disease. 1993 , 118, 929-36	116
1685	Mediastinal lymphadenopathy preceding skin and lung fibrosis in systemic sclerosis. 1994 , 61, 169-71	1
1684	Effect of erythromycin administration on upper gastrointestinal motility in scleroderma patients. 1994 , 29, 807-13	39
1683	Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance. 1994 , 150, 462-8	90
1682	Long-term thymopentin treatment in systemic scleroderma. 1994 , 13, 195-201	1
1681	Association of anti-U1RNP- and anti-Scl-70-antibodies with neurological manifestations in systemic sclerosis (scleroderma). 1994 , 23, 64-7	26
1680	Functional study of the dermal microcirculation in systemic sclerosis. 1994 , 23, 73-6	7
1679	Increased frequency of in vivo hprt gene-mutated T cells in the peripheral blood of patients with systemic sclerosis. 1994 , 53, 122-7	16
1678	Phenotypic and functional activation of alveolar macrophages, T lymphocytes and NK cells in patients with systemic sclerosis and primary Sjögren's syndrome. 1994 , 53, 574-9	26
1677	Increased mitogenic activity of scleroderma serum: inhibitory effect of human recombinant interferon-gamma. 1994 , 53, 776-9	3
1676	Activation of peripheral blood mononuclear cells in bronchoalveolar lavage fluid from patients with sarcoidosis: visualisation of single cell activation products. 1994 , 49, 1146-51	3
1675	Increase of pulmonary diffusing capacity in systemic sclerosis. 1994 , 33, 437-41	5
1674	Significance of anti-entactin antibodies in patients with systemic lupus erythematosus and related disorders. 1994 , 53, 659-65	6

1673	Imaging of pulmonary disease in scleroderma with J001X scintigraphy. 1994 , 49, 504-8	9
1672	The European Community Study Group on diagnostic criteria for Sjögren's syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren's syndrome. 1994 , 53, 637-47	240
1671	Vasculitis in patients with systemic sclerosis and severe digital ischaemia requiring amputation. 1994 , 53, 323-6	38
1670	Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. 1994 , 149, 1583-90	223
1669	Risk of connective-tissue diseases and other disorders after breast implantation. 1994 , 330, 1697-702	382
1668	Anticardiolipin, anticentromere and anti-Scl-70 antibodies in patients with systemic sclerosis and severe digital ischaemia. 1994 , 53, 540-2	43
1667	Anti-Ro(SS-A) autoantibodies in central nervous system disease associated with Sjögren's syndrome (CNS-SS): clinical, neuroimaging, and angiographic correlates. 1994 , 44, 899-908	118
1666	Interleukin-8 and neutrophils in systemic sclerosis with lung involvement. 1994 , 150, 1363-7	30
1665	Rheumatic Disease Among 1167 Women Reporting Local Implant and Systemic Problems After Breast Implant Surgery. 1994 , 3, 165-177	4
1664	Von Willebrand factor antigen in assessment of vasculitis in patients with connective tissue diseases. 1994 , 13, 34-8	7
1663	Clinical correlation of anticentromere antibodies. 1994 , 13, 427-32	13
1662	Detection of anti-double and anti-single stranded DNA antibodies in chronic liver disease: significance of anti-double stranded DNA antibody in autoimmune hepatitis. 1994 , 29, 152-8	13
1661	Coxsackievirus infection and the development of polymyositis/dermatomyositis. 1994 , 14, 43-6	15
1660	Intravenous dexamethasone pulse therapy in diffuse systemic sclerosis. A randomized placebo-controlled study. 1994 , 14, 91-4	39
1659	Serum concentration of procollagen type I carboxyterminal propeptide in systemic sclerosis. 1994 , 286, 77-80	18
1658	Long-term manometry of tubular esophagus in progressive systemic sclerosis. 1994 , 72, 343-9	4
1657	P-31 MR spectroscopy of skeletal and cardiac muscle metabolism in patients with systemic sclerosis: a multiple case study. 1994 , 4, 165-8	8
1656	Abnormalities of renal physiology in systemic sclerosis. A prospective study with 10-year followup. <i>Arthritis and Rheumatism</i> , 1994 , 37, 67-74	36

1655	Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1994 , 37, 75-83	221
1654	Silicone breast implants and rheumatic disease. Clinical, immunologic, and epidemiologic studies. <i>Arthritis and Rheumatism</i> , 1994 , 37, 158-68	88
1653	Anticentromere autoantibodies. Evaluation of an ELISA using recombinant fusion protein CENP-B as antigen. <i>Arthritis and Rheumatism</i> , 1994 , 37, 248-52	29
1652	Effects of peripheral cold exposure on microvascular dynamics in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1994 , 37, 384-90	17
1651	Antihistone antibodies in systemic sclerosis. Association with pulmonary fibrosis. <i>Arthritis and Rheumatism</i> , 1994 , 37, 391-4	104
1650	Xerostomia in systemic sclerosis: systematic evaluation by salivary scintigraphy and lip biopsy in thirty-four patients. <i>Arthritis and Rheumatism</i> , 1994 , 37, 439-41	15
1649	Criteria for rheumatic disease. Different types and different functions. The American College of Rheumatology Diagnostic and Therapeutic Criteria Committee. <i>Arthritis and Rheumatism</i> , 1994 , 37, 454-62	96
1648	Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. <i>Arthritis and Rheumatism</i> , 1994 , 37, 729-35	130
1647	Application of neural networks to the classification of giant cell arteritis. <i>Arthritis and Rheumatism</i> , 1994 , 37, 760-70	31
1646	Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies. <i>Arthritis and Rheumatism</i> , 1994 , 37, 902-6	104
1645	Anti-topoisomerase I antibodies in silica-associated systemic sclerosis. A model for autoimmunity. <i>Arthritis and Rheumatism</i> , 1994 , 37, 1198-205	38
1644	Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. <i>Arthritis and Rheumatism</i> , 1994 , 37, 1528-33	76
1643	Interferon-gamma-inducible protein p16. A new target of antinuclear antibodies in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1994 , 37, 1672-83	48
1642	Expression and shedding of intercellular adhesion molecule 1 and lymphocyte function-associated antigen 3 by normal and scleroderma fibroblasts. Effects of interferon-gamma, tumor necrosis factor alpha, and estrogen. <i>Arthritis and Rheumatism</i> , 1994 , 37, 1689-97	41
1641	Analysis of the oral manifestations of systemic sclerosis. 1994 , 77, 141-6	59
1640	Gastrointestinal manifestations of systemic sclerosis. 1994 , 24, 29-39	100
1639	Serial nailfold capillary microscopy in primary Raynaud's phenomenon and scleroderma. 1994 , 24, 40-7	23
1638	Gastrointestinal transit through esophagus, stomach, small and large intestine in patients with progressive systemic sclerosis. 1994 , 39, 2209-15	60

- 1637 Anticytoskeletal antibodies in systemic autoimmune diseases. **1994**, 3, 31-35
- 1636 Disaccharide analysis of the skin glycosaminoglycans in patients with Werner's syndrome. **1994**, 19, 487-91 8
- 1635 Sclerodermatous syndrome after occupational exposure to herbicides--response to systemic steroids. **1994**, 19, 518-20 18
- 1634 Screening for autoantibodies to the nucleolar U3- and Th(7-2) ribonucleoproteins in patients' sera using antisense riboprobes. **1994**, 169, 173-82 21
- 1633 Atrial natriuretic peptide: relation to left ventricular filling properties in patients with systemic sclerosis. **1994**, 47, 151-6 2
- 1632 Severe systemic sclerosis with anti-topoisomerase I antibodies is associated with an HLA-DRw11 allele. **1994**, 40, 101-10 42
- 1631 Scleroderma and augmentation mammoplasty--a causal relationship?. **1994**, 24, 74-80 57
- 1630 The skin in systemic sclerosis. **1994**, 12, 229-36 4
- 1629 Increased levels of circulating intercellular adhesion molecule-1 in patients with localized scleroderma. **1994**, 31, 591-5 36
- 1628 Observer variation in pattern type and extent of disease in fibrosing alveolitis on thin section computed tomography and chest radiography. **1994**, 49, 236-40 89
- 1627 High-resolution CT and pulmonary function tests in collagen vascular disease: comparison with idiopathic pulmonary fibrosis. **1994**, 18, 113-21 19
- 1626 Classification of scleroderma. **1994**, 12, 225-8 3
- 1625 Classification of systemic sclerosis. **1994**, 12, 217-23 8
- 1624 Epidemiology of systemic sclerosis. **1994**, 12, 207-16 41
- 1623 Environmental scleroderma. **1994**, 12, 467-73 44
- 1622 Ischaemia of the small intestine in patients with systemic sclerosis: Raynaud's phenomenon or chronic vasculopathy?. **1994**, 1 1
- 1621 Quantification of Ca(2+)-ATPase in erythrocytes from subjects with essential hypertension or Raynaud's phenomenon. **1994**, 7, 90-5 3
- 1620 Control of IL-6 expression and response in fibroblasts from patients with systemic sclerosis. **1994**, 17, 309-18 42

1619	Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. 1994 , 120, 199-206	272
1618	Interrelationships between pulmonary and extrapulmonary involvement in systemic sclerosis. A longitudinal analysis. 1994 , 105, 489-95	17
1617	Interleukin 6 secretion by monocytes and alveolar macrophages in systemic sclerosis with lung involvement. 1994 , 149, 1260-5	42
1616	Concurrent validity of the Health Assessment Questionnaire Disability Index in Scleroderma. <i>Arthritis and Rheumatism</i> , 1995 , 8, 189-93	50
1615	Fibrosing alveolitis in systemic sclerosis: increase in memory T-cells in lung interstitium. 1995 , 8, 266-71	47
1614	Image analysis of nailfold capillaries in patients with undifferentiated connective tissue syndromes. 1995 , 22, 921-5	5
1613	Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. 1995 , 270, 3423-8	107
1612	Cardiac involvement in collagen diseases. 1995 , 16, 257-62	20
1611	Silica-associated connective tissue disease. A study of 24 cases. 1995 , 74, 221-37	71
1610	Scleroderma in children. 1995 , 42, 1171-203	36
1609	Myocardial gallium-67 citrate scintigraphy in patients with systemic sclerosis. 1995 , 54, 856-8	9
1608	Elevated procollagen type I carboxyterminal propeptide production in cultured scleroderma fibroblasts. 1995 , 190, 104-8	5
1607	Abnormal ventricular long-axis function in systemic sclerosis. 1995 , 108, 1533-40	33
1606	Scleroderma. 1995 , 9, 471-82	8
1605	Inflammatory myopathies. 1995 , 9, 497-514	12
1604	Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. <i>Arthritis and Rheumatism</i> , 1995 , 38, 184-9	121
1603	Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. <i>Arthritis and Rheumatism</i> , 1995 , 38, 351-60	101
1602	Major histocompatibility complex class II gene associations with anti-U1 small nuclear ribonucleoprotein antibody. Relationship to immunoreactivity with individual constituent proteins. <i>Arthritis and Rheumatism</i> , 1995 , 38, 396-405	21

1601	Cross-linked elastin and collagen degradation products in the urine of patients with scleroderma. <i>Arthritis and Rheumatism</i> , 1995 , 38, 517-24	25
1600	Selection of study population in the development of rheumatic disease criteria: comment on the article by the American College of Rheumatology Diagnostic and Therapeutic Criteria Committee. <i>Arthritis and Rheumatism</i> , 1995 , 38, 722-3	4
1599	Autoimmune response to the spliceosome. An immunologic link between rheumatoid arthritis, mixed connective tissue disease, and systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1995 , 38, 777-85	107
1598	Elevated levels of eosinophil major basic protein in the sera of patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1995 , 38, 939-45	21
1597	Autoantibodies to pyruvate dehydrogenase complex in patients with systemic sclerosis. Possible role of anti-E1 alpha antibody as a serologic indicator for development of primary biliary cirrhosis. <i>Arthritis and Rheumatism</i> , 1995 , 38, 985-9	20
1596	Lack of association between antihistone antibodies and pulmonary fibrosis in patients with systemic sclerosis: comment on the article by Sato et al. <i>Arthritis and Rheumatism</i> , 1995 , 38, 1024-5	2
1595	Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1995 , 38, 1060-7	75
1594	The major dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved in transcriptional activation. <i>Arthritis and Rheumatism</i> , 1995 , 38, 1389-99	117
1593	Antibody reactivity to the HRES-1 endogenous retroviral element identifies a subset of patients with systemic lupus erythematosus and overlap syndromes. Correlation with antinuclear antibodies and HLA class II alleles. <i>Arthritis and Rheumatism</i> , 1995 , 38, 1660-71	87
1592	Segregation of autoantibodies with disease in monozygotic twin pairs discordant for systemic sclerosis. Three further cases. <i>Arthritis and Rheumatism</i> , 1995 , 38, 1845-50	12
1591	Reduced bone mass and normal calcium metabolism in systemic sclerosis with and without calcinosis. 1995 , 14, 407-12	42
1590	High resolution computed tomography for the evaluation of lung involvement in 101 patients with scleroderma. 1995 , 14, 633-40	20
1589	Silicone breast implant--associated musculoskeletal manifestations. 1995 , 14, 667-72	38
1588	Left ventricular wall motion abnormalities in 80 patients with systemic sclerosis. 1995 , 14, 161-4	17
1587	High prevalence of activated protein C resistance in patients with systemic sclerosis. 1995 , 25, 226-7	6
1586	Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. 1995 , 287, 193-7	97
1585	Autoantibodies to the heat-shock protein hsp73 in localized scleroderma. 1995 , 287, 581-5	12
1584	Functional explanation for increased atrial natriuretic peptide in systemic sclerosis. 1995 , 18, 647-52	3

1583	Analysis of randomness of atrial and ventricular rhythm in atrial fibrillation. 1995 , 16, 971-6	7
1582	Lack of natural killer cell augmentation in vitro by human interferon gamma in a subset of patients with systemic sclerosis. 1995 , 63, 288-92	4
1581	Clinical significance of anticardiolipin antibodies in patients with systemic sclerosis. 1995 , 20, 1-7	24
1580	Anti-neutrophil cytoplasm antibodies in patients with ACR criteria for polyarteritis nodosa: help for systemic vasculitis classification?. 1995 , 20, 33-7	7
1579	HLA class II genes associated with anticentromere antibody in Japanese patients with systemic sclerosis (scleroderma). 1995 , 54, 983-7	29
1578	Growth regulation in scleroderma fibroblasts: increased response to transforming growth factor-beta 1. 1995 , 105, 128-32	77
1577	Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. 1995 , 105, 280-4	216
1576	Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 24-1995. A 46-year-old woman with dermatomyositis, increasing pulmonary insufficiency, and terminal right ventricular failure. 1995 , 333, 369-77	5
1575	Detection of antiribosomal P protein antibodies in patients with systemic sclerosis. 1995 , 34, 908-11	10
1574	Evidence of omeprazole-induced small bowel bacterial overgrowth in patients with scleroderma. 1995 , 34, 976-7	25
1573	Natural killer cells and gamma delta T cells in scleroderma: relationship to disease duration and anti-Scl-70 antibodies. 1995 , 54, 69-72	18
1572	Silicone breast implants and the risk of connective-tissue diseases and symptoms. 1995 , 332, 1666-70	294
1571	Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. 1995 , 34, 1048-54	86
1570	Plasma endothelin-1 levels in patients with systemic sclerosis: influence of pulmonary or systemic arterial hypertension. 1995 , 54, 730-4	27
1569	Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis. 1995 , 34, 814-9	59
1568	Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. 1995 , 54, 853-5	84
1567	Novel 68 kDa autoantigen detected by rheumatoid arthritis specific antibodies. 1995 , 54, 355-60	29
1566	Disease distribution of beta 2-glycoprotein I-dependent anticardiolipin antibodies in rheumatic diseases. 1995 , 4 Suppl 1, S27-31	10

1565	Expression of ectopeptidases in scleroderma. 1995 , 54, 111-6	16
1564	A connective tissue disease screening questionnaire for population studies. 1995 , 5, 297-302	183
1563	Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis. 1995 , 33, 973-8	64
1562	The use of serologic markers for collagen synthesis and degradation in systemic sclerosis. 1995 , 32, 584-8	41
1561	[Mechanisms of cardiac involvement in systemic scleroderma. Apropos of 3 cases]. 1995 , 16, 319-24	
1560	Frequency of augmentation mammoplasty in patients with systemic sclerosis: data from the Johns Hopkins-University of Maryland Scleroderma Center. 1995 , 48, 565-9	12
1559	Pediatric gastrointestinal motility studies. 1995 , 25, 339-47	10
1558	Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. 1995 , 99, 255-60	80
1557	Oligoclonal expansion of V delta 1+ gamma/delta T-cells in systemic sclerosis patients. 1995 , 756, 382-91	14
1556	A study of scleroderma in South Australia: prevalence, subset characteristics and nailfold capillaroscopy. 1995 , 25, 688-94	38
1555	Arthritis in scleroderma. 1995 , 34, 831-7	46
1554	Systemic Sclerosis. 1995 , 4, 93-102	1
1553	Density gradient of the lung parenchyma at computed tomographic scanning in patients with pulmonary hypertension and systemic sclerosis. 1996 , 3, 724-30	13
1552	Treatment of systemic sclerosis. 1996 , 22, 893-907	14
1551	Scleroderma epidemiology. 1996 , 22, 751-64	46
1550	Diastolic abnormalities in systemic sclerosis: evidence for associated defective cardiac functional reserve. 1996 , 55, 455-60	45
1549	The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. 1996 , 101, 576-83	142
1548	Signal-averaged electrocardiography and echocardiography in the evaluation of myocardial involvement in progressive systemic sclerosis. 1996 , 53, 171-7	6

1547	Skewing of the CD8+ T-cell repertoire in the lungs of patients with systemic sclerosis. 1996 , 48, 84-97	68
1546	Endothelin-1 and cold provocation in health, primary Raynaud's phenomenon, and progressive systemic sclerosis. 1996 , 52, 193-7	7
1545	Quantification of cutaneous sclerosis with a skin elasticity meter in patients with generalized scleroderma. 1996 , 35, 381-7	82
1544	Serum concentrations of basic fibroblast growth factor in collagen diseases. 1996 , 35, 392-7	41
1543	Relationships between electrocardiographic and echocardiographic findings in systemic sclerosis (scleroderma). 1996 , 57, 151-60	20
1542	Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status. 1996 , 90, 223-30	42
1541	Rheumatic disorders in patients with silicone implants: a critical review. 1995 , 7, 147-57	14
1540	Systemic sclerosis in German uranium miners under special consideration of autoantibody subsets and HLA class II alleles. 1996 , 63, 368-75	16
1539	Anti-ribosomal P protein antibodies in a Japanese patient with systemic sclerosis. 1996 , 23, 33-6	
1538	Antiphospholipid syndrome associated with progressive systemic sclerosis. 1996 , 23, 347-51	8
1537	Neutrophil activation in fibrosing alveolitis: a comparison of lone cryptogenic fibrosing alveolitis and systemic sclerosis. 1996 , 9, 992-9	27
1536	Blotting patterns of IgG anti-(U1)RNP antibodies in mixed connective tissue disease. 1996 , 16, 145-50	10
1535	Elevated soluble CD23 levels in the sera from patients with localized scleroderma. 1996 , 288, 74-8	17
1534	Soluble CD4 and CD8 in serum from patients with localized scleroderma. 1996 , 288, 358-62	30
1533	Plasma concentration of total and transformed alpha 2-macroglobulin in systemic sclerosis. 1996 , 288, 405-7	3
1532	Antineutrophil cytoplasmic antibodies in systemic sclerosis. 1996 , 15, 519-20	9
1531	Colon involvement in systemic sclerosis: clinical-radiological correlations. 1996 , 15, 271-6	12
1530	Premictional volume and contractility of the urinary bladder in patients with systemic sclerosis. 1996 , 15, 118-20	10

1529	Predictive value of nailfold capillaroscopy in the diagnosis of connective tissue diseases. 1996 , 15, 148-53	56
1528	Nodular regenerative hyperplasia of the liver in a patient with systemic sclerosis. 1996 , 15, 613-6	22
1527	Scleroderma and silicone gel breast prostheses--the Sydney study revisited. 1996 , 26, 349-55	25
1526	Electrophysiologic abnormalities of cardiac function in progressive systemic sclerosis. 1996 , 29, 17-25	31
1525	Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. 1996 , 26, 459-67	157
1524	Incidence of rare systemic rheumatic and connective tissue diseases in Finland. 1996 , 240, 81-4	38
1523	Antigen association of total HEp-2 cell extract in the screening of autoimmune diseases by western blot. 1996 , 10, 140-3	
1522	Autoantibodies to glycyl-transfer RNA synthetase in myositis. Association with dermatomyositis and immunologic heterogeneity. <i>Arthritis and Rheumatism</i> , 1996 , 39, 146-51	29
1521	Sensitivity and specificity of anti-Jo-1 antibodies in autoimmune diseases with myositis. <i>Arthritis and Rheumatism</i> , 1996 , 39, 292-6	54
1520	Gastric antral vascular ectasia (watermelon stomach) in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1996 , 39, 341-6	86
1519	Early undifferentiated connective tissue disease. IV. Musculoskeletal manifestations in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of patients with well-established connective tissue diseases: followup analyses in patients with unexplained polyarthritis and patients with rheumatoid arthritis at baseline. <i>Arthritis and Rheumatism</i> , 1996 , 39, 657-62	37
1518	Hair dye use and the risk of developing systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1996 , 39, 657-62	75
1517	An epitope on Ki antigen recognized by autoantibodies from lupus patients shows homology with the SV40 large T antigen nuclear localization signal. <i>Arthritis and Rheumatism</i> , 1996 , 39, 855-62	4
1516	Strong association of dermatomyositis-specific Mi-2 autoantibodies with a tryptophan at position 9 of the HLA-DR beta chain. <i>Arthritis and Rheumatism</i> , 1996 , 39, 868-76	60
1515	Clinical correlations with HLA type in Japanese patients with connective tissue disease and anti-U1 small nuclear RNP antibodies. <i>Arthritis and Rheumatism</i> , 1996 , 39, 938-42	15
1514	Depressive symptoms associated with scleroderma. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1035-40	82
1513	Childhood-onset scleroderma: is it different from adult-onset disease. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1041-9	88
1512	Utility of anti-Sm, anti-RNP, anti-Ro/SS-A, and anti-La/SS-B (extractable nuclear antigens) detected by enzyme-linked immunosorbent assay for the diagnosis of systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1055-61	50

1511	Comprehensive noninvasive assessment of cardiac involvement in limited systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1138-45	73
1510	Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1146-50	136
1509	Autoantibodies to fibrillar in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1151-60	140
1508	Early expression of E-selectin, tumor necrosis factor alpha, and mast cell infiltration in the salivary glands of patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1161-5	27
1507	Detection of autoantibodies to nucleolar transcription factor NOR 90/hUBF in sera of patients with rheumatic diseases, by recombinant autoantigen-based assays. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1313-8	25
1506	Heterogeneity of collagen synthesis in normal and systemic sclerosis skin fibroblasts. Increased proportion of high collagen-producing cells in systemic sclerosis fibroblasts. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1338-46	105
1505	Transcriptional activation of the alpha 1(I) procollagen gene in systemic sclerosis dermal fibroblasts. Role of intronic sequences. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1347-54	49
1504	Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1362-70	168
1503	Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1507-18	136
1502	Two major autoantigen-antibody systems of the mitotic spindle apparatus. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1643-53	66
1501	Identification of autoantibodies to the I protein of the heterogeneous nuclear ribonucleoprotein complex in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1669-76	23
1500	Novel autoantibodies against muscle-cell membrane proteins in patients with myositis. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1860-8	8
1499	Autoimmunity to RNA polymerase II is focused at the carboxyl terminal domain of the large subunit. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1886-91	5
1498	Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma. 1996 , 134, 843-847	8
1497	Antineutrophil cytoplasmic autoantibodies in patients with systemic sclerosis. 1996 , 134, 407-410	3
1496	VCAM-1 expression on endothelium in lesions from cutaneous lupus erythematosus is increased compared with systemic and localized scleroderma. 1996 , 135, 678-686	6
1495	Presence of antibodies to replication protein A in some patients with systemic lupus erythematosus (SLE). 1996 , 103, 74-6	7
1494	Impairment of the inhibitory effect of sodium on basophil histamine release in patients with systemic sclerosis. 1996 , 104, 97-102	

1493	Clinical features of anti-chromo antibodies associated with anti-centromere antibodies. 1996 , 105, 285-90	20
1492	Measurement of anticardiolipin antibodies by ELISA using beta 2-glycoprotein I (beta 2-GPI) in systemic sclerosis. 1996 , 105, 475-9	55
1491	Autoantibodies that stabilize the molecular interaction of Ku antigen with DNA-dependent protein kinase catalytic subunit. 1996 , 105, 460-7	26
1490	Anti-RNA polymerase antibodies in systemic sclerosis (SSc): association with anti-topoisomerase I antibodies and identification of autoreactive subunits of RNA polymerase II. 1996 , 105, 468-74	15
1489	Primary pulmonary hypertension: immunogenetic response to high-mobility group (HMG) proteins and histone. 1996 , 106, 389-95	21
1488	Antibodies to membranes of endothelial cells and fibroblasts in scleroderma. 1996 , 106, 491-7	52
1487	Influence of calcitonin on eicosanoid serum levels in the treatment of patients with systemic sclerosis. 1996 , 7, 139-148	
1486	Digital calcification in systemic sclerosis: effective treatment with good tissue preservation using the carbon dioxide laser. 1996 , 135, 302-304	50
1485	c-myb proto-oncogene is expressed by quiescent scleroderma fibroblasts and, unlike B-myb gene, does not correlate with proliferation. 1996 , 106, 1281-6	17
1484	Non-invasive assessment of vascular reactivity in forearm skin of patients with primary Raynaud's phenomenon and systemic sclerosis. 1996 , 35, 1281-8	32
1483	Comparative assessment of the effects of vasodilators on peripheral vascular reactivity in patients with systemic scleroderma and Raynaud's phenomenon: color Doppler flow imaging study. 1996 , 47, 475-80	10
1482	Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome. 1996 , 55, 116-21	312
1481	Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. 1996 , 35, 1122-6	90
1480	Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. 1996 , 55, 122-7	88
1479	Computer based quantitative analysis of capillary abnormalities in systemic sclerosis and its relation to plasma concentration of von Willebrand factor. 1996 , 55, 52-6	23
1478	Investigation of anal function in patients with systemic sclerosis. 1996 , 55, 370-4	15
1477	Intravital microscopy and capillaroscopically guided nail fold biopsy in scleroderma. 1996 , 55, 305-10	11
1476	Diagnosis of alveolitis in interstitial lung manifestation in connective tissue diseases: importance of late inspiratory crackles, 67 gallium scan and bronchoalveolar lavage. 1996 , 5, 606-12	20

1475	Expression of Interleukin-4 in Scleroderma Skin Specimens and Scleroderma Fibroblast Cultures. 1996 , 132, 802	81
1474	Quantitative nailfold capillaroscopy findings in a population with connective tissue disease and in normal healthy controls. 1996 , 55, 507-12	108
1473	Anti-double stranded DNA antibodies in systemic lupus erythematosus: detection and clinical relevance of IgM-class antibodies. 1996 , 25, 352-9	24
1472	Intermittent iloprost infusion therapy of pulmonary hypertension in scleroderma--a pilot study. 1996 , 35, 1187-8	14
1471	Predominance of IgM anti-U1RNP antibodies in patients with systemic lupus erythematosus. 1996 , 35, 534-41	18
1470	Left ventricular function in scleroderma. 1996 , 35, 983-8	52
1469	Increased nailfold capillary dimensions in primary Raynaud's phenomenon and systemic sclerosis. 1996 , 35, 1127-31	48
1468	Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. 1996 , 35, 989-93	251
1467	Prevalence of pulmonary hypertension in limited and diffuse scleroderma. 1996 , 110, 1515-9	124
1466	Cardiorespiratory responses to incremental exercise in patients with systemic sclerosis. 1996 , 110, 1520-5	23
1465	Die pulmonale Manifestation der Sklerodermie. 1996 , 21, 190-196	1
1464	The Doyne Lecture. Reflections on the tears. 1997 , 11 (Pt 5), 583-602	95
1463	Endothelin-1 secretion by alveolar macrophages in systemic sclerosis. 1997 , 156, 1429-35	27
1462	Intestinal pseudo-obstruction as an initial presentation of systemic sclerosis in two children. 1997 , 36, 280-4	19
1461	Circulating intercellular adhesion molecule-1 in the sera of patients with systemic sclerosis: enhancement by inflammatory cytokines. 1997 , 36, 1270-5	36
1460	Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. 1997 , 36, 239-43	217
1459	Assessment of anti-endothelial cell antibodies in systemic sclerosis and Sjögren's syndrome. 1997 , 56, 230-4	15
1458	Prevalence and clinical relevance of 52-kDa and 60-kDa Ro/SS-A autoantibodies in Japanese patients with systemic sclerosis. 1997 , 56, 667-70	32

1457	Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis. 1997 , 56, 723-8	56
1456	Cryptogenic fibrosing alveolitis and the fibrosing alveolitis of systemic sclerosis: morphological differences on computed tomographic scans. 1997 , 52, 265-70	43
1455	High prolactin and low dehydroepiandrosterone sulphate serum levels in patients with severe systemic sclerosis. 1997 , 36, 426-32	47
1454	Elevated serum levels of neopterin in adult patients with polymyositis/dermatomyositis. 1997 , 36, 656-60	14
1453	Malignant lymphoma in patients with rheumatic diseases other than Sjögren's syndrome: a clinicopathologic study of five cases and a review of the Japanese literature. 1997 , 27, 84-90	23
1452	The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome. 1997 , 36, 1045-50	53
1451	Association of DM genes in systemic sclerosis is secondary to the association with HLA genes. 1997 , 26, 174-9	3
1450	Photopheresis treatment enhances CD95 (fas) expression in circulating lymphocytes of patients with systemic sclerosis and induces apoptosis. 1997 , 36, 1276-82	46
1449	Peripheral neuropathy associated with sicca complex. 1997 , 48, 855-62	144
1448	Autonomic dysfunction in systemic sclerosis: time and frequency domain 24 hour heart rate variability analysis. 1997 , 36, 669-76	50
1447	Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. 1997 , 52, 1051-5	97
1446	ET-1 plasma levels during cold stress test in sclerodermic patients. 1997 , 48, 965-8	10
1445	Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographic study of 135 Japanese patients. 1997 , 111, 36-43	54
1444	Autoantibody testing for connective tissue diseases. Comparison of immunodiffusion, immunoblot, and enzyme immunoassay. 1997 , 108, 406-10	14
1443	Chest pain and reappearance of esophageal peristalsis in treated achalasia. 1997 , 32, 1190-4	9
1442	Functional impairment in fibrosing alveolitis: relationship to reversible disease on thin section computed tomography. 1997 , 10, 280-5	35
1441	Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. 1997 , 107, 89-95	79
1440	Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. 1997 , 126, 866-73	147

1439	Prevalence of scleroderma spectrum disorders in the general population of Estonia. 1997 , 26, 419-25	14
1438	Scleroderma and related conditions. 1997 , 81, 129-49	32
1437	Impaired quantitative cerebral blood flow in scleroderma patients. 1997 , 152, 63-71	30
1436	Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. 1997 , 156, 1897-901	238
1435	Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. 1997 , 156, 631-6	119
1434	Low frequency of autoantibodies against Ki-67 antigen in Japanese patients with systemic autoimmune diseases. 1997 , 10, 499-503	5
1433	Antiendothelial cell antibodies: useful markers of systemic sclerosis. 1997 , 102, 178-85	99
1432	Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies. 1997 , 103, 242-8	71
1431	Scleroderma fibroblasts show increased responsiveness to endothelial cell-derived IL-1 and bFGF. 1997 , 108, 269-74	22
1430	Endothelin may be pathogenic in systemic sclerosis of the heart. 1997 , 60, 31-9	8
1429	[Systemic scleroderma and cancer. Search for predictive factors of cancer in 123 patients with scleroderma]. 1997 , 18, 528-32	20
1428	[Spontaneous rupture of the esophagus (Boerhaave syndrome) in a patient with scleroderma treated by continuous ambulatory peritoneal dialysis]. 1997 , 18, 566-70	4
1427	Carpal tunnel syndrome as a herald of autoimmune rheumatic disorders. 1997 , 90, 216-7	2
1426	Enzyme Immunoassays for Antinuclear Antibodies. 1997 , 17, 355-365	5
1425	Atrial conduction abnormalities in patients with systemic progressive sclerosis. 1997 , 18, 1995-2001	22
1424	Estudo da densidade ósea na esclerodermia sistêmica. 1997 , 43, 40	6
1423	In vitro spontaneous and UVB-induced lymphocyte apoptosis are not specific to SLE. 1997 , 13, 204-7	3
1422	Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts. 1997 , 108, 281-4	73

1421	Extracorporeal photochemotherapy (photopheresis) induces apoptosis in lymphocytes: a possible mechanism of action of PUVA therapy. 1997 , 65, 177-80	47
1420	Analysis of IgG subclasses of human antitopoisomerase I autoantibodies suggests chronic B cell stimulation. 1997 , 84, 65-72	4
1419	Impedance planimetric characterization of esophagus in systemic sclerosis patients with severe involvement of esophagus. 1997 , 42, 2317-26	29
1418	Intestinal perforation. A common complication of scleroderma. 1997 , 42, 549-53	23
1417	Jaccoud's arthropathy of the hands in overlap syndrome. 1997 , 16, 65-9	25
1416	Predictors of survival in 171 patients with systemic sclerosis (scleroderma). 1997 , 16, 454-60	39
1415	Clinical setting of patients with systemic sclerosis by serum autoantibodies. 1997 , 16, 378-83	32
1414	A longitudinal study of pulmonary function in Danish patients with systemic sclerosis. 1997 , 16, 384-90	36
1413	Clinical, laboratory and radiological findings in pulmonary fibrosis with and without connective tissue disease. 1997 , 16, 570-7	11
1412	Three cases of progressive systemic sclerosis treated with extracorporeal photochemotherapy. 1997 , 289, 120-2	19
1411	Extracorporeal photochemotherapy in progressive systemic sclerosis: a follow-up study. 1997 , 36, 380-5	24
1410	Nailfold capillary abnormality and pulmonary hypertension in systemic sclerosis. 1997 , 36, 116-22	29
1409	Increased levels of type I and III collagen and hyaluronan in scleroderma skin. 1997 , 136, 47-53	26
1408	The presence of antiBasement membrane zone antibodies in the sera of patients with nonBullous lupus erythematosus. 1997 , 136, 222-226	4
1407	Unique digital skin lesions associated with systemic sclerosis. 1997 , 136, 598-600	1
1406	A cross-reactive idiotype in scleroderma. 1997 , 108, 420-7	4
1405	Autoantibody reactive with the human general transcription factor TFIIF in sera from patients with autoimmune disorders. 1997 , 109, 488-94	7
1404	Cytoplasmic detection of a novel protein containing a nuclear localization sequence by human autoantibodies. 1997 , 107, 501-6	5

1403	Up-regulation of IL-8 secretion by alveolar macrophages from patients with fibrosing alveolitis: a subpopulation analysis. 1997 , 108, 95-104	28
1402	Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease. 1997 , 108, 42-6	39
1401	Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963-1982. <i>Arthritis and Rheumatism</i> , 1997 , 40, 441-5	126
1400	Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-gamma and tumor necrosis factor alpha in the early disease stage. <i>Arthritis and Rheumatism</i> , 1997 , 40, 540-50	56
1399	Characteristic epitope recognition pattern of autoantibodies against eukaryotic ribosomal protein L7 in systemic autoimmune diseases. <i>Arthritis and Rheumatism</i> , 1997 , 40, 661-71	18
1398	Racial differences in scleroderma among women in Michigan. <i>Arthritis and Rheumatism</i> , 1997 , 40, 734-42	135
1397	Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1997 , 40, 743-51	107
1396	The transcriptional activator Sp1, a novel autoantigen. <i>Arthritis and Rheumatism</i> , 1997 , 40, 1085-95	7
1395	Fibrosing alveolitis in systemic sclerosis. Indices of lung function in relation to extent of disease on computed tomography. <i>Arthritis and Rheumatism</i> , 1997 , 40, 1229-1236	5
1394	Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis. <i>Arthritis and Rheumatism</i> , 1997 , 40, 1237-1244	
1393	Human autoantibodies stabilize the quaternary structure of Ku antigen. <i>Arthritis and Rheumatism</i> , 1997 , 40, 1344-1353	1
1392	Connective tissue disease registries. <i>Arthritis and Rheumatism</i> , 1997 , 40, 1556-9	17
1391	Range of antinuclear antibodies in "healthy" individuals. <i>Arthritis and Rheumatism</i> , 1997 , 40, 1601-11	622
1390	Esophageal dysfunction in scleroderma: relationship with disease subsets. <i>Arthritis and Rheumatism</i> , 1997 , 40, 2252-9	81
1389	Immunological features of patients with primary biliary cirrhosis (PBC) overlapping systemic sclerosis: a comparison with patients with PBC alone. 1998 , 13, 897-901	17
1388	Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud's phenomenon secondary to systemic sclerosis. 1998 , 82, 1555-7, A8	46
1387	Circulating Vdelta1+ T cells are activated and accumulate in the skin of systemic sclerosis patients. <i>Arthritis and Rheumatism</i> , 1998 , 41, 327-34	66
1386	Mature type of skin collagen crosslink, histidinoxylysinoonorleucine, is significantly increased in the skin of systemic sclerosis patients. <i>Arthritis and Rheumatism</i> , 1998 , 41, 376-7	10

1385	The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1998 , 41, 466-9	33
1384	Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. <i>Arthritis and Rheumatism</i> , 1998 , 41, 670-7	142
1383	Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. <i>Arthritis and Rheumatism</i> , 1998 , 41, 778-99	2004
1382	Is occupational organic solvent exposure a risk factor for scleroderma?. <i>Arthritis and Rheumatism</i> , 1998 , 41, 1111-8	111
1381	Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. <i>Arthritis and Rheumatism</i> , 1998 , 41, 1215-20	118
1380	Different distribution of HLA class II and tumor necrosis factor alleles (TNF-308.2, TNFa2 microsatellite) in anti-topoisomerase I responders among scleroderma patients with and without exposure to quartz/metal dust. <i>Arthritis and Rheumatism</i> , 1998 , 41, 1306-11	17
1379	Spectrum and clinical significance of autoantibodies against transfer RNA. <i>Arthritis and Rheumatism</i> , 1998 , 41, 1625-31	21
1378	Association of microsatellite markers near the fibrillin 1 gene on human chromosome 15q with scleroderma in a Native American population. <i>Arthritis and Rheumatism</i> , 1998 , 41, 1729-37	81
1377	Manometry of the upper intestinal tract in patients with systemic sclerosis: a prospective study. <i>Arthritis and Rheumatism</i> , 1998 , 41, 1874-83	50
1376	Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts. <i>Arthritis and Rheumatism</i> , 1998 , 41, 2039-47	60
1375	Identification of elements in the promoter region of the alpha1(I) procollagen gene involved in its up-regulated expression in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1998 , 41, 2048-58	56
1374	Frequent clonal expansion of peripheral T cells in patients with autoimmune diseases: a novel detecting system possibly applicable to laboratory examination. 1998 , 12, 162-7	15
1373	Effects of the hypoxic test on left and right ventricular contractility in progressive systemic sclerosis with pulmonary arterial hypertension. 1998 , 7, 25-27	2
1372	How useful are serum autoantibodies in the diagnosis and prognosis of systemic sclerosis?. 1998 , 17, 179-80	3
1371	Undifferentiated connective tissue disease: natural history and evolution into definite CTD assessed in 84 patients initially diagnosed as early UCTD. 1998 , 17, 195-201	52
1370	Serum soluble Fas/APO-1 is increased in patients with primary Sjögren's syndrome. 1998 , 17, 496-9	9
1369	Systemic sclerosis stimulates angiogenesis in the chick embryo chorioallantoic membrane. 1998 , 17, 115-20	16
1368	A case-control study on risk factors for scleroderma. 1998 , 8, 239-248	

1367	Determination of procollagen type I carboxyterminal propeptide in Japanese patients with systemic sclerosis. 1998 , 8, 147-155	
1366	The immunopathology of siliconosis. History, clinical presentation, and relation to silicosis and the chemistry of silicon and silicone. 1998 , 18, 125-73	44
1365	The relation between nailfold bleeding and capillary microscopic abnormality in patients with connective tissue diseases. 1998 , 37, 23-6	12
1364	Cutaneous responses to endothelin-1 and histamine in patients with vibration white finger. 1998 , 110, 127-31	11
1363	Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts. 1998 , 110, 416-21	50
1362	Increased expression of heat-shock protein 47 is associated with overproduction of type I procollagen in systemic sclerosis skin fibroblasts. 1998 , 111, 1023-8	42
1361	Dermal mast cells in scleroderma: their skin density, tryptase/chymase phenotypes and degranulation. 1998 , 138, 399-406	52
1360	The significance of the 'dust-like particles' pattern of immunofluorescence. A study of 66 cases. 1998 , 138, 1039-42	23
1359	The predictive value of quantitative nailfold capillary microscopy in patients with undifferentiated connective tissue disease. 1998 , 139, 622-9	21
1358	Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. 1998 , 139, 639-48	84
1357	Circulating type I collagen degradation products: a new serum marker for clinical severity in patients with scleroderma?. 1998 , 139, 1020-5	28
1356	Elevated expression of epidermal ornithine decarboxylase mRNA in scleroderma. 1998 , 139, 1047-8	4
1355	Serum concentrations of vascular endothelial growth factor in collagen diseases. 1998 , 139, 1049-51	86
1354	Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. 1998 , 351, 559-62	496
1353	Soluble HLA-I in rheumatic diseases. 1998 , 59, 644-9	15
1352	[Primary biliary cirrhosis and systemic scleroderma (Reynolds syndrome): apropos of 8 new cases. The contribution of accessory salivary gland biopsy]. 1998 , 19, 393-8	1
1351	Interstitial lung disease in systemic sclerosis: comparison of BALF lymphocyte phenotype and DLCO impairment. 1998 , 92, 1295-301	13
1350	Classification and epidemiology of scleroderma. 1998 , 17, 22-6	52

1349	Clinical manifestations of systemic sclerosis. 1998 , 17, 48-54	63
1348	Maternal scleroderma: placental findings and perinatal outcome. 1998 , 29, 1524-30	32
1347	Announcements. 1998 , 27, 380-380	
1346	A case-control study on risk factors for scleroderma. 1998 , 8, 239-248	2
1345	Determination of procollagen type I carboxyterminal propeptide in Japanese patients with systemic sclerosis. 1998 , 8, 147-155	
1344	Vascular endothelial growth factor in patients with rheumatoid arthritis. 1998 , 27, 377-80	108
1343	Reactive oxygen species modified polyguanylic acid: immunogenicity and implications for systemic autoimmunity. 1998 , 11, 371-8	15
1342	Mutations in T cell receptor zeta chain mRNA of peripheral T cells from systemic lupus erythematosus patients. 1998 , 11, 381-5	54
1341	Diversity of myocardial involvement in systemic sclerosis: an 8-year study of 95 Japanese patients. 1998 , 135, 960-9	36
1340	Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. 1998 , 338, 1186-91	401
1339	Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis. 2000 , CD000954	12
1338	Two populations of endothelial cell antibodies cross-react with heparin. 1998 , 7, 86-94	22
1337	Undifferentiated connective tissue diseases: the clinical and serological profiles of 91 patients followed for at least 1 year. 1998 , 7, 95-100	81
1336	Cerebral calcification in a patient with systemic lupus erythematosus and a monoclonal IgG reactive with glial fibrillary acidic protein. 1998 , 37, 1355-7	8
1335	Mortality and causes of death in a Swedish series of systemic sclerosis patients. 1998 , 57, 682-6	161
1334	Sensorineural hearing loss, iritis and ankylosing spondylitis. 1998 , 37, 1363	9
1333	Aortitis in relapsing polychondritis. 1998 , 37, 1359-61	10
1332	Digital gangrene and anticentromere antibodies without scleroderma. 1998 , 37, 1352-3	9

1331	Heart involvement in systemic sclerosis: an ultrasonic tissue characterisation study. 1998 , 57, 296-302	27
1330	Unusual occurrence of acute low back pain in a patient with ruptured urachal cyst. 1998 , 37, 1354-5	
1329	Successful treatment with antithymocyte globulin and cyclosporin A of a severe aplastic anaemia associated with an eosinophilic fasciitis. 1998 , 37, 1358-9	18
1328	Distribution of macrovascular disease in scleroderma. 1998 , 57, 476-9	50
1327	An objective method to estimate the severity of Raynaud phenomenon: digital blood pressure response to cooling. 1998 , 3, 109-13	19
1326	Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. 2000 , CD000953	35
1325	Haemophagocytic syndrome in a patient with dermatomyositis. 1998 , 37, 1357-8	14
1324	Microvascular involvement in systemic sclerosis: laser Doppler evaluation of reactivity to acetylcholine and sodium nitroprusside by iontophoresis. 1998 , 57, 52-5	33
1323	Anti-Jo-1 antibodies in polymyositis or dermatomyositis: evaluation by ELISA using recombinant fusion protein Jo-1 as antigen. 1998 , 37, 357-61	17
1322	Infection with an unenveloped DNA virus (TTV) associated with non-A to G hepatitis in patients with rheumatoid arthritis. 1998 , 37, 1361-2	10
1321	Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. 1998 , 158, 595-600	130
1320	Antigen specificity of antihistone antibodies in systemic sclerosis. 1998 , 57, 470-5	22
1319	Bronchoalveolar lavage cellularity: lone cryptogenic fibrosing alveolitis compared with the fibrosing alveolitis of systemic sclerosis. 1998 , 157, 1474-82	76
1318	Association of esophageal dysfunction and pulmonary function impairment in systemic sclerosis. 1998 , 93, 341-5	63
1317	Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. 1998 , 37, 39-45	69
1316	Outcome in systemic vasculitis. 1998 , 37, 1362-3	
1315	8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. 1998 , 158, 1524-7	211
1314	^{99m} Tc SESTAMIBI scintigraphic evaluation of skeletal muscle disease in patients with systemic sclerosis: diagnostic reliability and comparison with cardiac function and perfusion. 1998 , 49, 641-8	12

1313	Immunoglobulin allotype gene polymorphisms in systemic sclerosis: interactive effect of MHC class II and KM genes on anticentromere antibody production. 1998 , 57, 366-70	22
1312	Sternum tumour revealing a chronic myeloid leukaemia. 1998 , 37, 1353-4	5
1311	Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. 1998 , 37, 15-20	110
1310	Expression of stem cell factor in the lesional skin of systemic sclerosis. 1998 , 197, 109-14	24
1309	Molecular heterogeneity of second and fourth components of complement and their genes in systemic sclerosis and association of HLA alleles A1, B8 and DR3 with limited and DR5 with diffuse systemic sclerosis. 1998 , 15, 90-9	5
1308	Defective endothelially mediated pulmonary vasodilation in systemic sclerosis. 1998 , 114, 178-84	20
1307	African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. 1998 , 114, 801-7	99
1306	Relationship between abnormalities on high-resolution CT and pulmonary function in systemic sclerosis. 1998 , 114, 1623-9	92
1305	Silicone gel-filled breast implants and connective tissue diseases. 1998 , 101, 261-8	47
1304	Prazosin for Raynaud's phenomenon in progressive systemic sclerosis. 2000 , CD000956	25
1303	Cyclofenil for Raynaud's phenomenon in progressive systemic sclerosis. 2000 , CD000955	5
1302	Malignancy-Associated Rheumatic Disorders. 1998 , 52, 138-149	1
1301	Life span of skin fibroblasts in patients with systemic sclerosis. 1998 , 196, 204-7	2
1300	South Australian Scleroderma Register: analysis of deceased patients. 1998 , 30, 386-90	11
1299	Blood yield stress in systemic sclerosis. 1999 , 276, H771-7	7
1298	Atrial involvement in patients with progressive systemic sclerosis: relationship between ultrasonic tissue characterization of the atrium and interatrial conduction. 1999 , 91, 134-9	8
1297	Petroleum distillate solvents as risk factors for undifferentiated connective tissue disease (UCTD). 1999 , 149, 761-70	22
1296	Fibronectin gene polymorphisms associated with fibrosing alveolitis in systemic sclerosis. 1999 , 20, 106-12	50

1295	The prognosis and outcome of patients referred to an outpatient clinic for rheumatic diseases characterized by the presence of antinuclear antibodies (ANA). 1999 , 28, 33-7	19
1294	Mortality in rheumatoid arthritis patients. 1999 , 58, 723-4	4
1293	Serum levels of soluble TNF alpha receptor type I and the severity of systemic sclerosis. 1999 , 79, 207-10	14
1292	Nitric oxide synthesis in peripheral blood mononuclear and polymorphonuclear cells from patients with systemic sclerosis. 1999 , 38, 1301-4	6
1291	Recurrent pregnancy loss and autoantibody profile in autoimmune diseases. 1999 , 38, 1228-33	26
1290	HLA-B27+ anterior uveitis with or without associated spondyloarthritis: clinical and immunological features. 1999 , 58, 721-2	4
1289	Systemic sclerosis (scleroderma) in two iron ore mines. 1999 , 49, 161-9	8
1288	Pulmonary involvement in diffuse cutaneous systemic sclerosis: bronchoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. 1999 , 58, 635-40	68
1287	Crystals in arthritis: new age nonsense or novel therapeutic target?. 1999 , 58, 723	6
1286	Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. 1999 , 38, 992-6	93
1285	Bowel problems in patients with systemic sclerosis. 1999 , 34, 409-13	53
1284	RS3PE: six years later. 1999 , 58, 722-3	7
1283	A successful renal transplantation in Behçet's syndrome. 1999 , 58, 719	6
1282	Lymphocyte phenotypes in systemic sclerosis. 1999 , 58, 719-20	4
1281	Microvascular abnormalities in Sjögren's syndrome: nailfold capillaroscopy. 1999 , 38, 826-30	71
1280	HLA haplotypes and microsatellite polymorphisms in and around the major histocompatibility complex region in a Native American population with a high prevalence of scleroderma (systemic sclerosis). 1999 , 53, 74-80	31
1279	Fibroblast expression of collagen integrin receptors alpha1beta1 and alpha2beta1 is not changed in systemic scleroderma. 1999 , 141, 218-23	16
1278	Augmented production of chemokines (monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis. 1999 , 117, 159-65	165

- 1277 Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis. **1999**, 117, 383-7 32
- 1276 Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis. **1999**, 117, 395-402 42
- 1275 Flowcytometric analysis of bronchoalveolar lavage fluid cells in polymyositis/dermatomyositis with interstitial pneumonia. **1999**, 4, 223-8 31
- 1274 Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion. **1999**, 112, 78-84 80
- 1273 Dermatopontin expression is decreased in hypertrophic scar and systemic sclerosis skin fibroblasts and is regulated by transforming growth factor-beta1, interleukin-4, and matrix collagen. **1999**, 112, 706-10 59
- 1272 Serum xylosyltransferase: a new biochemical marker of the sclerotic process in systemic sclerosis. **1999**, 112, 919-24 64
- 1271 Systemic sclerosis prevalence and mortality in Sydney 1974-88. **1999**, 29, 42-50 40
- 1270 Centrosome proteins: a major class of autoantigens in scleroderma. **1999**, 19, 166-71 23
- 1269 Expression of CD80 and CD86 on peripheral blood T lymphocytes in patients with systemic lupus erythematosus. **1999**, 19, 58-66 17
- 1268 Coronary artery imaging. **1999**, 8, 41-48
- 1267 Circulating P- and L-selectin and T-lymphocyte activation and patients with autoimmune rheumatic diseases. **1999**, 18, 28-32 36
- 1266 Cardiac involvement in limited systemic sclerosis: non-invasive assessment in asymptomatic patients. **1999**, 18, 136-9 17
- 1265 Investigation of the alveolar macrophages and T lymphocytes in 15 patients with systemic sclerosis. **1999**, 18, 357-63 2
- 1264 Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. **1999**, 18, 455-61 86
- 1263 Comparative clinical and epidemiological study of hypersensitivity vasculitis versus Henoch-Schönlein purpura in adults. **1999**, 28, 404-12 97
- 1262 Does early and aggressive treatment improve the prognosis in psoriatic arthritis? Comment on the article by Wong et al. *Arthritis and Rheumatism*, **1999**, 42, 189
- 1261 Reply. *Arthritis and Rheumatism*, **1999**, 42, 189-189 2
- 1260 Acute-phase response and risk of developing ischemic complications in giant cell arteritis: comment on the article by Cid et al. *Arthritis and Rheumatism*, **1999**, 42, 190 1

1259	Reply. <i>Arthritis and Rheumatism</i> , 1999 , 42, 190-190	
1258	Clinical, immunologic, and immunogenetic evidence that mixed connective tissue disease is a distinct entity: comment on the article by Smolen and Steiner. <i>Arthritis and Rheumatism</i> , 1999 , 42, 190-1; author reply 193-6	6
1257	Naming names! Comment on the article by Smolen and Steiner. <i>Arthritis and Rheumatism</i> , 1999 , 42, 191-6	8
1256	Reply. <i>Arthritis and Rheumatism</i> , 1999 , 42, 193-196	3
1255	Illoprost treatment in systemic sclerosis: comment on the concise communication by Tedeschi et al. <i>Arthritis and Rheumatism</i> , 1999 , 42, 196-8	1
1254	Reply. <i>Arthritis and Rheumatism</i> , 1999 , 42, 197-198	6
1253	Increased serum levels of antibodies against human cytomegalovirus and prevalence of autoantibodies in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1999 , 42, 389-92	81
1252	Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. <i>Arthritis and Rheumatism</i> , 1999 , 42, 465-74	107
1251	Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. <i>Arthritis and Rheumatism</i> , 1999 , 42, 899-909	287
1250	Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1999 , 42, 930-41	95
1249	An immunodominant epitope on DNA topoisomerase I is conformational in nature: heterogeneity in its recognition by systemic sclerosis sera. <i>Arthritis and Rheumatism</i> , 1999 , 42, 1179-88	29
1248	High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. <i>Arthritis and Rheumatism</i> , 1999 , 42, 1194-203	261
1247	Identification of multiple, differentially expressed messenger RNAs in dermal fibroblasts from patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1999 , 42, 1451-7	56
1246	Octreotide treatment of chronic intestinal pseudoobstruction secondary to connective tissue diseases. <i>Arthritis and Rheumatism</i> , 1999 , 42, 1545-9	75
1245	Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1999 , 42, 2372-80	84
1244	Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. <i>Arthritis and Rheumatism</i> , 1999 , 42, 2646-55	218
1243	Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. <i>Arthritis and Rheumatism</i> , 1999 , 42, 2660-5	154
1242	Rheumaderm. 1999 ,	3

1241	Circulating myeloperoxidase and anti-myeloperoxidase antibody in patients with vasculitis. 1999 , 28, 94-9	12
1240	Plasma noradrenaline and neuropeptide-Y may not be of primary importance in the pathophysiology of cardiac involvement in systemic sclerosis. 1999 , 28, 238-43	2
1239	Free radical activity and antioxidative systems in patients with systemic sclerosis. 1999 , 10, 206-208	4
1238	Acute effects of nebulised epoprostenol in pulmonary hypertension due to systemic sclerosis. 1999 , 93, 75-8	7
1237	Autonomic neuropathy associated with sicca complex. 1999 , 75, 70-6	47
1236	TNF-alpha and TNF-beta gene polymorphisms in systemic sclerosis. 1999 , 60, 1128-30	38
1235	[Influence of age on the clinical and biological characteristics of systemic scleroderma]. 1999 , 20, 1088-92	4
1234	[Connective tissue diseases in the hospital outpatient service in Lomé (Togo)]. 1999 , 20, 13-7	13
1233	Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis). 1999 , 41, 915-22	70
1232	In vivo study of skin mechanical properties in patients with systemic sclerosis. 1999 , 40, 436-42	58
1231	Autoantibodies to RNA polymerases recognize multiple subunits and demonstrate cross-reactivity with RNA polymerase complexes. <i>Arthritis and Rheumatism</i> , 1999 , 42, 275-84	24
1230	Expression of TGF-beta 1, -beta 2 and -beta 3 in localized and systemic scleroderma. 1999 , 21, 13-22	90
1229	Multicenter evaluation study on a new HEp2 ANA screening enzyme immune assay. 1999 , 13, 89-93	40
1228	Clinical features and IgG subclass distribution of anti-p80 coilin antibodies. 1999 , 13, 225-32	9
1227	Laser doppler imaging--a new technique for quantifying microcirculatory flow in patients with primary Raynaud's phenomenon and systemic sclerosis. 1999 , 57, 284-91	60
1226	Anticentromere autoantibodies in patients without Raynaud's disease or systemic sclerosis. 1999 , 90, 182-9	7
1225	Anti-alpha-fodrin antibodies in Sjögren syndrome and lupus erythematosus. 1999 , 135, 535-9	40
1224	Subclinical alveolar bleeding in pulmonary vasculitides: correlation with indices of disease activity. 1999 , 14, 118-24	55

1223	Clearance of inhaled technetium-99m-DTPA as a clinical index of pulmonary vascular disease in systemic sclerosis. 1999 , 13, 133-6	11
1222	An imbalance in plasma prostanoids in patients with Raynaud's phenomenon and pulmonary vasospasm. 1999 , 13, 137-44	16
1221	Exhaled nitric oxide is increased in active fibrosing alveolitis. 1999 , 115, 1352-6	86
1220	Lymphocyte populations and cytokine concentrations in pericardial fluid from a systemic lupus erythematosus patient with cardiac tamponade. 1999 , 58, 720-1	11
1219	Intracerebral calcification in systemic sclerosis. 1999 , 30, 2183-5	31
1218	Comparison of an enzyme immunoassay to an indirect fluorescent immunoassay for the detection of antinuclear antibodies. 1999 , 111, 503-6	15
1217	Comparison of self-reported diagnosis of connective tissue disease with medical records in female health professionals: the Women's Health Cohort Study. 1999 , 150, 652-60	50
1216	Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis. 1999 , 11, 475-482	104
1215	Systemic vasculitis in adults in northwestern Spain, 1988-1997. Clinical and epidemiologic aspects. 1999 , 78, 292-308	155
1214	Clinical and immunological characterization of patients with systemic sclerosis overlapping primary biliary cirrhosis: a comparison with patients with systemic sclerosis alone. 1999 , 26, 18-22	30
1213	A Case Series Survey of Silicone Breast Implant Patients. 1999 , 5, 119-126	
1212	Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis?. 1999 , 116, 715-20	41
1211	Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. 2000 , 132, 425-34	710
1210	Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis. 2000 , 55, 958-61	73
1209	Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis. 2000 , 200, 196-201	38
1208	The effect of lung biopsy on lung function in diffuse lung disease. 2000 , 16, 67-73	11
1207	Anti-ribosomal P protein antibodies detected by immunoblotting in patients with connective tissue diseases: their specificity for SLE and association with IgG anticardiolipin antibodies. 2000 , 59, 975-81	49
1206	Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2000 , 43, 76-84	208

1205	Autoantibodies to DEK oncoprotein in human inflammatory disease. <i>Arthritis and Rheumatism</i> , 2000 , 43, 85-93	51
1204	Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. <i>Arthritis and Rheumatism</i> , 2000 , 43, 444-51	215
1203	Quantitative radioligand assays using de novo-synthesized recombinant autoantigens in connective tissue diseases: new tools to approach the pathogenic significance of anti-RNP antibodies in rheumatic diseases. <i>Arthritis and Rheumatism</i> , 2000 , 43, 689-98	60
1202	Reliability and validity of the Arthritis Hand Function Test in adults with systemic sclerosis (scleroderma). <i>Arthritis and Rheumatism</i> , 2000 , 13, 69-73	34
1201	Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2000 , 43, 889-93	109
1200	Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis: evidence of free radical-mediated injury. <i>Arthritis and Rheumatism</i> , 2000 , 43, 894-900	68
1199	Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen. <i>Arthritis and Rheumatism</i> , 2000 , 43, 1054-61	42
1198	Errata. <i>Arthritis and Rheumatism</i> , 2000 , 43, 1061	
1197	Detection of cellular microchimerism of male or female origin in systemic sclerosis patients by polymerase chain reaction analysis of HLA-Cw antigens. <i>Arthritis and Rheumatism</i> , 2000 , 43, 1062-7	47
1196	Microsatellites and intragenic polymorphisms of transforming growth factor beta and platelet-derived growth factor and their receptor genes in Native Americans with systemic sclerosis (scleroderma): a preliminary analysis showing no genetic association. <i>Arthritis and Rheumatism</i> , 2000 , 43, 1068-73	31
1195	Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2000 , 43, 1074-84	102
1194	Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. <i>Arthritis and Rheumatism</i> , 2000 , 43, 1085-93	79
1193	Spectrum of autoantibodies against a dynamin-related protein, dymp1e. <i>Arthritis and Rheumatism</i> , 2000 , 43, 1516-9	3
1192	Inhibition of type I collagen gene expression in normal and systemic sclerosis fibroblasts by a specific inhibitor of geranylgeranyl transferase I. <i>Arthritis and Rheumatism</i> , 2000 , 43, 1624-32	27
1191	Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. <i>Arthritis and Rheumatism</i> , 2000 , 43, 1633-40	91
1190	Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. <i>Arthritis and Rheumatism</i> , 2000 , 43, 1886-90	71
1189	HLA-DQA1*0501 is associated with diffuse systemic sclerosis in Caucasian men. <i>Arthritis and Rheumatism</i> , 2000 , 43, 2005-10	56
1188	CCAAT binding transcription factor binds and regulates human COL1A1 promoter activity in human dermal fibroblasts: demonstration of increased binding in systemic sclerosis fibroblasts. <i>Arthritis and Rheumatism</i> , 2000 , 43, 2219-29	40

1187	Role of apoptosis and transforming growth factor beta1 in fibroblast selection and activation in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2000 , 43, 2230-9	137
1186	Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2000 , 43, 2307-15	139
1185	Severe organ involvement in systemic sclerosis with diffuse scleroderma. <i>Arthritis and Rheumatism</i> , 2000 , 43, 2437-44	657
1184	Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. <i>Arthritis and Rheumatism</i> , 2000 , 43, 2445-54	221
1183	Increased interleukin-17 production in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2000 , 43, 2455-63	325
1182	Autoantibodies to fibrillin 1 in systemic sclerosis: ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles. <i>Arthritis and Rheumatism</i> , 2000 , 43, 2464-71	62
1181	Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. <i>Arthritis and Rheumatism</i> , 2000 , 43, 2550-62	186
1180	Diversity and plasticity of the anti-DNA topoisomerase I autoantibody response in scleroderma. <i>Arthritis and Rheumatism</i> , 2000 , 43, 2733-42	21
1179	Surface expression of a glycolytic enzyme, alpha-enolase, recognized by autoantibodies in connective tissue disorders. 2000 , 30, 3575-84	58
1178	Suppressive effect of saprogrelate hydrochloride on Raynaud's phenomenon and respiratory failure in patients with systemic sclerosis. 2000 , 5, 27-32	7
1177	Development of systemic sclerosis in a patient with systemic lupus erythematosus and topoisomerase I antibody. 2000 , 142, 1030-3	6
1176	Increased serum levels of soluble vascular cell adhesion molecule-1 and soluble E-selectin in patients with polymyositis/dermatomyositis. 2000 , 143, 392-8	15
1175	Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis. 2000 , 119, 203-9	70
1174	Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35. 2000 , 121, 539-43	44
1173	Clinical importance of antibodies against platelet activating factor in antiphospholipid syndrome manifestations. 2000 , 30, 646-52	17
1172	Fine specificity of anti-fibrillin-1 autoantibodies in primary pulmonary hypertension syndrome. 2000 , 51, 607-11	23
1171	Correlation between diffuse pigmentation and keratinocyte-derived endothelin-1 in systemic sclerosis. 2000 , 39, 899-902	13
1170	Anti-centromere antibodies as a marker of Raynaud's phenomenon in pediatric rheumatologic diseases. 2000 , 11, 250-5	17

1169	The liver in collagen diseases: pathologic study of 160 cases with particular reference to hepatic arteritis, primary biliary cirrhosis, autoimmune hepatitis and nodular regenerative hyperplasia of the liver. 2000 , 20, 366-73	123
1168	Extended extracorporeal photochemotherapy with extracorporeal administration of 8-methoxypsoralen in systemic sclerosis. An Austrian single-center study. 2000 , 16, 216-23	17
1167	Spécificité 52 kDa et 60 kDa des anti-Ro(SS-A) dans les connectivites inclassables. 2000 , 67, 197-202	
1166	Single nucleotide polymorphisms in the coding regions of human CXC-chemokine receptors CXCR1, CXCR2 and CXCR3. 2000 , 1, 330-7	25
1165	Scleroderma: oral manifestations and treatment challenges. 2000 , 20, 240-4	25
1164	Systemic sclerosis (scleroderma) and related disorders: clinical aspects. 2000 , 14, 1-16	44
1163	Mixed connective tissue disease: overlap syndromes. 2000 , 14, 111-24	32
1162	Unclassified or undifferentiated connective tissue disease. 2000 , 14, 125-37	23
1161	Immunoglobulin isotypes of anti-myeloperoxidase and anti-lactoferrin antibodies in patients with collagen diseases. 2000 , 20, 279-86	26
1160	Gynaecologic history in systemic sclerosis. 2000 , 19, 184-7	40
1159	Bibliographical study of the concurrent existence of anticentromere and antitopoisomerase I antibodies. 2000 , 19, 435-41	9
1158	The establishment and utility of a population-based registry to understand the epidemiology of systemic sclerosis. 2000 , 2, 512-6	14
1157	Scleroderma renal crisis with limited cutaneous sclerosis and positive anti-RNA polymerase antibody. 2000 , 4, 152-155	3
1156	Measurement of soluble adhesion molecules in primary Raynaud's phenomenon and in Raynaud's phenomenon secondary to connective tissue diseases. 2000 , 30, 75-81	6
1155	Anticentromere antibody as a risk factor for cancer in patients with systemic sclerosis. 2000 , 19, 123-6	42
1154	Sensitivity and Specificity of Immunological Methods for the Detection of Anti-Topoisomerase I (Scl70) Autoantibodies: Results of a Multicenter Study. 2000 , 46, 1681-1685	19
1153	Diagnostic and prognostic relevance of autoantibodies in uranium miners. 2000 , 123, 77-91	29
1152	Induction of heme oxygenase-1 by hypoxia and free radicals in human dermal fibroblasts. 2000 , 278, C92-C101	87

1151	Esophageal tone in patients with total aperistalsis: gastroesophageal reflux disease versus achalasia. 2000 , 279, G374-9	13
1150	Pulmonary hypertension is associated with impaired exercise performance in patients with systemic sclerosis. 2000 , 29, 236-42	25
1149	Analysis of soluble and cell surface factors regulating anti-DNA topoisomerase I autoantibody production demonstrates synergy between Th1 and Th2 autoreactive T cells. 2000 , 164, 6138-46	26
1148	Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele. 2000 , 59, 359-67	53
1147	Development of the antinuclear and anticytoplasmic antibody consensus panel by the Association of Medical Laboratory Immunologists. 2000 , 7, 436-43	16
1146	Elevated serum xylosyltransferase activity correlates with a high level of hyaluronate in patients with systemic sclerosis. 2000 , 80, 60-1	25
1145	Ultrasonic measurement of skin thickness in patients with systemic sclerosis. 2000 , 80, 59-60	15
1144	ASE-1: an autoantigen in systemic lupus erythematosus. 2000 , 9, 681-7	10
1143	Favourable outcome in 135 children with juvenile systemic sclerosis: results of a multi-national survey. 2000 , 39, 556-9	89
1142	Progressive scleroderma in a patient with recent nasopharyngeal carcinoma. 2000 , 39, 1299-301	5
1141	Macrovascular disease and systemic sclerosis. 2000 , 59, 39-43	120
1140	Assessment of microvascular changes in Raynaud's phenomenon and connective tissue disease using colour doppler ultrasound. 2000 , 39, 1206-13	40
1139	Evidence of cerebral hypoperfusion in scleroderma patients. 2000 , 39, 1366-73	46
1138	Anti-telomere antibodies in systemic lupus erythematosus: a new ELISA test for anti-DNA with potential pathogenetic implications. 2000 , 9, 328-32	14
1137	Clinical and laboratory features of scleroderma patients with pulmonary hypertension. 2000 , 39, 1269-71	57
1136	Quantitation of microcirculatory abnormalities in patients with primary Raynaud's phenomenon and systemic sclerosis by video capillaroscopy. 2000 , 39, 506-12	65
1135	Determination of autoantibodies to annexin XI in systemic autoimmune diseases. 2000 , 9, 515-20	26
1134	Quantitative genetic variation in CD19 expression correlates with autoimmunity. 2000 , 165, 6635-43	255

1133	Suppressive effect of sarpogrelate hydrochloride on respiratory failure and right ventricular failure with pulmonary hypertension in patients with systemic sclerosis. 2000 , 28, 258-68	14
1132	Re: Tager and Tikly. Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in black South Africans. 2000 , 39, 220-2	
1131	Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus. 2000 , 9, 110-5	80
1130	Circulating collagen metabolites in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement. 2000 , 39, 1110-3	24
1129	Soluble thrombomodulin concentration is raised in scleroderma associated pulmonary hypertension. 2000 , 59, 132-4	14
1128	Association of the TNF α 13 microsatellite with systemic sclerosis in Japanese patients. 2000 , 59, 293-6	21
1127	Derangement of apoptosis-related lymphocyte homeostasis in systemic sclerosis. 2000 , 39, 1341-50	30
1126	Association of functional microsatellites in the human type I collagen alpha2 chain (COL1A2) gene with systemic sclerosis. 2000 , 272, 36-40	21
1125	Immune stimulation in scleroderma patients treated with thalidomide. 2000 , 97, 109-20	62
1124	Kinetics of anti-fibrillin-1 autoantibodies in MCTD and CREST syndrome. 2000 , 14, 267-74	14
1123	Increased expression of CD40 ligand in activated CD4+ T lymphocytes of systemic sclerosis patients. 2000 , 15, 61-6	42
1122	MHC class II associations with autoantibody and T cell immune responses to the scleroderma autoantigen topoisomerase I. 2000 , 15, 451-8	14
1121	Increased nitric oxide production in patients with systemic sclerosis. 2000 , 4, 615-9	35
1120	Increased serum levels of soluble vascular cell adhesion molecule 1 and E-selectin in patients with localized scleroderma. 2000 , 42, 64-9	45
1119	Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis. 2000 , 42, 70-5	35
1118	Thermographic parameters in the diagnosis of secondary Raynaud's phenomenon. 2000 , 81, 495-9	32
1117	Quantitative nailfold capillary microscopy findings in patients with acrocyanosis compared with patients having systemic sclerosis and control subjects. 2000 , 42, 787-90	28
1116	Raynaud's phenomenon, anticentromere antibodies, and digital necrosis without sclerodactyly: an entity independent of scleroderma?. 2000 , 43, 631-4	16

1115	Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. 2000 , 43, 1017-23	92
1114	Clinical spectrum of Raynaud's phenomenon in patients referred to vascular clinic. 2000 , 8, 457-62	9
1113	Increased pulmonary epithelial permeability in systemic sclerosis is associated with enhanced cutaneous nerve growth factor expression. 2000 , 11, 156-160	3
1112	Domain reactivity of autoantibodies to calpastatin in patients with systemic rheumatic diseases. 2000 , 10, 38-44	2
1111	Mechanical properties of the gastro-esophageal junction in health, achalasia, and scleroderma. 2000 , 35, 705-10	7
1110	Elevated serum levels of soluble L-selectin in patients with systemic sclerosis declined after intravenous injection of lipo-prostaglandin E1. 2001 , 25, 78-82	5
1109	Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. 2001 , 27, 140-6	216
1108	The inhibitory effects of camptothecin, a topoisomerase I inhibitor, on collagen synthesis in fibroblasts from patients with systemic sclerosis. 2001 , 3, 311-8	10
1107	Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma). 2001 , 3, 178-82	40
1106	Reactivities to the Sm autoantigenic complex and the synthetic SmD1-aa83-119 peptide in systemic lupus erythematosus and other autoimmune diseases. 2001 , 17, 347-54	21
1105	Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. 2001 , 100, 144-8	225
1104	Tumour necrosis factor-alpha production in fibrosing alveolitis is macrophage subset specific. 2001 , 2, 365-72	14
1103	Localized and systemic scleroderma. 2001 , 20, 27-37	50
1102	Hearing loss in progressive systemic sclerosis patients: a comparative study. 2001 , 124, 522-5	27
1101	Reply. 2001 , 44, 147	
1100	[Pulmonary hypertension screening in systemic scleroderma: a cohort study of 67 patients]. 2001 , 22, 819-29	11
1099	Antibodies to Th/To ribonucleoprotein in patients with localized scleroderma. 2001 , 40, 683-6	24
1098	Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. 2001 , 40, 1135-40	73

1097	Long-term therapy with plasma exchange in systemic sclerosis: effects on laboratory markers reflecting disease activity. 2001 , 25, 25-31	24
1096	Ambulatory electrogastrography in patients with sclerodermia, delayed gastric emptying, dyspepsia, and irritable bowel syndrome. Is there any clinical relevance?. 2001 , 12, 366-371	6
1095	Recognition and management of scleroderma in children. 2001 , 3, 575-83	12
1094	Autoantibodies against C-reactive protein (CRP) in sera of patients with systemic rheumatic diseases. 2001 , 11, 127-31	5
1093	Anti-endothelial cell antibodies (AECA) in systemic sclerosis--increased sensitivity using different endothelial cell substrates and association with other autoantibodies. 2001 , 33, 171-9	31
1092	Analysis of autoantibodies to cell cycle-associated antigens. 2001 , 11, 222-9	3
1091	Gastro-intestinal permeability is increased in patients with limited systemic sclerosis. 2001 , 30, 77-81	15
1090	Relative roles of endothelial cell damage and platelet activation in primary Raynaud's phenomenon (RP) and RP secondary to systemic sclerosis. 2001 , 30, 290-6	35
1089	Detection of Antinuclear Antibodies by Use of an Enzyme Immunoassay with Nuclear HEp-2 Cell Extract and Recombinant Antigens: Comparison with Immunofluorescence Assay in 307 Patients. 2001 , 47, 1649-1659	37
1088	Anti-fibrillin-1 autoantibodies in systemic sclerosis are GM and KM allotype-restricted. 2001 , 18, 123-9	19
1087	Autoantibody profile in progressive systemic sclerosis as markers for esophageal involvement. 2001 , 32, 123-7	13
1086	Primary pulmonary hypertension is not associated with scleroderma-like changes in nailfold capillaries. 2001 , 120, 796-800	18
1085	Interstitial pneumonia in progressive systemic sclerosis: serial high-resolution CT findings with functional correlation. 2001 , 25, 757-63	37
1084	Iontophoretic evaluation of vascular reactivity to acetylcholine in patients with primary Raynaud's phenomenon and systemic sclerosis. 2001 , 20, 451-2	11
1083	Static lung compliance as an index of early pulmonary disease in systemic sclerosis. 2001 , 20, 177-80	11
1082	Neurological complications of primary Sjögren's syndrome. 2001 , 248, 577-84	108
1081	Les troubles moteurs de l'œophage au cours de la sclérodémie systémique. A propos de 97 cas. 2001 , 31, 211-222	3
1080	Elevated serum L-selectin levels and decreased L-selectin expression on CD8(+) lymphocytes in systemic sclerosis. 2001 , 124, 474-9	19

1079	Circulating gamma/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization. 2001 , 125, 310-5	30
1078	Prevalence in myositis of antibodies recognizing anti-U3 RNA probably in a novel complex with 22/25 kD protein and not fibrillarin. 2001 , 126, 339-44	4
1077	Scleroderma in South Australia: epidemiological observations of possible pathogenic significance. 2001 , 31, 220-9	72
1076	Oesophageal pressure-cross-sectional area distributions and secondary peristalsis in relation to subclassification of systemic sclerosis. 2001 , 13, 199-210	34
1075	The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigen. <i>Arthritis and Rheumatism</i> , 2001 , 44, 389-96	61
1074	Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. <i>Arthritis and Rheumatism</i> , 2001 , 44, 550-60	207
1073	The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. <i>Arthritis and Rheumatism</i> , 2001 , 44, 653-61	84
1072	Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. <i>Arthritis and Rheumatism</i> , 2001 , 44, 735-6	171
1071	Possible role of antiidiotypes in the loss of anti-topoisomerase I antibodies: Comment on the article by Kuwana et al. <i>Arthritis and Rheumatism</i> , 2001 , 44, 737-737	
1070	Possible role of antiidiotypes in the loss of anti-topoisomerase I antibodies: comment on the article by Kuwana et al. <i>Arthritis and Rheumatism</i> , 2001 , 44, 737-8	1
1069	Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. <i>Arthritis and Rheumatism</i> , 2001 , 44, 893-901	105
1068	Pulmonary capillary endothelial dysfunction in early systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2001 , 44, 902-11	38
1067	Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1127-38	158
1066	Enhanced in vivo lipid peroxidation in scleroderma spectrum disorders. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1143-8	43
1065	Microchimerism in Japanese patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1226-8	27
1064	A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1351-8	302
1063	Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1359-62	211
1062	Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1363-9	78

1061	Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1382-6	89
1060	Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1667-76	73
1059	Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1841-7	206
1058	Abnormalities in fibrillin 1-containing microfibrils in dermal fibroblast cultures from patients with systemic sclerosis (scleroderma). <i>Arthritis and Rheumatism</i> , 2001 , 44, 1855-64	47
1057	Esophageal involvement and pulmonary manifestations in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2001 , 45, 346-54	164
1056	Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. <i>Arthritis and Rheumatism</i> , 2001 , 44, 2653-64	179
1055	Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. <i>Arthritis and Rheumatism</i> , 2001 , 44, 2665-78	141
1054	High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. 2001 , 31, 2936-41	64
1053	Proximal stomach function in systemic sclerosis: relationship with autonomic nerve function. 2001 , 46, 723-30	28
1052	Rheumatic manifestations in danish women with silicone breast implants. 2001 , 20, 345-52	15
1051	Levels of antibodies against C1q and 60 kDa family of heat shock proteins in the sera of patients with various autoimmune diseases. 2001 , 75, 103-9	39
1050	Glutathione S-transferase genotypes in systemic sclerosis and their association with clinical manifestations in early disease. 2001 , 2, 236-8	21
1049	Lack of association of a functionally relevant single nucleotide polymorphism of matrix metalloproteinase-1 promoter with systemic sclerosis (scleroderma). 2001 , 2, 273-5	12
1048	Women's health after plastic surgery. 2001 , 31, 77-89	11
1047	Comparative study of circulating immune complexes quantity detection by three assays--CIF-ELISA, C1q-ELISA and anti-C3 ELISA. 2001 , 253, 13-21	39
1046	Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. 2001 , 30, 332-46	184
1045	Pulmonary-renal syndrome in systemic sclerosis. 2001 , 30, 403-10	34
1044	Epidemiologic associations between occupational and environmental exposures and autoimmune disease: report of a meeting to explore current evidence and identify research needs. 2001 , 203, 483-95	11

1043	Evaluating the cutaneous involvement in scleroderma: torsional stiffness revisited. 2001 , 40, 128-32	9
1042	Increased urinary pyridinoline cross-link compounds of collagen in patients with systemic sclerosis and Raynaud's phenomenon. 2001 , 40, 140-6	12
1041	European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. 2001 , 60, 592-8	223
1040	Systemic sclerosis (scleroderma): specific autoantigen genes are selectively overexpressed in scleroderma fibroblasts. 2001 , 167, 7126-33	62
1039	Morphologic capillary changes and manifestations of connective tissue diseases in patients with primary biliary cirrhosis. 2001 , 10, 628-31	17
1038	Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. 2001 , 40, 1431-2	30
1037	Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale. 2001 , 60, 1117-22	51
1036	Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. 2001 , 60, 281-3	90
1035	Rigorous new approach to constructing a gold standard for validating new diagnostic criteria, as exemplified by the eosinophilia-myalgia syndrome. 2001 , 161, 2301-6	9
1034	Anti-fibrillar antibodies in systemic sclerosis. 2001 , 40, 1157-62	97
1033	Outcome measures and classification criteria for the rheumatic diseases. A compilation of data from OMERACT (Outcome Measures for Arthritis Clinical Trials), ILAR (International League of Associations for Rheumatology), regional leagues and other groups. 2001 , 40, 896-906	43
1032	Heavy cigarette smoking and RA. 2001 , 60, 1154-5	2
1031	Genotyping method for point mutation detection in the endothelial nitric oxide synthase exon 7 using fluorescent probes. Clinical validation in systemic sclerosis patients. 2001 , 39, 281-2	10
1030	Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. 2001 , 80, 252-62	199
1029	Study of Raynaud's phenomenon by means of infrared functional imaging.	1
1028	T-cell activation in the lungs of patients with systemic sclerosis and its relation with pulmonary fibrosis. 2001 , 120, 66S-68S	5
1027	Thrombotic thrombocytopenic purpura in a case of scleroderma renal crisis treated with twice-daily therapeutic plasma exchange. 2001 , 23, 737-42	16
1026	Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. 2001 , 40, 84-8	98

1025	Role of the free radical release process in the pathogenesis of morphea in contrast to systemic sclerosis. 2001 , 11, 321-7	2
1024	Gastric involvement in systemic sclerosis: a prospective study. 2001 , 96, 77-83	93
1023	Autoantibodies to the amino-terminal fragment of beta-fodrin expressed in glandular epithelial cells in patients with Sjögren's syndrome. 2001 , 167, 5449-56	30
1022	Distinct autoreactive T cell responses to native and fragmented DNA topoisomerase I: influence of APC type and IL-2. 2001 , 166, 5456-63	17
1021	Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients. 2001 , 60, 1046-9	78
1020	Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). 2001 , 40, 89-94	78
1019	Impaired catecholaminergic signalling of B lymphocytes in patients with chronic rheumatic diseases. 2001 , 60, 505-10	18
1018	Assessment of pituitary gonadotropin release to gonadotropin releasing hormone/thyroid-stimulating hormone stimulation in women with systemic sclerosis. 2001 , 40, 310-4	15
1017	Autoantibodies to the 27 C-terminal amino acids of calpastatin are detected in a restricted set of connective tissue diseases and may be useful for diagnosis of rheumatoid arthritis in community cases of very early arthritis. 2001 , 40, 1126-34	18
1016	Pyrexia and normal C-reactive protein (CRP) in patients with systemic lupus erythematosus: always consider the possibility of infection in febrile patients with systemic lupus erythematosus regardless of CRP levels. 2001 , 40, 349-50	12
1015	European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. 2001 , 60, 585-91	65
1014	Psychiatric symptoms associated with scleroderma. 2001 , 70, 145-50	51
1013	Prevalence of TTV DNA and GBV-C RNA in patients with systemic sclerosis, rheumatoid arthritis, and osteoarthritis does not differ from that in healthy blood donors. 2001 , 60, 806-9	11
1012	Systemic sclerosis with pencil-in-cup deformity. 2001 , 40, 594-5	3
1011	Imaging of the pulmonary manifestations of systemic disease. 2001 , 77, 621-38	18
1010	Low levels of nitric oxide (NO) in systemic sclerosis: inducible NO synthase production is decreased in cultured peripheral blood monocyte/macrophage cells. 2001 , 40, 1089-96	32
1009	Isolated digital infarction associated with anticentromere antibody. 2001 , 40, 355-7	6
1008	Renal vascular damage in Japanese patients with systemic sclerosis. 2001 , 40, 406-9	30

1007	Psychiatric dysfunction in connective tissue diseases: association with Sjögren's syndrome. 2001 , 11, 197-204	
1006	Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis. 2002 , 61, 121-7	49
1005	Dermatomyositis-scleroderma overlap syndrome presenting as autoimmune haemolytic anaemia. 2002 , 41, 956-8	7
1004	Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. 2002 , 168, 3649-59	163
1003	Non-invasive measurement of biomechanical skin properties in systemic sclerosis. 2002 , 61, 237-41	36
1002	Identification of human autoantibodies to the DNA ligase IV/XRCC4 complex and mapping of an autoimmune epitope to a potential regulatory region. 2002 , 169, 3413-21	38
1001	Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. 2002 , 61, 554-8	3675
1000	T cell reactivity against the SmD1(83-119) C terminal peptide in patients with systemic lupus erythematosus. 2002 , 61, 779-85	13
999	Systemic sclerosis and occupational risk factors: a case-control study. 2002 , 59, 545-9	76
998	Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases. 2002 , 61, 842-6	35
997	Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. 2002 , 61, 161-6	149
996	Analysis of transforming growth factor beta1 gene polymorphisms in patients with systemic sclerosis. 2002 , 61, 678-81	64
995	Raynaud's phenomenon: Infrared functional imaging applied to diagnosis and drug effects. 2002 , 15, 41-52	20
994	T-cell receptor β mRNA with an alternatively spliced 3' untranslated region is generated predominantly in the peripheral blood T cells of systemic lupus erythematosus patients. 2002 , 12, 167-73	14
993	Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. 2002 , 165, 1581-6	594
992	Elevated levels of circulating CD44 in patients with systemic sclerosis: association with a milder subset. 2002 , 41, 1149-54	9
991	The wafer test: a semi-quantitative test to screen for xerostomia. 2002 , 41, 381-9	28
990	Influence of prior pregnancies on disease course and cause of death in systemic sclerosis. 2002 , 61, 346-50	29

989	Anti-U5 snRNP antibody as a possible serological marker for scleroderma-polymyositis overlap. 2002 , 41, 531-4	11
988	Superior mesenteric artery blood flow in systemic sclerosis patients. 2002 , 41, 730-4	6
987	Inflammatory myositis associated with anti-U1-small nuclear ribonucleoprotein antibodies: a subset of myositis associated with a favourable outcome. 2002 , 41, 1040-6	34
986	Preliminary thermographic evaluation of new nitroglycerine tape on the peripheral circulatory disturbance in systemic sclerosis. 2002 , 61, 177-9	25
985	Elevated expression of the genes encoding TNF-alpha and thromboxane synthase in leucocytes from patients with systemic sclerosis. 2002 , 41, 869-75	24
984	Pertechnegas lung clearance in different forms of interstitial lung disease. 2002 , 19, 31-6	6
983	Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to the detailed serotype. 2002 , 61, 1090-4	36
982	Pregnancy outcome in patients with undifferentiated connective tissue disease: a preliminary study on 25 pregnancies. 2002 , 11, 304-7	26
981	Connective tissue disease and the skin. 2002 , 2, 9-14	1
980	Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. 2002 , 81, 139-53	516
979	Pulmonary involvement in mixed connective tissue disease: comparison with other collagen vascular diseases using high resolution CT. 2002 , 26, 349-57	46
978	Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. 2002 , 81, 154-67	241
977	Male microchimerism in healthy women and women with scleroderma: cells or circulating DNA? A quantitative answer. 2002 , 100, 2845-51	154
976	Sclerodermatous graft-vs-host disease: clinical and pathological study of 17 patients. 2002 , 138, 924-34	79
975	Thyroid hormone autoantibodies in primary Sjögren syndrome and rheumatoid arthritis are more prevalent than in autoimmune thyroid disease, becoming progressively more frequent in these diseases. 2002 , 25, 447-54	41
974	High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis. 2002 , 112, 540-4	59
973	Expression of the costimulatory molecule BB-1 and its receptors in patients with scleroderma-polymyositis overlap syndrome. 2002 , 205, 65-70	5
972	Functions of the stratum corneum in systemic sclerosis as distinct from hypertrophic scar and keloid functions. 2002 , 29, 49-53	12

971	Antibody-mediated gastrointestinal dysmotility in scleroderma. 2002 , 123, 1144-50	117
970	Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. 2002 , 4, R11	192
969	Autoantibodies directed to novel components of the PM/Scl complex, the human exosome. 2002 , 4, 134-8	69
968	Autoantibody to DNA binding protein B as a novel serologic marker in systemic sclerosis. 2002 , 299, 549-54	15
967	Systemic Sclerosis. 2002 , 30, 36-41	3
966	Long-term administration of beraprost, an oral prostacyclin analogue, improves pulmonary diffusion capacity in patients with systemic sclerosis. 2002 , 67, 45-9	4
965	A variant of acrokeratoelastoidosis in systemic scleroderma: report of 7 cases. 2002 , 46, 767-70	17
964	Prevalence of 52-kd and 60-kd Ro/SS-A autoantibodies in Japanese patients with polymyositis/dermatomyositis. 2002 , 47, 148-51	17
963	Sleep disruption in systemic sclerosis (scleroderma) patients: clinical and polysomnographic findings. 2002 , 3, 341-5	62
962	Vasoactive intestinal peptide binding autoantibodies in autoimmune humans and mice. 2002 , 23, 2251-7	17
961	[Immunological diagnosis of scleroderma]. 2002 , 50, 243-55	1
960	Association of 5'-untranslated region of the Fibrillin-1 gene with Japanese scleroderma. 2002 , 297, 61-7	21
959	High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. 2002 , 100, 1602-1610	149
958	Homocysteine levels in patients with Raynaud's phenomenon. 2002 , 31, 87-90	12
957	Infrared functional imaging applied to Raynaud's phenomenon. 2002 , 21, 73-9	44
956	Quantifying the relevance and stage of disease with the Tau image technique. 2002 , 21, 86-91	26
955	Systemic sclerosis. 2002 , 16, 807-16	36
954	Feto-maternal microchimerism in connective tissue diseases. 2002 , 32, 3405-13	49

953	Effect of dynamic strength training on functional capacity in rheumatoid arthritis: comment on the article by H&Kinen et al. <i>Arthritis and Rheumatism</i> , 2002 , 46, 274-6	1
952	Reply. <i>Arthritis and Rheumatism</i> , 2002 , 46, 274-276	2
951	Absence of anti-p53 antibodies in Chinese patients with rheumatoid arthritis and systemic lupus erythematosus: comment on the concise communication by Kovacs et al. <i>Arthritis and Rheumatism</i> , 2002 , 46, 276-7	4
950	Reply. <i>Arthritis and Rheumatism</i> , 2002 , 46, 276-277	3
949	Onset of rheumatoid arthritis following curative treatment of a somatostatinoma. <i>Arthritis and Rheumatism</i> , 2002 , 46, 277-8	7
948	Clinical and prognostic value of antineutrophil cytoplasmic antibodies in Wegener's granulomatosis and microscopic polyangiitis: comment on the article by Russell et al. <i>Arthritis and Rheumatism</i> , 2002 , 46, 278-80	5
947	Reply. <i>Arthritis and Rheumatism</i> , 2002 , 46, 279-280	1
946	Failure to detect antinucleosome antibodies in scleroderma: comment on the article by Amoura et al. <i>Arthritis and Rheumatism</i> , 2002 , 46, 280-2	23
945	Reply. <i>Arthritis and Rheumatism</i> , 2002 , 46, 281-282	9
944	Erratum. <i>Arthritis and Rheumatism</i> , 2002 , 46, 282-282	2
943	Presence of microchimerism in labial salivary glands in systemic sclerosis but not in Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1039-43	40
942	Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1019-27	1324
941	Assessment of vascular function in systemic sclerosis: indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1324-32	48
940	Increased urinary F2-isoprostanes in systemic sclerosis, but not in primary Raynaud's phenomenon: effect of cold exposure. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1319-23	39
939	Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1857-65	100
938	Rituximab for the treatment of type II mixed cryoglobulinemia. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2252-4; author reply 2254-5	47
937	Parvovirus B19 infection of cultured skin fibroblasts from systemic sclerosis patients: comment on the article by Ray et al. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2262-3; author reply 2263-4	22
936	Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2257-8; author reply 2259	22

935	Reply. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2254-2255	4
934	Reply. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2263-2264	2
933	Reply. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2259-2259	
932	Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1602-13	118
931	Antifibroblast antibodies from systemic sclerosis patients are internalized by fibroblasts via a caveolin-linked pathway. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1595-601	32
930	Reply. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2257-2257	36
929	Reply. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2260-2260	
928	Anti-tumor necrosis factor therapy and <i>Listeria monocytogenes</i> infection: report of two cases. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2255-7; author reply 2257	64
927	Criteria for TUNEL labeling in determining apoptosis in human osteoarthritis cartilage: Comment on the article by Aigner et al. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2260-1	11
926	Silicone breast implants do not cause rheumatic diseases, but can they influence them?. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2545	
925	Synovial lymphocyte responses to microbiologic antigen stimulation indicate the etiology of undifferentiated and reactive arthritis, and possibly of rheumatoid arthritis: Comment on the article by Schnarr et al. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2259-60; author reply 2260	0
924	Is the Sp1 polymorphism in the COL1A1 gene a risk factor for postmenopausal osteoporosis? Comment on the article by Keen et al. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2828-9	2
923	Treatment with gonadotropin-releasing hormone agonists and prevention of multiple gestations in lupus or antiphospholipid syndrome patients undergoing in vitro fertilization: comment on the article by Guballa et al. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2542; author reply 2542	3
922	Reply. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2542-2542	
921	Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima et al. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2539-41; author reply 2541-2	77
920	Reply. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2541-2542	4
919	Laboratory tests and "likelihood ratios": comment on the editorial by Kavanaugh. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2547; author reply 2547	1
918	Reply. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2547-2547	3

917	Recognition of Granzyme B-generated autoantigen fragments in scleroderma patients with ischemic digital loss. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1873-84	64
916	Use of triamcinolone hexacetonide for the treatment of osteoarthritis of the hip: comment on the letter by Margules. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2546-7; author reply 2547	3
915	Reply. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2547-2547	15
914	The neural network as a predictor of cancer in patients with inflammatory myopathies. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2547-8	8
913	Blocking tumor necrosis factor inhibits radiographic damage even in patients who show minimal or no clinical improvement: comment on the concise communication by Boers. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2817-8; author reply 2718-21	6
912	Reply. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2818-2820	1
911	Differentiation of hyaluronate products by qualitative differences in their immunogenicity in rabbits: possible mechanism for product-specific severe adverse reactions? Comment on the article by Martens. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2543-4; author reply 2544	31
910	Reply. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2544-2544	
909	Case series of selective anti-tumor necrosis factor alpha therapy using infliximab in patients with nonresponsive chronic HLA-B27-associated anterior uveitis: comment on the articles by Brandt et al. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2821-2; author reply 2822-4	14
908	Reply. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2822-2824	11
907	Is expression of intracellular citrullinated proteins in synovial tissue specific for rheumatoid arthritis? Comment on the article by Baeten et al. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2824-6; author reply 2826-7	9
906	Reply. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2826-2827	5
905	On my knees (Instructions to Authors). <i>Arthritis and Rheumatism</i> , 2002 , 46, 2264-2264	
904	Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2410-20	223
903	Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2829-30	44
902	Identification of an immunodominant epitope on RNA polymerase III recognized by systemic sclerosis sera: application to enzyme-linked immunosorbent assay. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2742-7	39
901	Reply. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2828-2828	
900	Is acquired C1 inhibitor deficiency associated with lupus a distinct disease entity? Comment on the article by Cacoub et al. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2827-8; author reply 2828	

899	Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. <i>Arthritis and Rheumatism</i> , 2002 , 47, 434-44	370
898	Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2983-9	159
897	Association of novel polymorphisms with the expression of SPARC in normal fibroblasts and with susceptibility to scleroderma. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2990-9	69
896	Microchimerism in systemic sclerosis: comment on the article by Johnson et al. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2538; author reply 2538-9	0
895	Reply. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2538-2539	0
894	Treatment of fibromyalgia with sibutramine hydrochloride monohydrate: comment on the article by Goldenberg et al. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2545-6; author reply 2546	11
893	Reply. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2546-2546	1
892	Comment on the reply by Boers. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2820-2821	1
891	Erratum. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2830-2830	1
890	The genetics of systemic sclerosis. 2002 , 4, 99-107	51
889	Exposure to solvents in female patients with scleroderma. 2002 , 21, 114-8	20
888	Effects of cisapride on oesophageal transit of solids in patients with progressive systemic sclerosis. 2002 , 21, 43-5	24
887	Autoantibodies against cytoskeletal proteins in rheumatoid arthritis. 2002 , 21, 505-10	19
886	Clinical features of liver disturbance in rheumatoid diseases: clinicopathological study with special reference to the cause of liver disturbance. 2002 , 37, 617-25	48
885	HLA class II haplotypes associated with pulmonary interstitial lesions of polymyositis/dermatomyositis in Japanese patients. 2002 , 59, 25-30	12
884	Histometric data obtained by in vivo confocal laser scanning microscopy in patients with systemic sclerosis. 2002 , 2, 8	14
883	The potential risk factors leading to peptic ulcer formation in autoimmune disease patients receiving corticosteroid treatment. 2002 , 16, 1241-8	15
882	The polymorphism of telomerase RNA component gene in patients with systemic sclerosis. 2002 , 147, 250-4	10

881	The polymorphism of transforming growth factor-beta1 gene in Japanese patients with systemic sclerosis. 2002 , 147, 458-63	42
880	Decreased MMP-9 activity in the serum of patients with diffuse cutaneous systemic sclerosis. 2002 , 27, 301-5	13
879	Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations. 2002 , 130, 532-40	55
878	Abnormal expression of intracellular cytokines and chemokine receptors in peripheral blood T lymphocytes from patients with systemic sclerosis. 2002 , 130, 548-56	39
877	Pulmonary diffusion capacity in patients with systemic lupus erythematosus. 2002 , 7, 45-9	31
876	Evolution of ambulatory measurement of blood pressure and parameters of arterial stiffness over a 1-year period in patients with systemic sclerosis: ERAMS study. 2002 , 16, 627-30	26
875	Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. 2002 , 966, 238-46	83
874	Thin-section chest CT findings of primary Sjögren's syndrome: correlation with pulmonary function. 2002 , 12, 1504-11	73
873	[Comparison between line immunoassay (LIA) and enzyme-linked immunosorbent assay (ELISA) for the determination of antibodies to extractable nuclear antigens (ENA) with reference to other laboratory results and clinical features]. 2002 , 61, 534-44	2
872	Helicobacter pylori infection in connective tissue disorders is associated with high levels of antibodies to mycobacterial hsp65 but not to human hsp60. 2002 , 7, 250-6	37
871	Simultaneous presence of neutrophil alveolitis and Ki-67 positivity of alveolar macrophages in dermato-/polymyositis and systemic sclerosis. 2003 , 23, 6-10	6
870	Elevated circulating soluble CD40 ligand in patients with mixed connective tissue disease. 2003 , 22, 37-9	8
869	Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities. 2003 , 22, 102-6	45
868	Vascular damage and lack of angiogenesis in systemic sclerosis skin. 2003 , 22, 196-202	39
867	Low-dose intravenous cyclophosphamide in systemic sclerosis: a preliminary safety study. 2003 , 22, 393-6	12
866	Interstitial lung disease in systemic sclerosis. 2003 , 44, 258-64	25
865	Peripheral neuropathy in scleroderma. 2003 , 28, 330-5	37
864	Identification of an IL1A gene segment that determines aberrant constitutive expression of interleukin-1 alpha in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2003 , 48, 193-202	17

863	Association of IL1A gene polymorphisms with susceptibility to and severity of systemic sclerosis in the Japanese population. <i>Arthritis and Rheumatism</i> , 2003 , 48, 186-92	61
862	A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. <i>Arthritis and Rheumatism</i> , 2003 , 48, 203-9	145
861	Cellular microchimerism as a lifelong physiologic status in parous women: an immunologic basis for its amplification in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2003 , 48, 1109-16	28
860	Autoantibodies against B23, a nucleolar phosphoprotein, occur in scleroderma and are associated with pulmonary hypertension. <i>Arthritis and Rheumatism</i> , 2003 , 49, 85-92	63
859	Selective stimulation of collagen synthesis in the presence of costimulatory insulin signaling by connective tissue growth factor in scleroderma fibroblasts. <i>Arthritis and Rheumatism</i> , 2003 , 48, 798-806	44
858	Association of common variation in glutathione S-transferase genes with premature development of cardiovascular disease in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2003 , 48, 854-5	29
857	Anti-c-Mpl (thrombopoietin receptor) autoantibody-induced amegakaryocytic thrombocytopenia in a patient with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2003 , 48, 1647-51	24
856	Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease. <i>Arthritis and Rheumatism</i> , 2003 , 48, 1639-46	39
855	Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. <i>Arthritis and Rheumatism</i> , 2003 , 48, 2246-55	683
854	Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients. <i>Arthritis and Rheumatism</i> , 2003 , 48, 2262-74	97
853	Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2003 , 48, 2256-61	53
852	Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. <i>Arthritis and Rheumatism</i> , 2003 , 48, 2593-604	79
851	Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. <i>Arthritis and Rheumatism</i> , 2003 , 48, 1964-78	154
850	Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse. <i>Arthritis and Rheumatism</i> , 2003 , 48, 1979-91	72
849	Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence. <i>Arthritis and Rheumatism</i> , 2003 , 48, 2585-92	77
848	N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. <i>Arthritis and Rheumatism</i> , 2003 , 48, 3503-8	109
847	Systemic sclerosis: patients' perceptions of their condition. <i>Arthritis and Rheumatism</i> , 2003 , 49, 689-96	77
846	Clinical and immunological profile of primary Sjogren's syndrome in Kuwait: First report from Middle East. 2003 , 6, 16-20	0

845	The prevalence and clinical significance of anti-U1 RNA antibodies in patients with systemic sclerosis. 2003 , 120, 204-10	26
844	Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. 2003 , 120, 542-7	71
843	Bronchoalveolar lavage fluid cells in mixed connective tissue disease. 2003 , 8, 149-56	18
842	Occurrence of peptic ulcer disease in connective tissue disease patients associated with xerostomia. 2003 , 17, 217-24	5
841	Elevated exhalation of hydrogen peroxide in patients with systemic sclerosis. 2003 , 33, 274-9	21
840	Serum nitric oxide (NO) levels in systemic sclerosis patients: correlation between NO levels and clinical features. 2003 , 134, 538-44	40
839	Analysis of transmural trends in myocardial integrated backscatter in patients with progressive systemic sclerosis. 2003 , 16, 340-6	13
838	Scleroderma epidemiology. 2003 , 29, 239-54	230
837	14. Immunologic rheumatic disorders. 2003 , 111, S593-601	7
836	Manifestaciones neurológicas en la esclerosis sistémica. 2003 , 203, 373-377	4
835	Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. 2003 , 9, 311-7	86
834	The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. 2003 , 42, 534-40	111
833	[Systemic lupus erythematosus in Tunisia. A multicentric study. About 295 cases]. 2003 , 24, 768-74	5
832	Pulmonary functional abnormalities in asymptomatic patients with systemic sclerosis. 2003 , 14, 162-165	0
831	Treatment of mechanical low back pain in a patient with progressive systemic sclerosis (scleroderma): a case report. 2003 , 6, 55-62	
830	Distinct immune profiles characterize patients with diffuse or limited systemic sclerosis. 2003 , 108, 21-8	24
829	The assessment of the patient with systemic sclerosis. 2003 , 2, 370-6	26
828	Autoantibodies to low-density-lipoprotein-receptor-related protein 2 (LRP2) in systemic autoimmune diseases. 2003 , 5, R174-80	11

827	Long-term outcome of primary Raynaud's phenomenon and its conversion to connective tissue disease: a 12-year retrospective patient analysis. 2003 , 32, 343-7	27
826	Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. 2003 , 62, 431-4	84
825	Connective tissue diseases in later life. 2003 , 13, 107-118	
824	Expression of macrophage migration inhibitory factor in diffuse systemic sclerosis. 2003 , 62, 460-4	38
823	Risk of cancer in patients with scleroderma: a population based cohort study. 2003 , 62, 728-31	134
822	Detection of early impairment of coronary flow reserve in patients with systemic sclerosis. 2003 , 62, 890-3	76
821	Systemic and cell type-specific gene expression patterns in scleroderma skin. 2003 , 100, 12319-24	334
820	Transcriptional inhibition of type I collagen gene expression in scleroderma fibroblasts by the antineoplastic drug ecteinascidin 743. 2003 , 278, 40400-7	14
819	Testing for anti-nucleosome antibodies in daily practice: a monocentric evaluation in 1696 patients. 2003 , 12, 833-7	20
818	Scleroderma and solvent exposure among women. 2003 , 157, 493-500	54
817	Plasma plasmin-alpha2-plasmin inhibitor complex levels are increased in systemic sclerosis patients with pulmonary hypertension. 2003 , 42, 240-3	22
816	Interstitial lung disease in systemic sclerosis: An HRCT-clinical correlative study. 2003 , 44, 258-264	33
815	Inhibition of fibrocyte differentiation by serum amyloid P. 2003 , 171, 5537-46	252
814	Simultaneous identification of various antinuclear antibodies using an automated multiparameter line immunoassay system. 2003 , 12, 623-9	26
813	The Assessment of Anti-Endothelial Cell Antibodies in Scleroderma-Associated Pulmonary Fibrosis. 2003 , 120, 596-606	43
812	A nuclear target for interleukin-1alpha: interaction with the growth suppressor necdin modulates proliferation and collagen expression. 2003 , 100, 10008-13	60
811	Analysis of the 5' flanking region of the interleukin 10 gene in patients with systemic sclerosis. 2003 , 42, 1295-8	25
810	Calculated glomerular filtration rate is a useful screening tool to identify scleroderma patients with renal impairment. 2003 , 42, 26-33	40

809	Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker. 2004 , 43, 220-4	80
808	Retinal findings in systemic sclerosis: a comparison with nailfold capillaroscopic patterns. 2003 , 62, 204-7	28
807	Autoantibodies to the epidermal growth factor receptor in systemic sclerosis, lupus, and autoimmune mice. 2003 , 17, 136-43	12
806	A novel protein highly expressed in testis is overexpressed in systemic sclerosis fibroblasts and targeted by autoantibodies. 2003 , 171, 6883-90	13
805	Predictors of end stage lung disease in a cohort of patients with scleroderma. 2003 , 62, 146-50	91
804	Seventeen-point dermal ultrasound scoring system--a reliable measure of skin thickness in patients with systemic sclerosis. 2003 , 42, 1559-63	110
803	Evaluation of caspase 1 and sFas serum levels in patients with systemic sclerosis: correlation with lung dysfunction, joint and bone involvement. 2003 , 12, 339-43	0
802	Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease. 2017 , 12, e0181692	44
801	Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease. 2017 , 12, e0187580	46
800	Scleroderma in hospital settings in Lombardy: 50 cases. 2017 , 27, 446-448	4
799	Anti-SmD1 antibodies are associated with renal disorder, seizures, and pulmonary arterial hypertension in Chinese patients with active SLE. 2017 , 7, 7617	9
798	The relationship between the degree of skin fibrosis by sonoelastography and the degree of pulmonary involvement in scleroderma. 2017 , 47, 1555-1559	6
797	Circulating angiostatin serum level in patients with systemic sclerosis. 2017 , 34, 543-546	2
796	Neutrophil-to-lymphocyte Ratio in Diagnosis of Systemic Sclerosis for Prediction of Interstitial Lung Disease. 2017 , 24, 138	2
795	Validity of the PROMIS-29 in a large Australian cohort of patients with systemic sclerosis. 2017 , 2, 188-195	4
794	Results of surgical interventions for critical limb ischemia due to vasculitis or collagen-tissue related disease. 2017 , 36, 332-339	0
793	Evaluation of Vitamin B12 Deficiency and Associated Factors in Patients With Systemic Sclerosis. 2018 , 24, 250-254	6
792	Common measure of quality of life for people with systemic sclerosis across seven European countries: a cross-sectional study. 2018 , 77, 1032-1038	9

791	High Prevalence of Antithyroid Antibodies in a New Zealand Cohort of Patients With Systemic Sclerosis. 2018 , 24, 264-271	5
790	High prevalence of occupational exposure to solvents or silica in male systemic sclerosis patients: a Belgian cohort analysis. 2018 , 37, 1977-1982	14
789	The impact of malnutrition on quality of life in patients with systemic sclerosis. 2018 , 72, 504-510	13
788	Free light chains of immunoglobulins in patients with systemic sclerosis: correlations with lung involvement and inflammatory milieu. 2018 , 71, 620-625	11
787	Development of a Neo-Epitope Specific Assay for Serological Assessment of Type VII Collagen Turnover and Its Relevance in Fibroproliferative Disorders. 2018 , 16, 123-131	3
786	Differences in clinical presentation and incidence of cardiopulmonary involvement in late-onset versus early-onset systemic sclerosis: inception cohort study. 2018 , 21, 1082-1092	4
785	Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. 2018 , 77, 1179-1186	42
784	Inhibitory Regulation of Skin Fibrosis in Systemic Sclerosis by Apelin/APJ Signaling. 2018 , 70, 1661-1672	21
783	Systemic sclerosis and malignancy. 2018 , 21, 1093-1097	9
782	Relationship between interstitial lung disease and oesophageal dilatation on chest high-resolution computed tomography in patients with systemic sclerosis: a cross-sectional study. 2018 , 123, 655-663	11
781	Diagnostic value of screening enzyme immunoassays compared to indirect immunofluorescence for anti-nuclear antibodies in patients with systemic rheumatic diseases: A systematic review and meta-analysis. 2018 , 48, 334-342	2
780	Anti-DFS70 autoantibodies in undifferentiated connective tissue diseases subjects: what's on the horizon?. 2018 , 57, 1293-1298	12
779	Performance of the St George's Respiratory Questionnaire in patients with connective tissue disease-associated interstitial lung disease. 2018 , 23, 851	13
778	Outcomes and Mortality Prediction Model of Critically Ill Adults With Acute Respiratory Failure and Interstitial Lung Disease. 2018 , 153, 1387-1395	20
777	Stem cell transplant in systemic sclerosis: An Indian experience. 2018 , 21, 859-865	5
776	Does nailfold capillaroscopy help predict future outcomes in systemic sclerosis? A systematic literature review. 2018 , 48, 482-494	32
775	Study of the osteoprotegerin/receptor activator of nuclear factor- κ B ligand system association with inflammation and atherosclerosis in systemic sclerosis. 2018 , 47, 241-250	9
774	Olfactory function in systemic lupus erythematosus and systemic sclerosis. A longitudinal study and review of the literature. 2018 , 17, 405-412	17

773	Pulmonary Arterial Hemodynamic Assessment by a Novel Index in Systemic Sclerosis Patients: Pulmonary Pulse Transit Time. 2018 , 196, 173-178	5
772	Changes in macrophage transcriptome associate with systemic sclerosis and mediate contribution to disease risk. 2018 , 77, 596-601	35
771	Moving towards a molecular taxonomy of autoimmune rheumatic diseases. 2018 , 14, 75-93	47
770	Antisense Long Non-Coding RNAs Are Deregulated in Skin Tissue of Patients with Systemic Sclerosis. 2018 , 138, 826-835	25
769	Autologous haematopoietic stem cell transplantation for Japanese patients with systemic sclerosis: Long-term follow-up on a phase II trial and treatment-related fatal cardiomyopathy. 2018 , 28, 879-884	10
768	Impact of double positive for anti-centromere and anti-SS-a/Ro antibodies on clinicopathological characteristics of primary Sjögren's syndrome: a retrospective cohort study. 2018 , 28, 872-878	6
767	Echocardiographic assessment of regional right ventricular systolic function using two-dimensional strain echocardiography and evaluation of the predictive ability of longitudinal 2D-strain imaging for pulmonary arterial hypertension in systemic sclerosis patients. 2018 , 34, 883-892	8
766	Anti-citrullinated peptides antibodies in systemic sclerosis: Meta-analysis of frequency and meaning. 2018 , 85, 147-153	10
765	Impact of Radiation Therapy on Scleroderma and Cancer Outcomes in Scleroderma Patients With Breast Cancer. 2018 , 70, 1517-1524	10
764	Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease. 2018 , 21, 477-486	24
763	Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group. 2018 , 38, 363-374	28
762	Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis. 2018 , 57, 712-717	26
761	Work productivity in systemic sclerosis, its economic burden and association with health-related quality of life. 2018 , 57, 73-83	13
760	Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression. 2018 , 20, 75	24
759	Different profile of cytokine production in patients with systemic sclerosis and association with clinical manifestations. 2018 , 198, 12-16	16
758	Novel optical assessments of tissue composition and viability using fluorescence spectroscopy and tissue oxygenation spectrophotometry in patients with systemic sclerosis: a pilot study. 2018 , 39, 03NT02	6
757	Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis. 2018 , 51,	50
756	The emerging application of semi-quantitative and quantitative capillaroscopy in systemic sclerosis. 2018 , 118, 113-120	13

755	Angiogenic and inflammatory biomarkers for screening and follow-up in patients with pulmonary arterial hypertension. 2018 , 47, 319-324	18
754	Prevalence and predictors of hand involvement in Thai patients with systemic sclerosis. 2018 , 21, 240-248	3
753	Elevated serum levels of interleukin-1 β and interleukin-33 in patients with systemic sclerosis in Chinese population. 2018 , 77, 151-159	11
752	Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group. 2018 , 57, 441-450	39
751	Optical coherence tomography as a method for quantitative skin evaluation in systemic sclerosis. 2018 , 77, 465-466	12
750	Role of STAT3 in skin fibrosis and transforming growth factor beta signalling. 2018 , 57, 1838-1850	28
749	Mechanics and prognostic value of left and right ventricular dysfunction in patients with systemic sclerosis. 2018 , 19, 660-667	9
748	The involvement of galectin-3 in skin injury in systemic lupus erythematosus patients. 2018 , 27, 621-627	8
747	Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial. 2018 , 70, 308-316	55
746	Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. 2018 , 57, 152-157	7
745	Capillary loss on nailfold capillary microscopy is associated with mortality in systemic sclerosis. 2018 , 37, 475-481	8
744	2013 ACR/EULAR systemic sclerosis classification criteria in patients with associated pulmonary arterial hypertension. 2018 , 47, 870-876	4
743	The EuroMyositis registry: an international collaborative tool to facilitate myositis research. 2018 , 77, 30-39	105
742	Red blood cell distribution width as a related factor of pulmonary arterial hypertension in patients with systemic sclerosis. 2018 , 37, 979-985	12
741	First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study. 2018 , 37, 999-1009	21
740	Autoimmune rheumatic diseases and the risk of Parkinson disease: a nationwide population-based cohort study in Taiwan. 2018 , 50, 83-90	26
739	14-3-3z sequesters cytosolic T-bet, upregulating IL-13 levels in T2 and CD8 lymphocytes from patients with scleroderma. 2018 , 142, 109-119.e6	11
738	Determining the Risk Factors and Clinical Features Associated With Severe Gastrointestinal Dysmotility in Systemic Sclerosis. 2018 , 70, 1385-1392	17

737	Interstitial lung disease in South Africans with systemic sclerosis. 2018 , 38, 657-662	14
736	An Ultrasound Surface Wave Technique for Assessing Skin and Lung Diseases. 2018 , 44, 321-331	36
735	High Baseline Serum Clara Cell 16 kDa Predicts Subsequent Lung Disease Worsening in Systemic Sclerosis. 2018 , 45, 242-247	3
734	Increased frequencies of circulating CXCL10-, CXCL8- and CCL4-producing monocytes and Siglec-3-expressing myeloid dendritic cells in systemic sclerosis patients. 2018 , 67, 169-177	18
733	Sirtuin1 Protects against Systemic Sclerosis-related Pulmonary Fibrosis by Decreasing Proinflammatory and Profibrotic Processes. 2018 , 58, 28-39	40
732	Systemic therapy with calcitonin has positive clinical effects on systemic sclerosis in patients with cutaneous manifestations. 2018 , 28, 364-369	3
731	Occupational Connective Tissue Disorders. 2018 , 1-34	0
730	Lung cancer in connective tissue disease-associated interstitial lung disease: clinical features and impact on outcomes. 2018 , 10, 799-807	15
729	The impact of slice-reduced computed tomography on histogram-based densitometry assessment of lung fibrosis in patients with systemic sclerosis. 2018 , 10, 2142-2152	14
728	Raynaud's Phenomenon. 2018 ,	
727	Clinical Characteristics of Systemic Sclerosis With Interstitial Lung Disease. 2018 , 33, 322-327	14
726	A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility. 2018 , 13, e0209343	3
725	Clinical Significance of Serum Galectin-9 and Soluble CD155 Levels in Patients with Systemic Sclerosis. 2018 , 2018, 9473243	9
724	Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study. 2018 , 20, 267	16
723	Value of Serum Carbohydrate Antigen 19-9 and Carcinoembryonic Antigen in Evaluating Severity and Prognosis of Connective Tissue Disease-Associated Interstitial Lung Disease. 2018 , 33, 190-197	7
722	Left Ventricular Diastolic Dysfunction Predicts Mortality in Patients With Systemic Sclerosis. 2018 , 72, 1804-1813	38
721	ADAMTS13 deficiency and immunological abnormalities in patients with systemic sclerosis. 2018 , 35, 182-184	
720	Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis. 2018 , 32, 223-240	33

719	New insights into the genetics and epigenetics of systemic sclerosis. 2018 , 14, 657-673	50
718	Prospective evaluation of the capillaroscopic skin ulcer risk index in systemic sclerosis patients in clinical practice: a longitudinal, multicentre study. 2018 , 20, 239	2
717	Association of low socioeconomic status and physician assessment of disease severity with oral health-related quality of life in patients with systemic sclerosis: a pilot study from Croatia, a country in transition. 2018 , 46, 5127-5136	6
716	Connective Tissue Related Interstitial Lung Disease. 2018 , 7, 133-148	
715	Anti-endothelial cell antibodies do not correlate with disease activity in systemic sclerosis. 2018 , 35, 185-191	5
714	Clinical pattern of systemic sclerosis in Central Ukraine. Association between clinical manifestations of systemic sclerosis and hypertension. 2018 , 56, 24-30	1
713	Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression. 2018 , 15, 1427-1433	26
712	Survival rate, causes of death, and risk factors in systemic sclerosis: a large cohort study. 2018 , 37, 3051-3056	11
711	Single Cell RNA Sequencing Identifies HSPG2 and APLNR as Markers of Endothelial Cell Injury in Systemic Sclerosis Skin. 2018 , 9, 2191	23
710	High burden of skin sclerosis is associated with severe organ involvement in patients with systemic sclerosis and systemic sclerosis overlap syndrome. 2018 , 38, 2279-2288	3
709	Hemodynamic heterogeneity of connective tissue disease patients with borderline mean pulmonary artery pressure and its distinctive characters from those with normal pulmonary artery pressure: a retrospective study. 2018 , 37, 3373-3380	3
708	Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. 2018 , 70, 1829-1834	6
707	Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. 2018 , 70, 912-919	18
706	Impact of systemic sclerosis oral manifestations on patients' health-related quality of life: A systematic review. 2018 , 47, 808-815	14
705	Genetic differences between type 1 diabetes with and without other autoimmune diseases. 2018 , 34, e3023	3
704	Reproducibility and Utility of the 6-minute Walk Test in Systemic Sclerosis. 2018 , 45, 1273-1280	10
703	Neurologische Komplikationen der Kollagenosen. 2018 , 183-203	
702	Novel classification for global gene signature model for predicting severity of systemic sclerosis. 2018 , 13, e0199314	

701	Treatment of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review. 2018 , 57, 1802-1811	35
700	Autoreactive T cells to citrullinated HSP90 are associated with interstitial lung disease in rheumatoid arthritis. 2018 , 21, 1398-1405	6
699	A prospective, open-label, non-comparative study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis. 2018 , 2, 13	1
698	Synovial involvement assessed by power Doppler ultra-sonography in systemic sclerosis: results of a cross-sectional study. 2018 , 57, 2012-2021	15
697	Dysregulated CD25 and Cytokine Expression by T Cells of Systemic Sclerosis Patients Stimulated With Cardiolipin and Zoledronate. 2018 , 9, 753	6
696	The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink. 2018 , 37, 2103-2111	47
695	Clinical and Laboratory Characteristics and Mortality in Korean Patients with Systemic Sclerosis: A Nationwide Multicenter Retrospective Cohort Study. 2018 , 45, 1281-1288	8
694	Immunotherapy of systemic sclerosis. 2018 , 14, 2559-2567	4
693	Pandemic non-adjuvanted influenza A H1N1 vaccine in a cohort of patients with systemic sclerosis. 2018 , 57, 1721-1725	4
692	Brief Report: Whole-Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African Americans. 2018 , 70, 1654-1660	8
691	Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. 2018 , 20, 17	60
690	Clinical features and risk factors of neurological involvement in Sjögren's syndrome. 2018 , 19, 26	7
689	Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study. 2018 , 70, 1634-1643	49
688	Unmet Needs in Systemic Sclerosis Understanding and Treatment: the Knowledge Gaps from a Scientist's, Clinician's, and Patient's Perspective. 2018 , 55, 312-331	14
687	Radiological images of interstitial pneumonia in mixed connective tissue disease compared with scleroderma and polymyositis/dermatomyositis. 2018 , 107, 26-32	6
686	Toe Gangrene Associated with Macroangiopathy in Systemic Sclerosis: A Case Series on the Unreliability of the Ankle-brachial Pressure Index. 2018 , 98, 532-533	
685	Autoimmune rheumatic diseases increase dementia risk in middle-aged patients: A nationwide cohort study. 2018 , 13, e0186475	21
684	Systemic Sclerosis at an Intensive Care Unit: A Case Series and Literature Review. 2019 , 25, 181-185	1

683	Increased risk of mortality in systemic sclerosis-associated digital ulcers: a systematic review and meta-analysis. 2019 , 33, 405-409	8
682	Autoimmune associations in a Mexican cohort with primary biliary cholangitis. 2019 , 84, 130-135	2
681	Differences associated with age at onset in early systemic sclerosis patients: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR) database. 2019 , 48, 42-51	11
680	Pulmonary Involvement in the Systemic Inflammatory Diseases of Childhood. 2019 , 850-875.e7	
679	Association between the BANK1 rs3733197 polymorphism and polymyositis/dermatomyositis in a Chinese Han population. 2019 , 38, 431-436	4
678	Osteoprotegrin interacts with biomarkers and cytokines that have roles in osteoporosis, skin fibrosis, and vasculopathy in systemic sclerosis: A potential multifaceted relationship between OPG/RANKL/TRAIL and Wnt inhibitors. 2019 , 29, 619-624	12
677	Serum uric acid as a marker of disease risk, severity, and survival in systemic sclerosis-related pulmonary arterial hypertension. 2019 , 9, 2045894019859477	20
676	[Systemic sclerosis-clinical picture, diagnosis, and treatment]. 2019 , 70, 723-741	
675	Role of Deleterious Rare Alleles for Acute-Onset Diffuse Interstitial Lung Disease in Collagen Diseases. 2019 , 13, 1179548419866443	1
674	Erstkontakt und strategisches Vorgehen bei Patienten mit seltener Erkrankung. 2019 , 13, 255-270	
673	Systolic Dysfunction in Systemic Sclerosis: Prevalence and Prognostic Implications. 2019 , 1, 258-266	5
672	IL-1 receptor blockade skews inflammation towards Th2 in a mouse model of systemic sclerosis. 2019 , 54,	14
671	Abnormalities of heart rate turbulence and heart rate variability as indicators of increased cardiovascular risk in patients with systemic sclerosis. 2019 , 36, 707-713	4
670	Performance evaluation of a line blot assay system for detection of anti-PM-Scl antibody in Japanese patients with systemic sclerosis. 2019 , 22, 1746-1751	3
669	Targeting very early systemic sclerosis: a case-based review. 2019 , 39, 1961-1970	9
668	Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study. 2019 , 21, 211	23
667	IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosis. 2019 , 9, 14834	11
666	Multiple External Root Resorption of Teeth as a New Manifestation of Systemic Sclerosis-A Cross-Sectional Study in Japan. 2019 , 8,	3

665	GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. 2019 , 10, 4955	46
664	Associations of Vitamin D Receptor Single Nucleotide Polymorphisms with Susceptibility to Systemic Sclerosis. 2019 , 50, 368-376	6
663	Association of NCF1 polymorphism with systemic lupus erythematosus and systemic sclerosis but not with ANCA-associated vasculitis in a Japanese population. 2019 , 9, 16366	9
662	Prevalence and incidence of systemic sclerosis: A systematic review and meta-analysis. 2019 , 22, 2096-2107	17
661	Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease. 2019 , 46, 1006-1013	24
660	Epigenome-Wide Comparative Study Reveals Key Differences Between Mixed Connective Tissue Disease and Related Systemic Autoimmune Diseases. 2019 , 10, 1880	15
659	Exosomes in Systemic Sclerosis: Messengers Between Immune, Vascular and Fibrotic Components?. 2019 , 20,	18
658	Renal pathology and clinical associations in systemic sclerosis: a historical cohort study. 2019 , 12, 323-331	2
657	Autoantibodies to Killer Cell Immunoglobulin-Like Receptors in Patients With Systemic Lupus Erythematosus Induce Natural Killer Cell Hyporesponsiveness. 2019 , 10, 2164	16
656	Very early systemic sclerosis. 2019 , 33, 101428	12
655	Quantitative Assessment of Skin Stiffness Using Ultrasound Shear Wave Elastography in Systemic Sclerosis. 2019 , 45, 902-912	22
654	Scleroderma-related interstitial lung disease: principles of management. 2019 , 13, 357-367	5
653	Prognostic properties of anti-topoisomerase antibodies in patients identified by the ACR/EULAR 2013 systemic sclerosis criteria. 2019 , 58, 730-732	2
652	CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I/II clinical trial conducted in Japan. 2019 , 21, 30	12
651	Performance of the COPD Assessment Test in patients with connective tissue disease-associated interstitial lung disease. 2019 , 150, 15-20	3
650	Increased serum uric acid levels are associated with digital ulcers in patients with systemic sclerosis. 2019 , 39, 255-263	5
649	Construction of an ICF core set and ICF-based questionnaire assessing activities and participation in patients with systemic sclerosis. 2019 , 58, 2260-2272	6
648	Distinctive association of peripheral immune cell phenotypes with capillaroscopic microvascular patterns in systemic sclerosis. 2019 , 58, 2273-2283	12

647	Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. 2019 , 71, 2059-2067	29
646	Imbalanced serum levels of Ang1, Ang2 and VEGF in systemic sclerosis: Integrated effects on microvascular reactivity. 2019 , 125, 103881	10
645	Dexamethasone inhibits cytokine production in PBMC from systemic sclerosis patients. 2019 , 27, 723-730	5
644	Common Causes of Pain in Systemic Sclerosis: Frequency, Severity, and Relationship to Disease Status, Depression, and Quality of Life. 2019 , 20, 331-336	3
643	Clinical and laboratory profile of juvenile-onset systemic sclerosis in a Brazilian cohort.. 2019 , 4, 43-48	1
642	Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. 2019 , 11, 257-273	66
641	[Systemic sclerosis-clinical picture, diagnosis, and treatment]. 2019 , 78, 439-457	
640	Anti-collagen type v: a marker of early systemic sclerosis?. 2019 , 59, 19	3
639	Serum concentrations of IL-17A, IL-17B, IL-17E and IL-17F in patients with systemic sclerosis. 2019 , 15, 706-712	13
638	Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features. 2019 , 5, e000826	16
637	Capillaroscopy changes are associated with disease progression in patients with early systemic sclerosis: A prospective study. 2019 , 22, 1319-1326	0
636	Role of lectin pathway complement proteins and genetic variants in organ damage and disease severity of systemic sclerosis: a cross-sectional study. 2019 , 21, 76	5
635	Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts. 2019 , 9, 4589	5
634	Protective Effect Against Cancer of Antibodies to the Large Subunits of Both RNA Polymerases I and III in Scleroderma. 2019 , 71, 1571-1579	16
633	Insight into the Contrasting Findings of Therapeutic Trials of Digital Ischaemic Manifestations of Systemic Sclerosis. 2019 , 5, 85-103	6
632	Gastrointestinal manifestations on impaired quality of life in systemic sclerosis. 2019 , 20, 256-261	8
631	Free light chains and autoimmunity. 2019 , 18, 484-492	25
630	Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias. 2019 , 35, 365-372	5

629	Respiratory management of acute exacerbation of interstitial pneumonia using high-flow nasal cannula oxygen therapy: a single center cohort study. 2019 , 11, 103-112	5
628	Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. 2019 , 78, 648-656	43
627	Invasive mycoses in patients with connective tissue disease from Southern China: clinical features and associated factors. 2019 , 21, 71	6
626	Hearing alterations in systemic sclerosis. 2019 , 31, e20170119	3
625	Pulmonary physiology is poorly associated with radiological extent of disease in systemic sclerosis-associated interstitial lung disease. 2019 , 53,	5
624	Overlap myositis, a distinct entity beyond primary inflammatory myositis: A retrospective analysis of a large cohort from the REMICAM registry. 2019 , 22, 1393-1401	13
623	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. 2019 , 71, 1553-1570	31
622	[Very early and early systemic sclerosis: An update]. 2019 , 40, 517-522	0
621	Méta-analyse de la fréquence et des implications de la présence d'anticorps anti-peptides cycliques citrullinés dans la sclérodémie systémique. 2019 , 86, 225-231	
620	The Complement System. 2019 , 65-79	
619	Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis. 2019 , 78, 807-816	16
618	Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature. 2019 , 21, 86	48
617	Do thermographic parameters help to classify patients with early systemic sclerosis?. 2019 , 58, 1105-1106	1
616	Prevalence and associated factors of small intestinal bacterial overgrowth among systemic sclerosis patients. 2019 , 22, 695-699	14
615	Predictors of Hand Contracture in Early Systemic Sclerosis and the Effect on Function: A Prospective Study of the GENISOS Cohort. 2019 , 46, 1597-1604	3
614	Microbiome dysbiosis is associated with disease duration and increased inflammatory gene expression in systemic sclerosis skin. 2019 , 21, 49	19
613	Systemic sclerosis: state of the art on clinical practice guidelines. 2018 , 4, e000782	53
612	Systemic Sclerosis in Childhood. 2019 , 1183-1194	

611	Inflammation in Fibrodysplasia Ossificans Progressiva and Other Forms of Heterotopic Ossification. 2019 , 17, 387-394	15
610	Neuropathic pain in Systemic Sclerosis patients: A cross-sectional study. 2019 , 15, e99-e101	1
609	Visfatin and chemerin levels correspond with inflammation and might reflect the bridge between metabolism, inflammation and fibrosis in patients with systemic sclerosis. 2019 , 36, 551-565	10
608	The effect and safety of exercise therapy in patients with systemic sclerosis: a systematic review. 2019 , 3, rkz044	13
607	TGF- β -mediated upregulation of brachyury contributes to constitutively up-regulated type I collagen expression in skin fibroblasts: possible role in systemic sclerosis. 2019 , 29, 359-365	1
606	The nosology of systemic sclerosis: how lessons from the past offer new challenges in reframing an idiopathic rheumatological disorder. 2019 , 1, e257-e264	7
605	Quantitative CT texture analysis for diagnosing systemic sclerosis: Effect of iterative reconstructions and radiation doses. 2019 , 98, e16423	5
604	High risk of gastrointestinal hemorrhage in patients with systemic sclerosis. 2019 , 21, 301	1
603	Colonic Manifestations and Complications Are Relatively Under-Reported in Systemic Sclerosis: A Systematic Review. 2019 , 114, 1847-1856	11
602	Systemic sclerosis. 2019 , 291-329	
601	Classification criteria for secondary Sjögren's syndrome. Current state of knowledge. 2019 , 57, 277-280	10
600	Thymectomy in patients with myasthenia gravis increases the risk of autoimmune rheumatic diseases: a nationwide cohort study. 2019 , 58, 135-143	9
599	Main Oral Manifestations in Immune-Mediated and Inflammatory Rheumatic Diseases. 2018 , 8,	16
598	Systemic sclerosis induced by the use of cocaine: is there an association?. 2019 , 39, 387-393	6
597	Ocular involvement in systemic sclerosis: A systematic literature review, it's not all scleroderma that meets the eye. 2019 , 49, 119-125	14
596	Serum levels of Krebs von den Lungen-6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis-associated interstitial lung disease from a Chinese cohort. 2019 , 22, 108-115	7
595	Less severe disease in patients with early systemic sclerosis?. 2019 , 29, 977-983	0
594	Digital Ulcerations and Classification of SSc Subsets and Overlap Syndromes. 2019 , 7-13	

593	Associations of Multiple Exonic Variants with Systemic Sclerosis. 2019 , 46, 184-189	7
592	Decreased biventricular longitudinal strain in patients with systemic sclerosis is mainly caused by pulmonary hypertension and not by systemic sclerosis per se. 2019 , 39, 215-225	12
591	Reduced Right Ventricular Output Reserve in Patients With Systemic Sclerosis and Mildly Elevated Pulmonary Artery Pressure. 2019 , 71, 805-816	17
590	Autoimmune associations in a Mexican cohort with primary biliary cholangitis. 2019 , 84, 130-135	1
589	Epigenetics of Systemic Sclerosis. 2019 , 505-528	
588	Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease. 2019 , 38, 803-815	13
587	Systemic sclerosis and primary biliary cholangitis: An overlapping entity?. 2019 , 4, 111-117	2
586	Pleuroparenchymal fibroelastosis as a histological background of autoimmune diseases. 2019 , 474, 97-104	16
585	Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry. 2019 , 38, 1117-1124	5
584	Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality. 2019 , 58, 636-644	18
583	Anti-RNPC-3 (U11/U12) Antibodies in Systemic Sclerosis in Patients With Moderate-to-Severe Gastrointestinal Dysmotility. 2019 , 71, 1164-1170	15
582	Analysis of the genetic component of systemic sclerosis in Iranian and Turkish populations through a genome-wide association study. 2019 , 58, 289-298	8
581	Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. 2019 , 46, 176-183	14
580	Abnormal esophageal motility during a solid test meal in systemic sclerosis-detection even in very early disease and association with disease progression. 2019 , 31, e13480	7
579	Dysregulation of the Wnt signaling pathway in South African patients with diffuse systemic sclerosis. 2019 , 38, 933-938	9
578	Statins Inhibit Cytokines in a Dose-Dependent Response in Patients with Systemic Sclerosis. 2019 , 42, 407-411	7
577	Neuropathic pain in Systemic Sclerosis patients: A cross-sectional study. 2019 , 15, e99-e101	3
576	Long-term follow-up of finger passive range of motion in Japanese systemic sclerosis patients treated with self-administered stretching. 2019 , 29, 484-490	5

575	Diagnostic utility of automated indirect immunofluorescence compared to manual indirect immunofluorescence for anti-nuclear antibodies in patients with systemic rheumatic diseases: A systematic review and meta-analysis. 2019 , 48, 728-735	5
574	Patient acceptable symptom state and minimal clinically important difference for patient-reported outcomes in systemic sclerosis: A secondary analysis of a randomized controlled trial comparing personalized physical therapy to usual care. 2019 , 48, 694-700	10
573	Ten Years of Interventional Research in Systemic Sclerosis: A Systematic Mapping of Trial Registries. 2020 , 72, 140-148	1
572	Incidence and prevalence of systemic sclerosis in Valcamonica, Italy, during an 18-year period.. 2020 , 5, 51-56	3
571	Association of radiographic findings in hand X-ray with clinical features and autoantibodies in patients with systemic sclerosis. 2020 , 39, 113-118	4
570	Comparison of clinical presentation and incidence of cardiopulmonary complications between male and female Thai patients with early systemic sclerosis: inception cohort study. 2020 , 39, 103-112	3
569	Pregnancy in Systemic Sclerosis: Results of a Systematic Review and Metaanalysis. 2020 , 47, 881-887	16
568	A multimodal ophthalmic analysis in patients with systemic sclerosis using ocular response analyzer, corneal topography and specular microscopy. 2020 , 40, 287-296	1
567	Acute exacerbations of fibrotic interstitial lung diseases. 2020 , 25, 525-534	34
566	Long-term clinical course and outcome of interstitial pneumonia with autoimmune features. 2020 , 25, 636-643	13
565	Comparative efficacy and safety of immunosuppressive therapies for systemic sclerosis related interstitial lung disease: A Bayesian network analysis. 2020 , 30, 687-695	8
564	Availability of EuroQol-5-Dimensions-5-Level (EQ-5D-5L) as health-related QOL assessment for Japanese systemic sclerosis patients. 2020 , 30, 681-686	3
563	Sex hormones and sex hormone-targeting therapies in systemic sclerosis: A systematic literature review. 2020 , 50, 140-148	9
562	Nailfold Videocapillaroscopy in Systemic Sclerosis-related Pulmonary Arterial Hypertension: A Systematic Literature Review. 2020 , 47, 888-895	9
561	The role of high-resolution manometry in the assessment of upper gastrointestinal involvement in systemic sclerosis: a systematic review. 2020 , 39, 149-157	6
560	Cardiopulmonary exercise testing in a combined screening approach to individuate pulmonary arterial hypertension in systemic sclerosis. 2020 , 59, 1581-1586	7
559	Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis. 2020 , 273, 103323	4
558	Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. 2020 , 59, 1684-1694	9

557	The Chinese herb <i>Tripterygium wilfordii</i> Hook F for the treatment of systemic sclerosis-associated interstitial lung disease: data from a Chinese EUSTAR Center. 2020 , 39, 813-821	3
556	Systemic Sclerosis (Scleroderma). 2020 , 575-605	
555	Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease. 2020 , 39, 1173-1179	7
554	Psychometric validation of the Hand Disability in Systemic Sclerosis-Digital Ulcers (HDISS-DU ²) patient-reported outcome instrument. 2020 , 22, 3	6
553	Validity and correlates of the Brief Satisfaction With Appearance Scale for patients with limited and diffuse systemic sclerosis: Analysis from the University of California, Los Angeles Scleroderma Quality of Life Study.. 2020 , 5, 143-151	1
552	Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. 2020 , 59, 2016-2023	5
551	Inhomogeneity of capillaroscopic findings in systemic sclerosis. 2020 , 23, 207-215	0
550	Exercise Echocardiography Predicts Future Development of Pulmonary Hypertension in a High-risk Cohort of Patients with Systemic Sclerosis. 2020 , 47, 708-713	1
549	Nutritional risk in patients with systemic sclerosis. 2020 , 39, 295-297	
548	Lower DLco% identifies exercise pulmonary hypertension in patients with parenchymal lung disease referred for dyspnea. 2020 , 10, 2045894019891912	7
547	Patterns of renal pathology in Chinese patients with systemic sclerosis undergoing renal biopsy at a tertiary medical center. 2020 , 48, 300060519894456	0
546	Common susceptibility loci in both systemic sclerosis and localized scleroderma identified using genetic analysis. 2020 , 133, 2370-2372	
545	Insulin-like growth factor binding protein-2: a new circulating indicator of pulmonary arterial hypertension severity and survival. 2020 , 18, 268	4
544	Novel classifications for systemic sclerosis: challenging historical subsets to unlock new doors. 2020 , 32, 463-471	5
543	Repetitive Antegrade Contractions: A novel response to sustained esophageal distension is modulated by cholinergic influence. 2020 ,	2
542	Undifferentiated connective tissue disease at risk for systemic sclerosis: Which patients might be labeled prescleroderma?. 2020 , 19, 102659	10
541	Association of functional (GA) _n microsatellite polymorphism in the FLI1 gene with susceptibility to human systemic sclerosis. 2020 , 59, 3553-3562	4
540	Coexistence of systemic and localized scleroderma: a systematic literature review and observational cohort study. 2020 , 59, 2725-2733	2

539	Clinical features of Japanese systemic sclerosis (SSc) patients negative for SSc-related autoantibodies: A single-center retrospective study. 2020 , 23, 1219-1225	2
538	May capillaroscopy be a candidate tool in future algorithms for SSC-ILD: Are we looking for the holy grail? A systematic review. 2020 , 19, 102619	7
537	Matrix Metalloproteinases MMP-2 and MMP-9, Their Inhibitors TIMP-1 and TIMP-2, Vascular Endothelial Growth Factor and sVEGFR-2 as Predictive Markers of Ischemic Retinopathy in Patients with Systemic Sclerosis-Case Series Report. 2020 , 21,	6
536	Systemic Sclerosis. 2020 ,	
535	Trends in Systemic Sclerosis Mortality Over Forty-Eight Years, 1968-2015: A US Population-Based Study. 2021 , 73, 1502-1510	5
534	Clinicopathological characteristics of lung cancer in patients with systemic sclerosis. 2020 , 14, 1131-1136	4
533	Coping profiles and health outcomes among individuals with systemic sclerosis: A latent profile analysis approach.. 2020 , 5, 231-236	1
532	Clinical features and long-term outcomes of Chinese patients with scleroderma renal crisis. 2020 , 23, 1194-1200	1
531	Enrichment Strategy for Systemic Sclerosis Clinical Trials Targeting Skin Fibrosis: A Prospective, Multiethnic Cohort Study. 2020 , 2, 496-502	1
530	Long-term follow-up of patients with anti-cyclic citrullinated peptide antibody-positive connective tissue disease: a retrospective observational study including information on the HLA-DRB1 allele and citrullination dependency. 2020 , 22, 248	0
529	Prévalence échographique des synovites et éthosynovites de la main et du pied dans la sclérodémie systémique et corrélation avec les caractéristiques de la maladie dont le handicap de la main. 2020 , 87, 380-385	
528	Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database. 2020 , 22, 257	4
527	The prognostic value of cardiopulmonary exercise testing in interstitial lung disease: a systematic review. 2020 , 6,	4
526	Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis. 2020 , 16, 931-942	0
525	Myopathy is a Risk Factor for Poor Prognosis of Patients with Systemic Sclerosis: A retrospective cohort study. 2020 , 99, e21734	3
524	The interstitial lung disease spectrum under a uniform diagnostic algorithm: a retrospective study of 1,945 individuals. 2020 , 12, 3688-3696	5
523	Epidemiology of systemic sclerosis in the UK: an analysis of the Clinical Practice Research Datalink. 2021 , 60, 2688-2696	2
522	Bilateral uniportal video-assisted thoracoscopic sympathectomy for managing secondary Raynaud's in CREST syndrome: A case report. 2020 , 75, 203-206	

521	Clinical characteristics and outcomes of 566 Thais with systemic sclerosis: A cohort study. 2020 , 23, 945-957	7
520	Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II. 2020 , 2, 362-370	9
519	Performance evaluation of a commercial line blot assay system for detection of myositis- and systemic sclerosis-related autoantibodies. 2020 , 39, 3489-3497	9
518	Risk of incident autoimmune diseases in patients with thymectomy. 2020 , 7, 1072-1082	5
517	The Role of Angiogenesis Factors in the Formation of Vascular Changes in Scleroderma by Assessment of the Concentrations of VEGF and sVEGFR2 in Blood Serum and Tear Fluid. 2020 , 2020, 7649480	3
516	Mechanical ventilation for acute respiratory failure due to idiopathic pulmonary fibrosis versus connective tissue disease-associated interstitial lung disease: Effectiveness and risk factors for death. 2020 , 14, 918-932	2
515	Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review. 2020 , 78, 17-25	13
514	Increased levels of the soluble oncostatin M receptor (sOSMR) and glycoprotein 130 (sgp130) in systemic sclerosis patients and associations with clinical parameters. 2020 , 225, 151964	2
513	Dry Eye in Systemic Sclerosis Patients: Novel Methods to Monitor Disease Activity. 2020 , 10,	1
512	Epidemiology and mortality of connective tissue disease-associated pulmonary arterial hypertension: A national cohort study in taiwan. 2020 , 50, 957-962	5
511	Association of two polymorphisms Asp299Gly and Thr399Ile in Toll-like receptor 4 with rheumatoid arthritis: A meta-analysis. 2020 , 23, 1117-1125	
510	T6746C and P72R Polymorphisms Are Associated with the Susceptibility to Diffuse Cutaneous Systemic Sclerosis. 2020 , 2020, 8465971	2
509	Prominence of IL6, IGF, TLR, and Bioenergetics Pathway Perturbation in Lung Tissues of Scleroderma Patients With Pulmonary Fibrosis. 2020 , 11, 383	13
508	Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation. 2020 , 19, 102507	8
507	Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort. 2020 , 22, 56	6
506	Pneumothorax in connective tissue disease-associated interstitial lung disease. 2020 , 15, e0235624	6
505	Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis. 2020 , 23, 532-539	7
504	A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn's disease. 2020 , 10, 1862	11

503	Early trajectories of skin thickening are associated with severity and mortality in systemic sclerosis. 2020 , 22, 30	7
502	Ultrasound prevalence of wrist, hand, ankle and foot synovitis and tenosynovitis in systemic sclerosis, and relationship with disease features and hand disability. 2020 , 87, 229-233	7
501	Ultrasound Surface Wave Elastography for Assessing Scleroderma. 2020 , 46, 1263-1269	7
500	Prevalence and predictors of proton pump inhibitor partial response in gastroesophageal reflux disease in systemic sclerosis: a prospective study. 2020 , 10, 769	3
499	Sensitivity and specificity of Interleukin 29 in patients with rheumatoid arthritis and other rheumatic diseases. 2020 , 220, 38-43	3
498	Analysis of myositis autoantibodies in Chinese patients with cancer-associated myositis. 2020 , 34, e23307	3
497	Infective patterns of cryptococcosis in patients with connective tissue disease: a retrospective study. 2020 , 39, 3071-3081	1
496	Characteristics and prognosis of interstitial pneumonias complicated with pneumomediastinum. 2020 , 58, 262-268	
495	CXCL4 triggers monocytes and macrophages to produce PDGF-BB, culminating in fibroblast activation: Implications for systemic sclerosis. 2020 , 111, 102444	13
494	Autoantibody profile in a cohort of Algerian patients with systemic sclerosis. 2020 , 78, 126-133	1
493	Clinical course of Japanese patients with early systemic sclerosis: A multicenter, prospective, observational study. 2021 , 31, 162-170	1
492	The Challenge of Very Early Systemic Sclerosis: A Combination of Mild and Early Disease?. 2021 , 48, 82-86	8
491	Neurological and electroneurography findings in patients with systemic sclerosis and symptoms of neuropathic pain in extremities. 2021 , 121, 205-209	1
490	Risk and prognosis factors for systemic sclerosis with lung cancer: A single-centre case-control study in China. 2021 , 75, e13819	0
489	Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis. 2021 , 60, 557-567	24
488	Anti-Ro52 antibodies in clinical practice: A single-centre experience. 2021 , 75, e13679	2
487	Lower risk of primary Sjogren's syndrome in patients with dengue virus infection: a nationwide cohort study in Taiwan. 2021 , 40, 537-546	3
486	Incidence, predictors, and survival of pulmonary hypertension determined by echocardiography in Thai patients with early systemic sclerosis (SSc): inception cohort study. 2021 , 40, 973-980	0

485	Applicability of radiomics in interstitial lung disease associated with systemic sclerosis: proof of concept. 2021 , 31, 1987-1998	7
484	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. 2021 , 6, 66-76	2
483	Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. 2021 , 80, 219-227	33
482	Incidence, prevalence and mortality of systemic sclerosis in Italy: a nationwide population-based study using administrative health data. 2021 , 41, 129-137	3
481	Prevalence and clinical associations with premature ovarian insufficiency, early menopause, and low ovarian reserve in systemic sclerosis. 2021 , 40, 2267-2275	4
480	The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: Systematic review and meta-analysis. 2021 , 20, 102713	10
479	Prognosis after acute exacerbation in patients with interstitial lung disease other than idiopathic pulmonary fibrosis. 2021 , 15, 336-344	5
478	Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease. 2021 , 73, 1005-1013	5
477	Evaluating skeletal muscle mass with ultrasound in patients with systemic sclerosis. 2021 , 84, 110999	1
476	Human epididymis protein 4 is a new biomarker to predict the prognosis of progressive fibrosing interstitial lung disease. 2021 , 59, 90-98	5
475	Worsening of esophageal dilatation is associated with increase in a high-resolution computed tomography (HRCT) score in early systemic sclerosis-associated interstitial lung disease (SSc-ILD). 2021 , 40, 955-963	1
474	Maternal and foetal placental vascular malperfusion in pregnancies with anti-phospholipid antibodies. 2021 , 60, 1148-1157	1
473	Association of Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis With Marked Improvement in Health-Related Quality of Life. 2021 , 73, 305-314	2
472	Polysomnography findings and risk factors for sleep-disordered breathing in patients with systemic sclerosis. 2021 , 36, 360-365	
471	Scleroderma. 2021 , 1-14	
470	Clinical assessment of cardiac impairment favored by two-dimensional speckle tracking echocardiology in patients with systemic sclerosis. 2021 ,	0
469	Distinct T cell chromatin landscapes in scleroderma subtypes.	0
468	Scleroderma epidemiology update. 2021 , 33, 122-127	5

467	Local and Systemic Associations. 2021 , 23-43	
466	Cutaneous Lupus Erythematosus and Scleroderma. 2021 , 27-38	
465	Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis. 2021 , 40, 2779-2789	2
464	Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review and meta-analysis. 2021 , 40, 3039-3051	5
463	The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. 2021 , 60, 5028-5041	8
462	A clinical comparison of an endothelin receptor antagonist and phosphodiesterase type 5 inhibitors for treating digital ulcers of systemic sclerosis. 2021 , 60, 5814-5819	2
461	Identification of Autoimmunity to Peptides of Collagen V α Chain as Newly Biomarkers of Early Stage of Systemic Sclerosis. 2020 , 11, 604602	3
460	HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis. 2021 , 23, 62	3
459	Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience. 2021 , 61, 9	8
458	Association of Systemic Sclerosis and Periodontitis with Vitamin D Levels. 2021 , 13,	5
457	Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis. 2021 , 16, e0247256	2
456	Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis. 2021 , 60, 3121-3133	12
455	Durometry in SSc: The hard facts. A systematic literature review and additional pilot study. 2021 , 60, 2099-2108	0
454	Epidemiology of systemic sclerosis: a multi-database population-based study in Tuscany (Italy). 2021 , 16, 90	4
453	Are troponin and B-type natriuretic peptides useful biomarkers for the diagnosis of systemic sclerosis heart involvement? A systematic literature review. 2021 , 51, 299-309	6
452	Circulating Plasma microRNAs In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. 2021 ,	2
451	Machine learning associated with respiratory oscillometry: a computer-aided diagnosis system for the detection of respiratory abnormalities in systemic sclerosis. 2021 , 20, 31	2
450	Cost-Effectiveness of Combination Therapy for Patients With Systemic Sclerosis-Related Pulmonary Arterial Hypertension. 2021 , 10, e015816	2

449	Prevalence of anti-dense fine speckled 70 antibodies in healthy individuals and patients with antinuclear antibody-associated autoimmune rheumatic diseases in Japan. 2021 , 100, e24556	2
448	Skleroderma hastalarının ağız ve periodontal bulgularıyla hastalık tutulumları arasındaki ilişki. 2021 , 46, 39-45	
447	Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study. 2021 , 40, 3755-3763	6
446	C-reactive protein and ground-glass opacity as predictors for intractable interstitial lung disease in patients with systemic sclerosis under cyclophosphamide treatment regardless of concomitant glucocorticoids. 2021 , 1-8	
445	Effect of combined pulmonary fibrosis and emphysema on patients with connective tissue diseases and systemic sclerosis: a systematic review and meta-analysis. 2021 , 23, 100	1
444	Nailfold Capillaroscopy in Systemic Sclerosis Patients with and without Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. 2021 , 10,	6
443	Anti-PM/Scl Antibody-positive Systemic Sclerosis Complicated by Multiple Organ Involvement. 2021 , 60, 1101-1107	0
442	Assessment of right ventricular reserve utilizing exercise provocation in systemic sclerosis. 2021 , 37, 2137-2147	3
441	[Atypical arthritis of the hands : Collagenosis-part 2]. 2021 , 61, 470-482	
440	Pregnancy-associated risk factors and incidence of systemic sclerosis in primiparous women: A nationwide population-based cohort study. 2021 , 1-6	1
439	Ophthalmic manifestations in patients with collagen vascular disorders: a hospital-based retrospective observational study. 2021 , 41, 2765-2775	1
438	Anti-Polymyositis/Scl Antibodies in Systemic Sclerosis: Clinical Associations in a Multicentric Spanish Cohort and Review of the Literature. 2021 ,	0
437	HRCT imaging features of systemic sclerosis-associated interstitial lung disease. 2021 , 5, 035-041	0
436	Comparison of the effectiveness of cyclophosphamide and rituximab treatment in patients with systemic sclerosis-related interstitial lung diseases: a retrospective, observational cohort study. 2021 , 40, 4071-4079	0
435	Proton Pump Inhibitor and Tacrolimus Uses are Associated With Hypomagnesemia in Connective Tissue Disease: a Potential Link With Renal Dysfunction and Recurrent Infection. 2021 , 12, 616719	1
434	Autoantibody Discovery, Assay Development and Adoption: Death Valley, the Sea of Survival and Beyond. 2021 , 12, 679613	5
433	Prevalence and predictive factors of osteoporosis in Thai systemic sclerosis. 2021 , 11, 9424	2
432	Bronchoalveolar Lavage in Systemic Sclerosis Patients: A Systematic Review. 2021 , 17, 176-183	0

431	New risk model is able to identify patients with a low risk of progression in systemic sclerosis. 2021 , 7,	0
430	Screening for the early detection of pulmonary arterial hypertension in patients with systemic sclerosis: A systematic review and meta-analysis of long-term outcomes. 2021 , 51, 495-512	3
429	Increased risk of end-stage renal disease in patients with systemic sclerosis. 2021 , 1-8	1
428	The impact of various entities of antiphospholipid antibodies positivity on adverse pregnancy outcome. An epidemiological perspective. 2021 , 145, 103304	1
427	H FPEF score predicts atherosclerosis presence in patients with systemic connective tissue disease. 2021 , 44, 946-954	2
426	Epidemiology and Trends in Survival of Systemic Sclerosis in Olmsted County (1980-2018): A Population-based Study.. 2021 , 6, 264-270	0
425	French recommendations for the management of systemic sclerosis. 2021 , 16, 322	3
424	Relation between nailfold capillaroscopic pattern (assessed using a dermoscope) and organ involvement in systemic sclerosis. 1-8	0
423	The prevalence and clinical features associated of hypothyroidism among Thai systemic sclerosis patients. 2021 , 11, 14902	0
422	An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod. 2021 , 23, 204	1
421	Identification of Plexin D1 on circulating extracellular vesicles as a potential biomarker of polymyositis and dermatomyositis. 2021 ,	1
420	Prospective nationwide multicentre cohort study of the clinical significance of autoimmune features in idiopathic interstitial pneumonias. 2021 ,	1
419	Clinical significance of anti-NOR90 antibodies in systemic sclerosis and idiopathic interstitial pneumonia. 2021 ,	2
418	Prevalence and risk factors of systemic sclerosis-associated interstitial lung disease in East Asia: A systematic review and meta-analysis. 2021 , 24, 1449-1459	2
417	Gastrointestinal manifestations of systemic sclerosis: An updated review. 2021 , 9, 6201-6217	1
416	Immune recognition of lysyl-tRNA synthetase and isoleucyl-tRNA synthetase by anti-OJ antibody-positive sera. 2021 , 122, 102680	3
415	Acute myocarditis with autoimmune features: one-year follow-up with CMR. 2021 , 1	
414	Predictive value of laser speckle contrast analysis in systemic sclerosis. A systematic review and pilot study. 2021 , e13672	0

413	Slow colonic transit in systemic sclerosis: an objective assessment of risk factors and clinical phenotype. 2021 ,	0
412	The relationship of ocular parameters with clinical parameters and disease-related quality of life in patients with systemic sclerosis: A cross-sectional study. 2021 , 24, 1308-1316	
411	The prognostic value of the COPD Assessment Test in fibrotic interstitial lung disease. 2021 ,	
410	Patients with Systemic Sclerosis with and without Overlap Syndrome Show Similar Microvascular Abnormalities. 2021 , 11,	1
409	Review for best practice in clinical rheumatology juvenile systemic sclerosis - Updates and practice points. 2021 , 35, 101688	0
408	Multimodality imaging of the gastrointestinal manifestations of scleroderma. 2021 , 76, 640-649	1
407	Predictive Factors for Pneumomediastinum During Management of Connective Tissue Disease-related Interstitial Lung Disease: A Retrospective Study. 2021 , 60, 2887-2897	1
406	Peripheral cells from patients with systemic sclerosis disease co-expressing M1 and M2 monocyte/macrophage surface markers: Relation to the degree of skin involvement. 2021 , 82, 634-639	2
405	CTLA-4 polymorphisms in Thai patients with rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis. 2021 , 24, 1378-1385	
404	Imaging in Diagnosis of Systemic Sclerosis. 2021 , 10,	2
403	Pain chronification and the important role of non-disease-specific symptoms in patients with systemic sclerosis. 2021 , 23, 34	2
402	Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. <i>Arthritis and Rheumatism</i> , 1997 , 40, 1229-36	122
401	Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis. <i>Arthritis and Rheumatism</i> , 1997 , 40, 1237-44	41
400	Human autoantibodies stabilize the quaternary structure of Ku antigen. <i>Arthritis and Rheumatism</i> , 1997 , 40, 1344-53	11
399	Progressive Systemic Scleroderma. 2005 , 165-182	0
398	Systemic Sclerosis. 2008 , 343-362	18
397	Sex and Gender Differences in Autoimmune Diseases. 2012 , 101-124	3
396	Gastrointestinal Smooth Muscle Mechanical Behaviour and Neural Circuits. 2003 , 137-196	1

395	Enalapril (10 Mg/Day) in Systemic Sclerosis. 1999 , 289-293	2
394	Epidemiology, Environmental, and Infectious Risk Factors. 2017 , 11-24	3
393	Disease Subsets in Clinical Practice. 2017 , 39-48	4
392	Evolving Concepts of Diagnosis and Classification. 2017 , 49-64	1
391	Capillary Microscopy. 2019 , 63-78	0
390	Neuromuscular Complications of Primary Sjögren's Syndrome. 1987 , 61-82	13
389	Diseases of Connective Tissue. 2000 , 751-832	3
388	Diseases of Connective Tissue. 1991 , 533-585	1
387	Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain. 2017 , 37, 1853-1861	22
386	IPAF should receive early treatment for sharing similar clinical characteristics as CTD-ILD: a report from 273 Chinese patients. 2020 , 39, 3817-3823	5
385	A case of systemic sclerosis complicated by idiopathic portal hypertension: case report and literature review. 2006 , 16, 183-7	4
384	Antifibrotic effects of hepatocyte growth factor on scleroderma fibroblasts and analysis of its mechanism. 2006 , 16, 364-71	11
383	Pulmonary-renal syndrome in systemic sclerosis: a report of three cases and review of the literature. 2007 , 17, 37-44	9
382	Anti-SS-A/Ro antibody determination by indirect immunofluorescence and comparison of different methods of anti-nuclear antibody screening: evaluation of the utility of HEp-2 cells transfected with the 60 kDa SS-A/Ro as a substrate. 2008 , 18, 585-92	9
381	Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis. 2009 , 19, 530-5	19
380	Autoantibodies against platelet-derived growth factor receptor alpha in patients with systemic lupus erythematosus. 2010 , 20, 458-65	13
379	Value of serum IgG4 in the diagnosis of IgG4-related disease and in differentiation from rheumatic diseases and other diseases. 2012 , 22, 419-25	47
378	Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity. 2012 , 22, 668-75	12

377	High prevalence of primary biliary cirrhosis and disease-associated autoantibodies in Japanese patients with systemic sclerosis. 2012 , 22, 892-8	11
376	Non-synonymous variant (Gly307Ser) in CD226 is associated with susceptibility in Japanese rheumatoid arthritis patients. 2013 , 23, 200-2	4
375	Clinical and laboratory features dependent on age at onset in Japanese systemic sclerosis. 2013 , 23, 913-9	5
374	Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center. 2013 , 23, 1211-20	7
373	Systemic Sclerosis. 2013 , 955-969	1
372	Assessing disease activity and outcome in scleroderma. 2011 , 1367-1371	3
371	Clinical features of systemic sclerosis. 2011 , 1373-1385.e2	8
370	Classification and epidemiology of scleroderma. 2015 , 1153-1158	3
369	Raynaud's Phenomenon. 2006 , 689-705	1
368	Idiopathic interstitial pneumonias and immunologic diseases of the lungs. 2010 , 561-639	1
367	Autoantibody Assays, Testing, and Standardization. 2006 , 1011-1022	6
366	Chromo Autoantibodies. 1996 , 168-171	1
365	Scleroderma. 2008 , 4461-4468	1
364	THE SYSTEMIC SCLERODERMAS AND RELATED DISORDERS. 2005 , 442-471	1
363	Systemic Sclerosis and the Scleroderma-Spectrum Disorders. 2009 , 1311-1351	8
362	Clinical Features and Treatment of Scleroderma. 2013 , 1366-1403.e4	7
361	Corticosteroid inhibits chemokines production in systemic sclerosis patients. 2017 , 127, 24-30	4
360	Connective Tissue Diseases. 1993 , 20, 77-90	3

359	DERMATOLOGIC MANIFESTATIONS OF RHEUMATIC DISORDERS. 1993 , 20, 925-941	5
358	Connective Tissue Disease in the Elderly. 1986 , 12, 11-32	23
357	Histopathologic differentiation between localized and systemic scleroderma. 1998 , 20, 242-5	59
356	Pattern of gastric emptying in patients with systemic sclerosis. 1996 , 21, 379-82	11
355	Abnormal uptake of Tc-99m MIBI, a novel myocardial imaging agent, in the lungs of patients with systemic sclerosis. 1998 , 23, 19-25	9
354	Air trapping in primary Sjögren syndrome: correlation of expiratory CT with pulmonary function tests. 1999 , 23, 169-73	39
353	Fecal incontinence in scleroderma. Clinical features, anorectal manometric findings, and their therapeutic implications. 1997 , 25, 513-7	41
352	VCAM-1 expression on endothelium in lesions from cutaneous lupus erythematosus is increased compared with systemic and localized scleroderma. 1996 , 135, 678-686	19
351	Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma. 1996 , 134, 843-847	25
350	Antineutrophil cytoplasmic autoantibodies in patients with systemic sclerosis. 1996 , 134, 407-410	26
349	Unique digital skin lesions associated with systemic sclerosis. 1997 , 136, 598-600	12
348	Increased levels of type I and III collagen and hyaluronan in scleroderma skin. 1997 , 136, 47-53	7
347	The presence of anti-basement membrane zone antibodies in the sera of patients with non-bullous lupus erythematosus. 1997 , 136, 222-226	13
346	Anti-endothelial cell antibody, thrombomodulin, and von Willebrand factor in idiopathic inflammatory myopathies. 1997 , 4, 519-21	10
345	Hematological Indices May Be Useful in the Diagnosis of Systemic Lupus Erythematosus and in Determining Disease Activity in Behçet's Disease. 2016 , 25, 510-516	36
344	Systemic sclerosis in sub-Saharan Africa: a systematic review. 2020 , 37, 176	2
343	Plasma endothelin correlates with antiendothelial antibodies in patients with mixed connective tissue disease. 1995 , 92, 2969-74	38
342	The U2 small nuclear ribonucleoprotein particle as an autoantigen. Analysis with sera from patients with overlap syndromes. 1988 , 81, 1716-24	70

341	Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (IIo) form by a subset of human sera. 1994 , 94, 1981-9	56
340	Distinctive immune response patterns of human and murine autoimmune sera to U1 small nuclear ribonucleoprotein C protein. 1996 , 97, 2619-26	38
339	Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. 2001 , 108, 241-50	152
338	Role of protein kinase C-delta in the regulation of collagen gene expression in scleroderma fibroblasts. 2001 , 108, 1395-403	29
337	Role of protein kinase C- η in the regulation of collagen gene expression in scleroderma fibroblasts. 2001 , 108, 1395-1403	99
336	Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. 1999 , 103, 1253-60	144
335	Improving sensitivity of the connective tissue disease screening questionnaire: A comparative study of various scoring methods. 2021 , 30, 35-44	1
334	Treatment of exercise pulmonary hypertension improves pulmonary vascular distensibility. 2018 , 8, 204589401378738	1
333	Functional Infrared Imaging in Clinical Applications. 2006 , 32-1-32-18	2
332	Biomedical Applications of Functional Infrared Imaging. 2007 , 15-1-15-20	1
331	Differential dynamic properties of scleroderma fibroblasts in response to perturbation of environmental stimuli. 2008 , 3, e1693	8
330	The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. 2009 , 4, e5903	128
329	Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression. 2009 , 4, e5981	126
328	Comparative proteomic analysis of serum from patients with systemic sclerosis and sclerodermatous GVHD. Evidence of defective function of factor H. 2010 , 5, e12162	14
327	Association of gender with clinical expression, quality of life, disability, and depression and anxiety in patients with systemic sclerosis. 2011 , 6, e17551	36
326	On the respiratory mechanics measured by forced oscillation technique in patients with systemic sclerosis. 2013 , 8, e61657	24
325	Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease. 2013 , 8, e71458	62
324	Relevance of partitioning DLCO to detect pulmonary hypertension in systemic sclerosis. 2013 , 8, e78001	13

323	Right bundle branch block: a predictor of mortality in early systemic sclerosis. 2013 , 8, e78808	29
322	Serum adhesion molecule levels as prognostic markers in patients with early systemic sclerosis: a multicentre, prospective, observational study. 2014 , 9, e88150	28
321	Clinical, functional and health-related quality of life correlates of clinically significant symptoms of anxiety and depression in patients with systemic sclerosis: a cross-sectional survey. 2014 , 9, e90484	30
320	Usual interstitial pneumonia preceding collagen vascular disease: a retrospective case control study of patients initially diagnosed with idiopathic pulmonary fibrosis. 2014 , 9, e94775	44
319	Significance of pulmonary arterial pressure as a prognostic indicator in lung-dominant connective tissue disease. 2014 , 9, e108339	11
318	Genetic association study of TNFAIP3, IFIH1, IRF5 polymorphisms with polymyositis/dermatomyositis in Chinese Han population. 2014 , 9, e110044	22
317	Personal Authentication Analysis Using Finger-Vein Patterns in Patients with Connective Tissue Diseases--Possible Association with Vascular Disease and Seasonal Change. 2015 , 10, e0144952	1
316	Human Leukocyte Antigen and Systemic Sclerosis in Japanese: The Sign of the Four Independent Protective Alleles, DRB1*13:02, DRB1*14:06, DQB1*03:01, and DPB1*02:01. 2016 , 11, e0154255	17
315	Metabolic Profiling of Systemic Lupus Erythematosus and Comparison with Primary Sjögren's Syndrome and Systemic Sclerosis. 2016 , 11, e0159384	70
314	Evaluation of Peripheral Blood Circulation Disorder in Scleroderma Patients Using an Optical Sensor with a Pressurization Mechanism. 2016 , 11, e0159611	2
313	Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. 2016 , 11, e0163894	99
312	The 2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis Could Classify Systemic Sclerosis Patients at Earlier Stage: Data from a Chinese EUSTAR Center. 2016 , 11, e0166629	6
311	A preliminary study of skin ultrasound in diffuse cutaneous systemic sclerosis: Does skin echogenicity matter?. 2017 , 12, e0174481	14
310	Radiologic pleuroparenchymal fibroelastosis-like lesion in connective tissue disease-related interstitial lung disease. 2017 , 12, e0180283	41
309	Antioxidants and NOX1/NOX4 inhibition blocks TGF β -induced CCN2 and α 5MA expression in dermal and gingival fibroblasts. 2017 , 12, e0186740	18
308	A hierarchical bivariate meta-analysis of diagnostic test accuracy to provide direct comparisons of immunoassays vs. indirect immunofluorescence for initial screening of connective tissue diseases. 2021 , 59, 547-561	7
307	Avaliaço da tomografia de alta resoluço versus radiografia de trax na doença intersticial pulmonar na esclerose sistmica. 2005 , 38, 95-99	4
306	Outcomes and organ dysfunctions of critically ill patients with systemic lupus erythematosus and other systemic rheumatic diseases. 2011 , 44, 1184-93	17

305	Systemic sclerosis and idiopathic interstitial pneumonia: histomorphometric differences in lung biopsies. 2009 , 35, 529-40	9
304	Serum concentrations of laminin-P1 in thrombotic microangiopathy: usefulness as an index of activity and prognostic value. 2000 , 11, 434-443	5
303	[Altered serum cytokine expression profile in systemic sclerosis and its regulatory mechanisms]. 2019 , 51, 716-722	4
302	Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study. 2008 , 2, 39-45	18
301	Work disability in scleroderma is greater than in rheumatoid arthritis and is predicted by high HAQ scores. 2008 , 2, 44-52	26
300	Long term effects of cyclophosphamide treatment on lung function and survival in scleroderma patients with interstitial lung disease. 2011 , 5, 1-6	9
299	Lack of CTGF*-945C/G Dimorphism in Thai Patients with Systemic Sclerosis. 2011 , 5, 59-63	13
298	Lack of Association of the CD247 SNP rs2056626 with Systemic Sclerosis in Han Chinese. 2014 , 8, 43-5	19
297	The Correlation of Muscle Biopsy Scores with the Clinical Variables in Idiopathic Inflammatory Myopathies. 2016 , 10, 141-149	1
296	Diminished production of TWEAK by the peripheral blood mononuclear cells is associated with vascular involvement in patients with systemic sclerosis. 2009 , 47, 465-9	15
295	Scleroderma and repeated spontaneous abortions treated with vitamin E--a case report--. 2005 , 52, 93-5	3
294	Detection and significance of anti-mitochondrial antibody in various collagen diseases. 2007 , 48, 210-218	5
293	Angiotensin-converting enzyme gene insertion/deletion polymorphism in Korean patients with systemic sclerosis. 2006 , 21, 329-32	9
292	Is spleen circulation impaired in systemic sclerosis and what is the role of liver fibrosis?. 2011 , 17, 1606-13	5
291	Irritable bowel syndrome and organic diseases: a comparative analysis of esophageal motility. 2013 , 19, 6408-15	2
290	Updated Classification Criteria for Systemic Sclerosis: the Concept of Early Diagnosis. 2014 , 87, 395	3
289	Short-Term Lung Function Changes and Predictors of Progressive Systemic Sclerosis-Related Interstitial Lung Disease. 2020 , 83, 312-320	2
288	Progressive systemic sclerosis in a child. 2013 , 58, 406	1

287	Liver pathology in collagen vascular disorders highlighting the vascular changes within portal tracts. 2011 , 54, 25-31	18
286	Pulmonary involvement in systemic sclerosis: A clinical profile. 2016 , 33, 144-7	4
285	Progressive systemic sclerosis with intraoral manifestations: A case report and review. 2016 , 7, 99-104	1
284	Endothelin-1 in systemic sclerosis. 2012 , 3, 14-6	9
283	Pulmonary arterial hypertension in Saudi patients with systemic sclerosis: Clinical and hemodynamic characteristics and mortality. 2019 , 14, 83-89	2
282	Evaluation of Serum Vitamin D Levels in Patients with Systemic Sclerosis and Healthy Controls: Results of a Pilot Study. 2018 , 9, 250-255	13
281	Histopathological differences between primary Sjögren's syndrome and Sjögren's syndrome accompanied by scleroderma. 2018 , 61, 319-322	4
280	Sonoelastography for Skin Evaluation in Sclerodermic Patients. 2019 , 10, 91	5
279	The Effects of Sex on Patient Reported Outcomes in Inflammatory Arthritis and Connective Tissue Diseases. 2013 , 03, 59-64	1
278	Serum salusin-B levels in systemic lupus erythematosus and systemic sclerosis. 2014 , 1, 14-17	5
277	Biomechanical podiatric evaluation in an Italian cohort of patients with systemic sclerosis: A pilot study. 2016 , 3, 169-174	3
276	Frequency of pulmonary hypertension in transthoracic echocardiography screening is not increased in Takayasu arteritis: Experience from a single center in Turkey. 2018 , 5, 249-253	3
275	Antikeratin antibodies in sera of patients with connective tissue disease and liver disease. 2002 , 48, 85-92	1
274	Esophageal involvement in scleroderma: clinical, endoscopic, and manometric features. 2011 , 2011, 325826	30
273	Immediate Effect of Xylitol Chewing Gum and Mouth Rinse on Salivary Levels of Mutans Streptococci in Adults with Systemic Sclerosis: A Pilot Study. 2012 , 2, 89-92	2
272	Oral manifestations of Systemic Sclerosis and Correlation with anti-Topoisomerase I Antibodies (SCL-70). 2015 , 69, 153-6	18
271	Incidence, prevalence and clinical manifestations of systemic sclerosis in dukagjini plain. 2013 , 25, 14-8	3
270	Serum levels of leptin receptor in patients with systemic sclerosis. 2013 , 2, 55-8	1

- 269 Application of a combined protocol for rational request and utilization of antibody assays improves clinical diagnostic efficacy in autoimmune rheumatic disease. **2007**, 131, 112-6 26
- 268 LOW REACTIVE-LEVEL LASER THERAPY IMPROVED SYSTEMIC SCLEROSIS-ASSOCIATED RAYNAUD'S PHENOMENON. **2007**, 16, 151-157 1
- 267 Tanshinone IIA attenuates interleukin-17A-induced systemic sclerosis patient-derived dermal vascular smooth muscle cell activation via inhibition of the extracellular signal-regulated kinase signaling pathway. **2015**, 70, 250-6 12
- 266 Relationship between Peripheral Arterial Stiffness and Estimated Pulmonary Pressure by Echocardiography in Systemic Sclerosis. **2017**, 33, 514-522 1
- 265 Systemic Sclerosis with Multiple Pulmonary Manifestations. **2016**, 10, OD16-7 3
- 264 Mild cognitive impairment in patients with systemic sclerosis and features analysis. 0
- 263 Mortality in Systemic Sclerosis-Associated Interstitial Lung Disease in Brazil: A Real-Life, Long-Term Follow-up Observational Study. **2021**, 28, 0
- 262 Early combination of pulmonary vasodilators prevents chronic kidney disease progression in connective tissue disease-associated pulmonary hypertension. **2021**, 24, 1419-1426
- 261 The disconnect between visual assessment of air trapping and lung physiology for assessment of small airway disease in scleroderma-related interstitial lung disease: An observation from the Scleroderma Lung Study II Cohort.. **2022**, 7, 117-127 1
- 260 Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition.. **2022**, 7, 24-32 5
- 259 Capsule endoscopy findings reflect the gastrointestinal conditions of patients with systemic sclerosis. **2021**, 11, 20163
- 258 Measurement in Scleroderma Clinical Trials. **2000**, 183-203
- 257 Occupational Connective Tissue Disorders. **2000**, 295-313 1
- 256 RHEUMATIC DISORDERS OF THE HAND AND WRIST IN CHILDHOOD AND ADOLESCENCE. **2000**, 16, 659-671 5
- 255 Scleroderma. **2001**, 123-168
- 254 Systemische Sklerose (M 34). **2001**, 904-920 2
- 253 Diagnostik bei Autoimmunerkrankungen. **2001**, 94-109
- 252 Expression de la NO synthase inductible et production du monoxyde d'azote par les cellules mononucléaires sanguines dans la sclérodémie systémique. **2001**, 185, 509-523

- 251 Raynaud's Phenomenon and Other Vasospastic Disorders. **2003**, 173-188 1
- 250 Pulmonary Fibrosis in Connective Tissue Disease. **2003**, 273-302
- 249 Occupational Connective Tissue Disorders. **2004**, 143-174
- 248 ORIGINS OF ANTINUCLEAR ANTIBODIES. **2004**, 401-431 1
- 247 Pregnancy and the Rheumatic Diseases. **2004**, 429-449
- 246 In-vitro-Diagnostik systemischer Autoimmunkrankheiten. **2005**, 725-738
- 245 ??????(?) ???????2005, 67, 378-386 1
- 244 A Case of Crow-Fukase Syndrome with Remarkable Sclerotic Skin Changes. **2005**, 67, 120-124
- 243 Systemic Sclerosis, Scleroderma. **2006**, 369-379
- 242 PROGRESSIVE SYSTEMIC SCLEROSIS. **2006**, 493-498
- 241 The scleroderma Assessment Questionnaire (SAQ). A new self-assessment questionnaire for evaluation of disease status in patients with systemic sclerosis. **2006**, 65, 168-75 5
- 240 The Connective Tissue Diseases. **2007**, 431-448
- 239 Connective Tissue Dysfunction. **2007**, 87-116
- 238 Systemic sclerosis in children. **2007**, 2, 51-60
- 237 Systemic Sclerosis. **2008**, 31-36
- 236 Systemic Sclerosis (Scleroderma). **2008**, 759-765
- 235 The Clinical and Pathological Characteristics of Polymyositis Using ENMC Diagnostic Criteria. **2008**, 15, 296
- 234 Vascular Injuries and Disorders of the Upper Extremity. **2009**, 1299-1322 1

233 The Skin and Rheumatic Diseases. **2009**, 685-702

232 Autoimmune Diseases. **2009**, 265-281

231 ?????????????????????????(??) ??????2009, 71, 428-433

230 Autoimmunerkrankungen. **2009**, 393-421

229 Sklerosierende Hauterkrankungen. **2009**, 267-273

228 Advances in Vascular Medicine. **2009**, 315-334

227 Sex and Gender Differences in Pulmonary Manifestations of Autoimmune Disease. **2010**, 277-285

226 Systemic Scleroderma. **2010**, 1177-1186.e1

225 The Lungs and Connective Tissue Diseases. **2010**, 1398-1426

224 An autopsy case of untreated systemic sclerosis with renal crisis and myocarditis. **2010**, 43, 865-871

223 Connective Tissue Diseases. **2010**, 407-426

222 Esclerodermia. **2010**, 187-195

221 Acroosteolysis of Scleroderma Associated with a Felon. **2010**, 45, 88

1

220 Pregnancy and Autoimmune Rheumatic Disease. **2010**, 627-644

219 Endoscopic Assessment of Gastroesophageal Reflux Disease (GERD) Associated with Systemic Scleroderma Patients-Evaluation of the Relationship between Endoscopic Severity and the Dermatological Findings, and of the Efficacy of Medical Treatment-. **2011**, 73, 170-173

218 A 35-Year-Old Woman with Puffy Hands, Raynaud's Phenomenon, and Positive Antinuclear Antibody Test. **2011**, 1-9

217 The Connective Tissue Diseases. **2011**, 396-412

216 Collagen Vascular Diseases. **2011**, 39-67

- 215 A Limited Cutaneous SSc Patient with Severe Calcinosis and Acro-osteolysis. **2011**, 259-266
- 214 Sclerodactyly and Raynaud's Phenomenon in a Patient Who Has Primary Biliary Cirrhosis. **2011**, 339-345
- 213 A Scleroderma Patient with Swollen and Tender Joints of Both Hands. **2011**, 239-250
- 212 Les atteintes pulmonaires de la sclérodermie. **2011**, 195, 79-92
- 211 Progressive Systemic Scleroderma. **2011**, 173-191
- 210 Epidemiologic concepts and the classification of musculoskeletal conditions. **2011**, 3-10.e1
- 209 Epidemiology and classification of scleroderma. **2011**, 1361-1366.e1
- 208 Clinical Significance of Anti-U1 RNP Antibodies Recognizing The Conformation Structure on U1 RNA/70-kd Protein Complex in Patients with Mixed Connective Tissue Disease. **2011**, 57, 477-487
- 207 Systemic sclerosis with hemoptysis and a huge lung cavity. **2011**, 1, e99
- 206 Kollagenosen. **2012**, 185-203
- 205 Kapitel E1 Literaturverzeichnis zu Peter, Pichler, Müller-Ladner (Hrsg.): Klinische Immunologie. **2012**, e1-e80
- 204 Idiopathic connective tissue disorders. **2012**, 711-759
- 203 Juvenile Scleroderma. **2012**, 1657-1665
- 202 Kollagenosen. **2012**, 103-131
- 201 Rheumatology and the Musculoskeletal System. **2012**, 565-598
- 200 Response of T-cell subpopulations to superantigen and recall antigen stimulation in systemic sclerosis. **2012**, 57, 175-80 1
- 199 Influence of sera from interstitial lung disease patients on angiogenic activity of mononuclear cells. **2013**, 756, 139-45
- 198 Inflammatory Disorders with Unique Clinical Features. **2013**, 45-90 1

- 197 [Comparison of nine second- and third-generation anti-cyclic citrullinated peptide antibody assays for the diagnosis of rheumatoid arthritis]. **2013**, 36, 104-14
- 196 Systemische Sklerodermie. **2013**, 177-182
- 195 The Skin and Rheumatic Diseases. **2013**, 599-616
- 194 Sklerodermie und Sharp-Syndrom. **2014**, 367-383
- 193 Brief Overview of Scleroderma: Localized Scleroderma and Systemic Sclerosis (SSc). **2014**, 1-3
- 192 Scleroderma. **1985**, 119-143
- 191 Pulmonale Manifestation bei Sklerodermie: Klinische Wertigkeit von Lungenfunktion, bronchoalveolarer Lavage, Ösophagusfunktions- und RES Szintigraphie. **1985**, 236-240
- 190 Serologisches Markerprofil der progressiven systemischen Sklerodermie. **1987**, 263-268
- 189 Störungen der Mikrozirkulation als pathogenetisches Prinzip bei der progressiven (systemischen) Sklerodermie (PSS). **1987**, 179-200
- 188 Systemic Sclerosis. **1988**, 193-215
- 187 Entzündliche Myokardbeteiligung bei Kollagenkrankheiten und weiteren rheumatischen Erkrankungen. **1989**, 296-325
- 186 Überlappungssyndrome bei Kollagenosen. **1990**, 79-87
- 185 International Study of Ketanserin in Raynaud's Phenomenon. **1990**, 429-433 1
- 184 Epidemiology and Natural History of Systemic Sclerosis. **1990**, 16, 1-10 6
- 183 Microvasculature in Systemic Sclerosis. **1990**, 16, 75-91 75
- 182 Systemic Sclerosis. **1990**, 16, 641-654 74
- 181 Two Cases of Mixed Connective Tissue Disease Initially Diagnosed as Rheumatoid Arthritis.. **1993**, 55, 243-247
- 180 Measurement of class-specific rheumatoid factors (RFs) in serum of patients with rheumatic diseases by ELISA. **1993**, 39, 55-64

- 179 Weichteilkalzifikation bei Crest-Syndrom. Ein Bericht von zwei Fällen. **1993**, 621-625
- 178 ARTHRITIS-ASSOCIATED SYNDROMES. **1993**, 20, 857-882 2
- 177 A confocal microscopy study of anticytoskeletal antibody activity in patients with connective tissue disease. **1994**, 1, 71-7
- 176 Diagnostische Kriterien. **1995**, 59-194
- 175 Re-evaluation of autoantibodies and clinical overview of silicone-related disorders. **1996**, 210, 291-8 1
- 174 Clinical and laboratory features of patients with scleroderma and silicone implants. **1996**, 210, 283-90 3
- 173 Scleroderma and the similar diseases (1). Points of diagnosis and treatment not written in textbooks.. **1998**, 60, 72-78
- 172 Scleroderma (Systemic Sclerosis) and Morphea. **1998**, 829-838
- 171 Autoimmune Diseases. **1998**, 299-307
- 170 Nailfold Capillaroscopy. **2015**, 187-197 0
- 169 Clinical features of systemic sclerosis. **2015**, 1165-1176 1
- 168 Scleroderma: Not an orphan disease any more. **2015**, 5, 131
- 167 Assessing disease activity and outcome in systemic sclerosis (scleroderma). **2015**, 1159-1164
- 166 Epidemiologic concepts and classification of rheumatic and musculoskeletal conditions. **2015**, 1-8
- 165 Evaluation of left atrial volume and function in systemic sclerosis patients using speckle tracking and real-time three-dimensional echocardiography. **2016**, 16, 316-22 12
- 164 Lung transplantation for connective tissue disorders. **2016**, 223-228
- 163 Historical Perspective of Scleroderma. **2017**, 3-7
- 162 Overlap Syndromes. **2017**, 65-74

161 Innovative Approaches to Clinical Trials in Systemic Sclerosis. **2017**, 649-656

160 Measuring Disease Activity and Outcomes in Clinical Trials. **2017**, 637-648

159 Clinical Trial Design in Systemic Sclerosis. **2017**, 623-635

158 TRADITIONAL RISK FACTORS FOR CARDIOVASCULAR DISEASES IN SYSTEMIC SCLEROSIS AND THEIR RELATIONSHIP TO STRUCTURAL CHANGES OF THE HEART. **2017**, 54, 687-692

157 Evaluation of Left Ventricular Diastolic Function by Echocardiography with Tissue Doppler in Systemic Sclerosis. **2017**, 109, 410-415 3

156 Kollagenosen. **2017**, 75-96

155 Epigenetics of Systemic Sclerosis. **2017**, 1-24

154 Ulnar artery vasculopathy: a common but nonspecific feature of systemic sclerosis. **2017**, 2, 221-224

153 [Chronic stress and mental disorders in patients with systemic scleroderma: Results of an interdisciplinary study]. **2017**, 89, 26-32 1

152 CREST Syndrome: Clinical Expression of the Disease. **2017**, 23, 285 0

151 Ultrastructural Aspects of Apoptosis in Systemic Sclerosis Inflammatory Myopathy. **2018**, 06, 1-7

150 Clinical Manifestation and Incidence of Cardiopulmonary Complications in Early Systemic Sclerosis Patients with Different Antibody Profiles. **2019**, 11, 524-531 0

149 Occupational Connective Tissue Disorders. **2020**, 393-425

148 Autoimmune Connective Tissue Diseases. **2020**, 451-497

147 The Relationship Between Tc-Pertechnetate Hand Perfusion Scintigraphy and Nailfold Capillaroscopy in Systemic Sclerosis Patients: A Pilot Study. **2020**, 35, 321-327 1

146 Spontanverlauf der Kollagenosen. **1983**, 15-35 1

145 Therapie der progressiven Sklerodermie. **1983**, 246-249

144 Premature Onset Aortic Stenosis in Systemic Sclerosis: A Report of a Series of Cases. **2020**, 59, 3177-3181 0

143	Relating Interferon Regulatory Factor 5 Rs2004640 Gene Polymorphism To Increased Risk Of Systemic Sclerosis In The Patients: Russian Federation Cohort. 2020 , 9,	0
142	Very Early Systemic Sclerosis: VEDOSS Type Case. 2021 , 315-324	
141	QT variability index in patients with systemic sclerosis. 2019 , 6, 179-183	4
140	Prevalence and clinical association of the presence of anti-neutrophilic cytoplasmic antibody in systemic sclerosis.. 2021 , 17, 1696-1705	
139	Epidemiology and clinical characteristics of systemic sclerosis overlap syndrome (SSc-OS), and the factors significantly associated with SSc-OS in Thai patients with systemic sclerosis.. 2021 ,	0
138	Orthopedic surgery. <i>Arthritis and Rheumatism</i> , 1983 , 26, 359-436	
137	Diagnostische Kriterien. 2007 , 57-172	
136	Sklerodermie und Sharp-Syndrom. 2007 , 347-362	
135	Systemische Sklerose (M 34). 801-816	3
134	Significant elevation of IgG anti-WRN (RecQ3 RNA/DNA helicase) antibody in systemic sclerosis. 2006 , 16, 229-34	2
133	Clinical significance of serum levels of secretory leukocyte protease inhibitor in patients with systemic sclerosis. 2012 , 22, 576-83	1
132	Serum antibodies against the 70k polypeptides of the U1 ribonucleoprotein complex are associated with psychiatric syndromes in systemic lupus erythematosus: a retrospective study. 2013 , 23, 71-80	4
131	Antibody-dependent cellular cytotoxicity of vascular endothelium: characterization and pathogenic associations in systemic sclerosis. 1989 , 78, 359-65	48
130	Differential isotype recognition of two centromere associated polypeptides by immunoblotting in connective tissue disease. 1988 , 72, 457-64	19
129	Clinical and laboratory characteristics of patients with speckled pattern antinuclear antibodies. 1986 , 55, 112-7	
128	High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. 2002 , 100, 1602-10	45
127	Plasma endogenous enkephalin levels in early systemic sclerosis: clinical and laboratory associations. 2010 , 28, S7-11	1
126	[Pulmonary hypertension in scleroderma: about 12 cases]. 2012 , 11, 9	1

125	Prevalence, prognosis, and factors associated with left ventricular diastolic dysfunction in systemic sclerosis. 2012 , 30, S30-7	42
124	Effect of a multi-faceted intervention on gingival health among adults with systemic sclerosis. 2011 , 29, S26-32	26
123	Differences in presentation of younger and older systemic sclerosis patients in clinical trials. 2010 , 28, S10-4	5
122	Clinical characteristics and survival in idiopathic pulmonary fibrosis and connective tissue disease-associated usual interstitial pneumonia. 2015 , 7, 386-93	2
121	Pilot study to determine whether transient receptor potential melastatin type 8 (TRPM8) antibodies are detected in scleroderma. 2015 , 33, S123-6	2
120	Quantitative volumetric assessment of pulmonary involvement in patients with systemic sclerosis. 2016 , 6, 50-6	9
119	Systemic sclerosis. The Watson Smith Lecture 1984. 1985 , 19, 23-30	2
118	Clinical Phenotype of Endothelial Dysfunction in a Lot of Romanian Scleroderma Patients. 2015 , 10, 336-341	
117	Clinical Phenotype of Endothelial Dysfunction in Romanian Scleroderma Patients. 2016 , 11, 26-31	
116	Increased incidence of carcinoma of the tongue in patients with systemic sclerosis. 2005 , 32, 637-41	39
115	High-flow nasal cannula therapy for acute respiratory failure in patients with interstitial pneumonia: a retrospective observational study. 2020 , 82, 301-313	1
114	Survival and prognostic factors of lung cancer patients with preexisting connective tissue disease: a retrospective cohort study. 2020 , 8, 1415	
113	Diagnostic value of chest spiral CT scan and Doppler echocardiography compared to right heart catheterization to predict pulmonary arterial hypertension in patients with scleroderma. 2021 , 92, e2021074	
112	Independent association between occupational exposure and decline of forced vital capacity in systemic sclerosis (SSc): a multicenter recruitment retrospective cohort study. 2021 ,	0
111	Systemic sclerosis: what's in a name?. 2021 , 3, e820-e821	
110	Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). 2021 , 3, e834-e843	2
109	Autoantibodies in the disease criteria for systemic sclerosis: The need for specification for optimal application.. 2022 , 5, 100141	0
108	Survival and prognostic factors of lung cancer patients with preexisting connective tissue disease: a retrospective cohort study. 2020 , 8, 1415-1415	0

- 107 Proximal heat stress up-regulates angiopoietin-1 in fingers and reduces the severity of Raynaud's phenomenon in systemic sclerosis: a single-centre pilot study. **2021**, 0
- 106 Persistent eosinophilia and associated organ involvement in Thai patients with systemic sclerosis: Data from the Siriraj scleroderma cohort.. **2021**, 36, 527-537
- 105 Serum lysyl oxidase concentration increases in long-standing systemic sclerosis: Can lysyl oxidase change over time?.
- 104 The Effect of Anti-Scl-70 Antibody Determination Method on Its Predictive Significance for Interstitial Lung Disease Progression in Systemic Sclerosis.. **2022**, 2
- 103 Autoantibody profiles associated with morbidity and mortality in scleroderma renal crisis.. **2022**, 1
- 102 Systemic Sclerosis. **2022**, 107-135
- 101 Early diagnosis of systemic sclerosis, where do we stand today?. **2022**, 1-3 0
- 100 Prediction of long-term mortality by using machine learning models in Chinese patients with connective tissue disease-associated interstitial lung disease.. **2022**, 23, 4 0
- 99 Computed Tomography Predictors of Mortality or Disease Progression in Systemic Sclerosis-Interstitial Lung Disease: A Systematic Review.. **2021**, 8, 807982 0
- 98 Ultrasound and elastography in the assessment of skin involvement in systemic sclerosis: A systematic literature review focusing on validation and standardization.. **2022**, 52, 151954 2
- 97 Eular Workshop on Rheumatology Research. Noordwijkerhout, February 19 82. Abstracts. **1982**, 1, 47-79
- 96 Predictive Value of Echocardiographic Strain for Myocardial Fibrosis and Adverse Outcomes in Autoimmune Diseases.. **2022**, 9, 836942 0
- 95 Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement/progression?. **2022**, 1
- 94 Serum markers of cardiac complications in a systemic sclerosis cohort.. **2022**, 12, 4661 0
- 93 Diastolic Dysfunction in Systemic Sclerosis: Risk Factors and Impact on Mortality.. **2021**, 2
- 92 Benefits and risks of Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis.. **2022**,
- 91 A Narrative Review of Pathogenetic and Histopathologic Aspects, Epidemiology, Classification Systems, and Disease Outcome Measures in Systemic Sclerosis.. **2022**, 1 0
- 90 Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype.. **2022**, 1

- 89 Determination of T Cell Responses in Thai Systemic Sclerosis Patients.. **2022**, 2022, 5072154
- 88 Increased risk of mortality in systemic sclerosis-associated pulmonary hypertension: a systemic review and meta-analysis.. **2022**, 62, 10 ○
- 87 47XXY and 47XXX in Scleroderma and Myositis.. **2022**, ○
- 86 SFRP4 Expression Is Linked to Immune-Driven Fibrotic Conditions, Correlates with Skin and Lung Fibrosis in SSc and a Potential EMT Biomarker.. **2021**, 10, ○
- 85 Genetic associations of non-MHC susceptibility loci with systemic sclerosis in a Han Chinese population.. **2021**,
- 84 Single-cell-level protein analysis revealing the roles of autoantigen-reactive B lymphocytes in autoimmune disease and the murine model. **2021**, 10, 2
- 83 The validity of systemic sclerosis diagnoses in two university hospitals in Finland.. **2022**, 1-4
- 82 Systemic Scleroderma-Definition, Clinical Picture and Laboratory Diagnostics.. **2022**, 11, ○
- 81 Data_Sheet_1.PDF. **2019**,
- 80 Table_1.XLSX. **2019**,
- 79 Table_3.DOCX. **2019**,
- 78 Data_Sheet_1.docx. **2019**,
- 77 Image_1.TIF. **2019**,
- 76 Image_2.TIF. **2019**,
- 75 Image_1.png. **2020**,
- 74 Image_10.PDF. **2020**,
- 73 Image_11.PDF. **2020**,
- 72 Image_2.PDF. **2020**,

71 Image_3.PDF. 2020,

70 Image_4.PDF. 2020,

69 Image_5.PDF. 2020,

68 Image_6.PDF. 2020,

67 Image_7.PDF. 2020,

66 Image_8.PDF. 2020,

65 Image_9.PDF. 2020,

64 Table_1.DOCX. 2020,

63 Table_2.DOCX. 2020,

62 Table_3.DOCX. 2020,

61 Table_4.docx. 2020,

60 Table_5.docx. 2020,

59 Detection of anti-extractable nuclear antigens in connective tissue diseases: comparison between passive hemagglutination, counterimmunoelectrophoresis and double immunodiffusion. **1985**, 15, 33-8 4

58 Scleroderma. **2022**, 7155-7168

57 Clinical, Serological, and Genetic Characteristics of a Hungarian Myositis-Scleroderma Overlap Cohort.. **2022**, 2022, 6251232 0

56 Skin model for improving the reliability of the modified Rodnan skin score for systemic sclerosis. **2022**, 6,

55 Changes on chest HRCT in systemic sclerosis-related interstitial lung disease after autologous hematopoietic stem cell transplantation. 0

54 Defining minimal detectable difference in echocardiographic measures of right ventricular function in systemic sclerosis. **2022**, 24, 0

53	CREST Syndrome in Systemic Sclerosis Patients ¶s Dystrophic Calcinosis a Key Element to a Positive Diagnosis?. Volume 15, 3387-3394	0
52	Contribution of HLA and KIR Alleles to Systemic Sclerosis Susceptibility and Immunological and Clinical Disease Subtypes. 13,	0
51	A Study on Pulmonary Complications of Systemic Sclerosis in Eastern India. 2022 , 56, 231-235	1
50	Role of interferons (IFNs) in the differentiation of T peripheral helper (Tph) cells 2. IFN- α and IFN- γ cooperatively contribute to the expansion of Tph cells in systemic lupus erythematosus.	0
49	Performance of the Revised Classification Criteria for Systemic Autoimmune Rheumatic Diseases and Their Overlap Syndromes. 2022 , 61, 1947-1952	0
48	Systemic sclerosis mortality trends in Spain from 1980 to 2019: age-period-cohort and Joinpoint analysis.	
47	SYSTEMIC SCLEROSIS. 1993 , 13, 313-334	1
46	Absolute decrease in regulatory T (Treg) cells and low-dose IL -2 therapy: restoring and expanding Treg cells to treat Systemic Sclerosis (SSc) - A 24 week study.	0
45	Elevated baseline serum creatine kinase in Thai early systemic sclerosis patients is associated with high incidence of cardiopulmonary complications and poor survival: an inception cohort study.	
44	Stem cell transplantation for systemic sclerosis. 2022 , 2022,	0
43	Survival in Swedish patients with systemic sclerosis: a nationwide population-based matched cohort study.	
42	Skin thickness affects the result of tuberculin skin test in systemic sclerosis. 2022 , 6,	
41	Prevalence of and factors independently associated with digital ischemic complications in patients with systemic sclerosis. 239719832211187	
40	Interstitial lung disease associated with systemic sclerosis in a patient with long-term employment as a marble worker. 2022 , 16, 63-68	
39	Epidemiology and Treatment of Systemic Sclerosis in Korea. 2022 , 29, 200-214	0
38	Restrictive Lung Diseases in Pregnancy. 2022 , 871-888	0
37	Insights into molecular and clinical characteristics of very early systemic sclerosis. 2022 , 34, 351-356	0
36	Relationship between digital ulcers and severity of lung function test in systemic sclerosis over a five-year period. 2022 , 60, 450-454	0

35	Associations of autoantibodies and clinical profile of the patients with systemic sclerosis. 2022 , 2, 141-149	0
34	Association of HLA-DRB1*15:02:01 , DQB1*05:01:24 and DPB1*13:01:01 in Thai patients with systemic sclerosis.	0
33	Improved Survival for Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension: The Johns Hopkins Registry.	2
32	The association of IL-33 and systemic sclerosis: a systematic review and meta-analysis.	0
31	Stress Echocardiographic Prediction of Emerging Pulmonary Vascular Disease in Systemic Sclerosis. 2022 ,	0
30	Development and validation of machine learning for early mortality in systemic sclerosis. 2022 , 12,	0
29	Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region.	1
28	Rituximab for the treatment of connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis. 13,	0
27	Impact of pregnancy on progression of preclinical autoimmune disorders: a prospective cohort study.	0
26	Association between anti-SSSCA1 antibodies and cancer in systemic sclerosis.	0
25	Systemic Sclerosis Sine Scleroderma: A Rare Entity. 2022 , 58, 265-268	0
24	Esclerose sistêmica: desafios no diagnóstico e avaliação da atividade e gravidade da doença. 2022 , 50-58	0
23	Different chest HRCT scan protocols change the extent of ground glass opacities. 2022 , 22,	0
22	Comparing clinical characteristics of systemic sclerosis with or without interstitial lung disease: A cross-sectional study from a single center of the Chinese Rheumatism Data Center. 9,	0
21	The Role of Anti-U1 RNP Antibody in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. 2023 , 12, 13	0
20	Autoantibodies to T Cell Costimulatory Molecules in Systemic Autoimmune Diseases. 1999 , 162, 4328-4335	15
19	Comprehensive description of the prevalence, serological and clinical characteristics, and visceral involvement of systemic sclerosis (scleroderma) in a large cohort from the United Arab Emirates Systemic Sclerosis Registry. 239719832211457	0
18	Autoantibodies and Clinical Correlations in Polish Systemic Sclerosis Patients: A Cross-Sectional Study. 2023 , 12, 657	0

- 17 Pulmonary Fibrosis and Progressive Pulmonary Fibrosis in a Prospective Registry of Interstitial Lung Diseases in Eastern Siberia. **2023**, 13, 212
- 16 Epidemiology of rheumatic and musculoskeletal diseases in a Nigerian peri-urban community: results of a cross-sectional survey using the COPCORD stage 1 model. **2022**, 60, 366-375
- 15 Scleromyositis: A distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis. 13,
- 14 Clinical Significance of Different Profiles of anti-Ro Antibodies in Connective Tissue Diseases. **2023**, 2023, 1-11
- 13 Clinical significance of anti-rheumatoid arthritis 33 antibody in patients with systemic lupus erythematosus. 108155892211506
- 12 Reduced digestion of circulating genomic DNA in systemic sclerosis patients with the DNASE1L3 R206C variant.
- 11 Autoimmune diseases. **2023**, 123-244
- 10 Incidence and prevalence of systemic sclerosis in Thailand in year 2017-2020: a database from the Ministry of Public Health.
- 9 Approach to Systemic Sclerosis Patient Assessment. **2023**, 49, 193-210
- 8 Differentially expressed genes in systemic sclerosis: Towards predictive medicine with new molecular tools for clinicians. **2023**, 22, 103314
- 7 Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis.
- 6 Global, regional, and national incidence and prevalence of systemic sclerosis. **2023**, 248, 109267
- 5 Clinical Characteristics of Patients with Primary Biliary Cholangitis Complicated with Sjogren's Syndrome. **2023**, 13, 2690-2699
- 4 The Role of Lung Ultrasound in Systemic Sclerosis. Publish Ahead of Print,
- 3 Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry of the Italian Society for Rheumatology. **2023**, 9, e002890
- 2 Brachial artery flow-mediated dilation in patients with systemic sclerosis: an experience from tertiary care center from North India.
- 1 Step forward in early recognition of systemic sclerosis: data from the Leiden CCISS cohort. **2023**, 9, e002971